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Abstract
Abstract
The deposition in the brain of the 4 kDa beta-amyloid peptide (PA4), from amyloid 
precursor protein (APP), is a key pathology in Alzheimer’s disease (AD). The single APP gene is 
spliced to give 3 major isoforms. In the majority of body tissues, the most common APP isoforms 
are APP751 and APPzzo, which both contain a Kunitz protease inhibitor (KPI) domain, APP695 is 
predominant in the brain. APP is processed through several pathways, not all of which lead to 
pA4 production. Central nervous system (CNS) neurones in vivo secrete PA4, which can be 
detected in the cerebrospinal fluid, though it is unknown why pA4 is deposited in the brain in AD.
NTera2 (NT2) cells derived from a human teratocarcinoma were used as a model of APP 
processing. Retinoic acid induces these cells to differentiate into a neuronal phenotype (NT2N 
cells), which has been shown to closely resemble immature human CNS neurones. Both cell 
types produce high levels of endogenous APP.
Intracellular and secreted APP was studied in both cell types by means of western 
blotting and immunoprecipitation with a panel of antibodies. It was found that NT2 cells 
predominantly make and secrete KPI containing APP. NT2N cells make and secrete 
predominantly APP695 though some KPI containing APP is also present.
There is evidence that neurones in the AD brain are in a state of stress, which could 
increase levels of APP due to a heat shock promotor region in its gene. To investigate this, NT2 
cells were subjected to a heat shock, which resulted in increased levels of heat shock protein 
(HSP) and APP. KPI containing APP predominated, but there was no corresponding increase in 
secreted APP. Both cell types were also serum deprived, which resulted in little effect on protein 
production in NT2 stem cells. However, the neuronal cells showed a small increase in 
intracellular, KPI-containing APP and in HSP. A reduction in overall APP secretion, and 
cessation of KPI secretion accompanied this.
To further investigate the effects of shock on APP production, mRNA levels in control and 
serum deprived NT2 and NT2N cells were studied using in situ hybridisation. Control NT2 cells 
contain low levels of APP751, APP695 and HSP mRNA, with higher levels of APP770 mRNA. After 
serum deprivation HSP, APP751 and APP770 mRNA levels all rose significantly, while APP695 
mRNA levels were unchanged. Control NT2N cells contained high levels of APP695 mRNA, lower 
levels of APP751 mRNA, and very low levels of APP770 and HSP mRNA. Serum deprivation 
resulted in unchanged levels of APP695 and APP770 mRNA, while APP751 and HSP levels were 
increased.
These findings indicate that cellular stress can result in increased levels of APP, 
specifically APP751, in both neuronal and non-neuronal cells. Increased levels of this isoform 
have also been reported in AD. Hence cellular stress leads to an increase in an APP isoform 
implicated in AD, and could also provide an explanation for the increased levels of pA4 in the 
disease.
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Chapter One -  Introduction
Chapter One - Introduction
1.1 ALZHEIMER’S DISEASE
Alois Alzheimer first described Alzheimer’s disease (AD) in 1907, in a 52-year-old woman. 
(Alzheimer, 1907) It is now the most common cause of dementia in the western world. The 
incidence of AD increases with age, 5% of the population over 65 are affected, rising to 20% of 
the population over the age of 80. (Katzman, 1988) As modem medicine advances and the 
average life span increases, AD is becoming an increasing and costly problem. The British 
government spends millions of pounds each year caring for AD suffers. As there is no cure for 
AD, and no effective long-term treatments, the cost keeps on rising.
1.1.1 Clinical Presentation
AD presents as a progressive dementia, beginning with a loss of short-term memory and 
proceeding to involve other cognitive functions. Common complaints of patients or families 
include forgetfulness about appointments or errands; inability to find the way to an accustomed 
destination; inability to use money and instruments of daily living, such as a telephone; 
deterioration in work or homemaking performance; difficulty adapting to changes in the workplace; 
difficulties in dressing, reading and writing; and inability to recognise previously familiar 
individuals. (McKhann etal. 1984) As the disease progresses language is affected, and in late 
stages motor function is impaired.
1.1.1.1 Diagnosis
There is no clinical test for AD, pre-mortem diagnosis of the disease relies on observed 
behavioural changes and is classified according to internationally agreed criteria (such as 
NINCDS-ADRA and DSM III). (McKhann et al. 1984) It principally relies on the exclusion of
1
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other systemic or neurological diseases that could account for the observed cognitive defects. 
The diagnosis of AD can only be confirmed at autopsy. The disease usually results with death 
after 5-15 years, commonly due to a complicating factor such as pneumonia.
1.1.2 Pathological Hallmarks
At post-mortem AD diagnosis is confirmed by the presence of neurodegeneration of specific brain 
areas, as well as neurofibrillary tangles (NFTs) and senile plaques (SPs), the classical 
pathological hallmarks of AD. (Tomlinson etal. 1970) Alzheimer first described NFTs and SPs in 
1907. The concentration of NFTs appears to correlate well with the degree of cognitive 
impairment, though the number of SPs correlates less well. (Wilcock etal. 1982) However 
“amyloid load” which takes into account all amyloid deposits in the grey matter and around blood 
vessels, does appear to correlate with the severity of dementia. (Braak and Braak, 1990)
1.1.2.1 Neurofibrillary Tangles
Neurofibrillary tangles (NFTs) are abnormal bundles of cytoplasmic fibres in the neuronal cell 
body. They are one of the classical hallmarks of AD, but are also present in other neurological 
diseases (e.g. normal ageing, dementia pugilistica, Down’s syndrome and Parkinson-dementia of 
Guam, Esiri et al. 1997). NFTs of AD are composed mainly of paired helical filaments (PHFs), 
approximately 10 nm in diameter, which cross each other at an 80 nm interval. Thus the 
maximum width of a PHF is 20 nm, and the minimum width 10 nm. (Goldman and Yen, 1986) 
PHFs are also present in dystrophic neurites.
PHFs are comprised primarily of the microtubule-associated protein tau (Goedert et al. 1991), 
which is in a hyperphosporylated form, (Grundke Iqbal etal. 1986) though normal microtubule- 
associated proteins may also be present. It is interesting to note that NFTs are also 
immunopositive for ubiquitin, a protein induced by the cellular heat shock response, and other
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heat shock proteins. Hyperphosphorylation of proteins is also a component of this response, 
indicating that NFTs may represent the end point of a failed attempt by affected neurones to 
respond to a form of cellular stress. (See Section 1.8 for a discussion of the heat shock response 
and its relevance to AD)
It is possible that the hyperphosphorylation of tau could lead to a destabilisation of the 
microtubules, resulting in the disruption of intracellular transport and eventual cell death (see 
Mandelkow and Mandelkow, 1998 for review of the possible role of tau in the pathogenesis of 
AD).
1.1.2.2 Amyloid
The term amyloid refers to a “pathological proteinaceous substance deposited extracellularly in 
tissue and most commonly identified by light microscopy as a homogeneous eosinophilic material 
which stains with alkaline Congo red”. (Glenner and Page, 1976) The deposits consist of an 
accumulation of fibrils, which allow histological identification of amyloid deposits by Congo red 
birefringence (amyloid deposits appear green under polarised light after Congo red staining). The 
proteins composing amyloid deposits are in a p-sheet configuration.
1.1.2.2.1 Plaques
Plaques are spherical extracellular protein deposits found in the brains of both normal aged and 
AD patients. There are four different types; primitive or diffuse plaques which consist of fibrillar 
amyloid deposits; dense plaques which contain a dense core of aggregated amyloid; neuritic or 
senile plaques (SPs) which contain a dense amyloid core surrounded by dystrophic neurites and 
reactive astrocytes; and burnt out plaques, which resemble SPs, but are not associated with 
dystrophic neurites. (Braak and Braak, 1990) Both diffuse and dense plaques are believed to be
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immature SPs, with plaques beginning as diffuse deposits, then progressing to develop the dense 
core and finally association with dystrophic neurites.
1.1.2.2.2 Cerebral Amyloid Angiopathy (CAA)
CAA is the deposition of amyloid fibrils around the cerebral vasculature, and occurs in normal 
ageing and other dementias, as well as in AD. (Esiri and Wilcock, 1986) The amyloid deposited 
around the blood vessels in AD brains has been shown to be identical to that which is found in 
senile plaques. (Masters etal. 1985; Glennerand Wong, 1984)
1.1.2.3 Neurochemical Deficits
The most consistent neurochemical deficit in AD brain is a marked reduction in presynaptic 
cholinergic markers, notably choline acetyltransferase (ChAT) activity. This is most probably due 
to the degeneration of cholinergic basal forebrain neurones. This deficit is likely to be secondary 
to the cortical pathology, caused by retrograde degeneration of the cells of the basal nucleus, 
which project to areas of the cortex exhibiting heavy pathology. (Pearson and Powell, 1989)
Since postsynaptic markers, such as the Mi muscarinic receptors, are relatively spared (though 
they may be partially uncoupled from their second messenger systems), treatment strategies 
which upregulate the cholinergic system have been attempted. Anti-cholinesterases such as 
tacrine and donepezil have been used in treatment trials, with moderate cognitive improvement. 
However, this strategy has several drawbacks: the drugs have a range of deleterious side effects; 
there are a number of neurochemical deficits (see below) so that treating one in isolation is not 
wholly effective; and the loss of ChAT is a consequence of pathology, not a causative effect, so 
the treatment is not effective in the long-term. (Cummings et al. 1998)
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Other neurochemical deficiencies associated with Alzheimer’s disease include depletion of amine 
neurotransmitter systems and neuropeptides, especially somatostatin and corticotrophin releasing 
factor. Changes in 5-hydroxytriptamine (5-HT) and noradrenaline appear to be related to 
behavioural symptoms such as anxiety and depression. As with the cholinergic system, attempts 
to combat these effects with drugs have not been successful, largely because they interfere with 
normal compensatory responses. Finally there is a major deficiency in cortical glutamate in AD. 
(Esiri etal. 1997; Cummings etal. 1998)
1.1.2,4 Other Pathology
Other pathological abnormalities include synaptic loss, decreased glucose metabolism, reactive 
gliosis, decreased protein production and phosphorylation with increased stress response 
proteins such as HSP70 and ubiquitin (see Section 1.8).
1.1.3 Spread of Pathology
The distribution of NFTs and SPs is not uniform throughout the cortex. The spread of neuronal 
pathology has been shown to correlate with cortico-cortical connectivity (Pearson, 1996; Pearson 
and Powell, 1989) with the medial temporal lobe being the end and most affected, and the 
primary sensory and motor areas the least affected. More specifically, the hippocampus, 
enthorinal cortex, uncal cortex, cortico-medial amygdala and parahippocampal gyrus are the most 
severely affected. The primary sensory and motor cortex is relatively unaffected, with the 
intervening association areas of pareito-temporal cortex involved to an intermediate degree. (Esiri 
et al 1990; Pearson and Powell, 1989). Neurones that project to affected cortical areas contain 
NFTs, while those receiving from such areas contain SPs. This distribution of pathology has lead 
to the belief that the spread of AD pathology is dependent on neuroanatomical pathways, though 
the identification of the agent responsible has yet to be confirmed (see Section 1.7).
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1.2 BETA-AMYLOID (J3A4)
The dense core of SPs consists of an insoluble aggregation of a 4 kDa, 39-43 amino acid peptide, 
beta-amyloid (pA4) (Masters et a/. 1985; Glenner and Wong, 1984), derived by proteolytic 
cleavage of the longer amyloid precursor protein (APP).
1.2.1 Function
PA4 is present in the blood and cerebrospinal fluid (CSF) of non-AD subjects (Shoji et al. 1992); 
it is also secreted from cultured cells under normal conditions. (Haass et al. 1992b) The function 
of pA4 is not well understood, though it has been reported to show neurotrophic effects at low 
concentration in vitro. (Yankner et al. 1990) This observation is supported by the reports that 
both neuronal (Turner et al. 1996; Wertkin et al. 1993) and glial cells (Morato and Mayor, 1993; 
Busciglio et al. 1993) under normal conditions produce pA4 in vitro.
1.2.2 Structure
The amino acid composition of pA4 promotes spontaneous aggregation into amyloid fibrils, with 
the longer forms (PA4m2/43) showing a markedly enhanced rate of aggregation in vitro, compared 
to that of pA41 -39/40• (Pike et ai. 1991) There is some evidence that the longer forms of pA4 are 
critically important in AD, and are deposited first in the SPs. (Gravina et al. 1995)
1.2.3 Neurotoxic Properties
PA4 forms fibrils when left in solution, in a process known as ageing. These aged solutions of 
PA4 have some neurotoxic effects. (Ueda et al. 1994; Pike et al. 1991; Yankner et al. 1990; 
Yankner et al. 1989) There are several theories as to the mechanism by which pA4 induces cell 
death. It has been reported to destabilise calcium homeostasis in neurones, and thus render 
them vulnerable to excitotoxicity. (Mattson et al. 1992; Koh et al. 1990)
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A second possibility is that pA4 may cause cell death by inducing apoptosis. (LaFerla et al.
1995; Loo et al. 1993) pA4 down-regulates bcl-2, an anti-apoptotic protein, and increases levels 
of bar, a protein known to promote cell death. (Paradis et al. 1996) Alternatively pA4 may cause 
cell death via oxidative mechanisms, or by the generation of free radicals. (Hensley et al. 1994) 
Cells exposed to pA4 mount a stress response similar to that seen in oxidative stress. (Davis, 
1996)
Another of the pathogenic processes seen in AD is cholinergic dysfunction, and there is some 
evidence that pA4 may be involved in this process. Non-aged pA4, which is not neurotoxic, has 
been shown to suppress acetylcholine synthesis in cholinergic neurones. This effect was only 
seen with solutions of pA4(i-42), not pA4(i-40). (Hoshi et al. 1997)
1.3 GENETICS OF AD
In approximately 5 percent of cases AD has a genetic component, and is inherited as an 
autosomal dominant disease. In many of these cases of familial AD (FAD) the age of onset is 
earlier than for sporadic AD, in the fifth or sixth decade as opposed to the seventh or eighth 
decade for sporadic AD. (Selkoe, 1993) Genes on chromosomes 1,14,19 and 21 are all 
implicated in FAD.
1.3.1 Early-Onset Familial AD (EOFAD)
The gene mutations responsible for EOFAD are found on chromosomes 1,14 and 21 and 
correspond to presenilin 2, presenilin 1 (see Section 1.3.1.2) and amyloid precursor protein.
1.3.1.1 Amyloid Precursor Protein (APP) Mutations
Neuropathological changes, such as those seen in AD, are observed in Downs Syndrome 
patients. Since these individuals are trisomic for chromosome 21, it was postulated that AD was
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caused by duplication of one or more genes on this chromosome. Mapping of the APP gene to a 
locus on this chromosome made it a possible candidate for EOFAD. (St George-Hyslop et al. 
1987)
In 1991 a point mutation in the APP gene, changing valine to isoleucine at codon 717, was found 
to co-segregate with APP. (Goate et al. 1991) This was followed by the discovery of two more 
mutations at this codon, substituting phenyalanine (Murrell et al. 1991) or glycine (Chartier- 
Harlin et al. 1991). A double mutation (known as the Swedish double mutation) at codons 670 
and 671 (lysine -»  asparginine and methionine - » leucine) was also found to co-segregate with 
the disease. (Mullan etal. 1992)
Two further mutations in the APP gene were identified in a Dutch family displaying cerebral 
haemorrhage (HCHWA-D), a disease in which amyloid is deposited in the cerebral vasculature, 
resulting in fatal haemorrhage. Dementia is also a common feature of the disease. The 
mutations causing HCHWA-D are at codon 693 (glutamate -»  glutamic acid) (Levy et al. 1990) 
and codon 692 (alanine glycine) (Hendriks etal. 1992).
All these mutations are either within the pA4 sequence, or close to the cleavage sites. These 
mutations all alter APP processing to make the deposition of pA4 more likely. The mutations at 
Val717 increase the production of the longer forms of pA4, which are more insoluble, (Thinakaran 
etal. 1996; Maruyama etal. 1996; Mann etal. 1996; Tamaoka etal. 1994; Suzuki etal. 1994) 
while the other mutations increase pA4 production by switching APP processing to the p- 
secretase pathway. (Haass etal. 1994; Citron etal. 1994; Cai etal. 1993; Citron etal. 1992)
They are all classical gain of misfunction mutations (see Section 1.5). However these mutations 
only account for less than three percent of early onset FAD cases. (Hardy, 1996)
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1.3.1.2 Mutations of the Presenilins
In 1995 a mutation in a gene on chromosome 14 was also found to co-segregate with the disease 
(Sherrington et al. 1995), swiftly followed by the finding of a similar gene on chromosome 1. 
(Levy-Lahad et al. 1995a; Levy-Lahad et al. 1995b) These genes have been named presenilin 1 
and 2, respectively and are highly homologous to each other. Several mutations of presenilin 2 
(PS2) and over 50 mutations of presenilin 1 (PS1) have now been identified, together with the 
APP mutations these account for all cases of early onset FAD. The presenilin mutations are 
among residues conserved between the two genes and occur in clusters. (See Section 1.5 for 
more detail of presenilin functions.)
1.3.2 Late-Onset Familial AD (LOFAD)
1.3.2.1 Apolipoprotein E
Apolipoprotein E (ApoE) expression is increased in AD, and both SPs and NFTs are 
immunopositive for ApoE. (Namba etal. 1991) LOFAD is associated with the ApoE gene on 
chromosome 19. (Strittmatter et al. 1993) ApoE exists in three isoforms, E2, E3 and E4, encoded 
by alleles e2, s3 and s4, respectively. There is a strong genetic association between the e4 allele 
and LOFAD. Possession of the s4 allele leads to a higher likelihood and an earlier age of onset 
of LOFAD, with individuals homozygous for that allele most at risk. (Strittmatter et al. 1993) The 
s2 allele appears to have a protective effect, increasing the age of onset of the disease. (Oyama 
etal. 1995)
It is unknown how ApoE interacts with the pathogenic processes, various alleles may stabilise the 
PA4 plaques or protect against tangles. It may be that it is solely involved with damage repair, 
with the s2 allele being the most effective and the s4 allele the least. (Hardy, 1996)
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1.4 APP
Glenner and Wong first proposed the idea of the involvement of a novel amyloid peptide in AD in 
1984. As previously described, this peptide was subsequently isolated and characterised. 
(Masters et al. 1985; Glenner and Wong, 1984) It was predicted that this was derived from a full- 
length precursor protein (Tanzi et al. 1987) and a cDNA clone coding for a protein with 695 
residues was isolated from foetal brain tissue and localised to chromosome 21 in 1987. The 
predicted protein (amyloid precursor protein or APP) resembled a cell surface receptor. (Kang et 
al. 1987) Further screening of peripheral tissue identified an APP mRNA coding for a 751 residue 
protein, with the 56 amino acid insert closely resembling a Kunitz-type serine protease inhibitor 
(now known as the KPI region). (Kitaguchi et al. 1988; Tanzi et al. 1988; Ponte et al. 1988)
1.4.1 APP Structure (See Figure 1.1)
APP is a type I transmembrane protein, with a short intracellular C-terminus, and a long, 
extracellular N-terminus. The PA4 region corresponds to the first 28 amino acids of the 
extracellular domain, and the adjacent 11-15 amino acids of the transmembrane domain. (Kang 
et al. 1987) It is now known that alternative splicing of the single APP gene on chromosome 21 
can give rise to at least 10 protein isoforms. The three most common isoforms are APP695 
(missing codons 7 and 8), APP751 (missing codon 8) and APP770, or full length APP. Codon 7 
encodes the KPI region of the protein, while codon 8 encodes a MRC OX-2 domain. (Clark et al. 
1985) The pA4 peptide is encoded by parts of codons 16 and 17. APP770 and APP751 are 
expressed ubiquitously throughout the body, while APP695 is found almost exclusively in 
neurones. (Rohan de Silva et al. 1997; Arai et al. 1991)
1.4.2 APP Processing (See Figures 1.1 and 1.2)
APP undergoes complex post-translational modifications, including sulphation, phosphorylation, 
and both N- and O-linked glycosylation. (Weidemann et al. 1989) It is co-translationally
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translocated into the endoplasmic reticulum (ER) via its signal peptide, then matured via the 
central secretory pathway. The holoprotein may undergo cleavage at the cell surface, or during 
trafficking through the ER and Golgi, by one of three secretase activities; or degradation in the 
endosomal I lysosomal system. (See Sections 1.4.2.1 and 1.4.2.2)
1.4.2.1 a-Secretase
The majority of the full-length APP molecules undergo proteolytic cleavage in the ER or Golgi 
(see below), with only a small percentage reaching the cell surface. A proportion of these 
molecules undergoes proteolysis by an unidentified protease designated a-secretase. This 
protease cleaves at amino acid 16 of the pA4 sequence, and therefore cannot lead to pA4 
production. (Esch et al. 1990) It requires APP to be membrane attached and in an a-helix, and 
does not appear to be specific for a particular peptide bond, instead cleaving at a set distance 
from the membrane. (Sisodia, 1992; Esch et al. 1990) This secretase activity releases the large, 
soluble, extracellular domain (referred to as APPsa) from the cell surface. The 83 residue (-10 
kDa) C-terminal fragment is retained in the membrane. a-Secretase activity can also occur in 
late Golgi and trans-Golgi network on the way to the cell surface. (Sambamurti et al. 1992)
Alternatively, full-length APP can undergo endocytosis via clathrin-coated vesicles, after which 
the protein is either trafficked to late endosomes and lysosomes for degradation, or is rapidly 
recycled within early endosomes to the cell surface. (Selkoe et al. 1996; Nordstedt et al. 1993; 
Haass et al. 1992) The endosomal/lysosomal pathway leads to the breakdown of APP into many 
different fragments, some of which contain pA4 which may then be released from the cell. (Estus 
et al. 1992; Golde et al. 1992; Haass et al. 1992)
1.4.2.2 p-And y-Secretase
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APP also undergoes proteolytic cleavage by a protease termed p-secretase. This enzyme 
activity cleaves after methionine 671 (APP770), at the amino terminal of pA4. This cleavage 
releases a truncated APPs molecule, APPsp, from the cell surface. (Seubert et al. 1993; 
Anderson et al. 1992) The remaining 12 kDa membrane attached fragment undergoes cleavage 
by a protease named y-secretase within the membrane domain to release soluble pA4 from the 
cell. This enzyme cleaves at residue 711 or 713 (APP770) to generate pA4i-4o or pA4i-42. y- 
secretase also cleaves the 83 amino acid C-terminal fragment resulting from a-secretase 
cleavage. This releases the approximately 3 kDa C-terminal fragment of pA4 (designated p3) 
from the cell. P3 is not amyloidogenic.
p- and y-secretase activities occur at several sites within the cell. It is assumed that a small 
proportion of the full-length, cell surface APP undergoes p-secretase cleavage (Anderson et al. 
1992), and that the resulting 99 residue C-terminal fragment is degraded to pA4, as well as other 
fragments, in the endosome/lysosome system. A proportion of the APP that undergoes 
endocytosis from the cell surface is processed by p- and y-secretase to pA4. This can be shown 
by radioiodinating cell surface APP and allowing reintemalisation, within 15 minutes 
radioiodinated pA4 is released from the cell. (Koo and Squazzo, 1994)
There is also evidence that suggests pA4 is generated in the ER and Golgi during early 
processing of APP. (Cook et al. 1997; Hartmann et al. 1997) Furthermore, it appears that the 
longer forms of pA4 (pA4i-42/43) are generated in the ER, while pA4uo is generated in the Golgi. 
(See Figure 1.2)
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1.4.3 APP Regulation
APPsa secretion is markedly increased by stimulation of the phospholipase C I protein kinase C 
(PKC) pathway. (Buxbaum et al. 1992; Nitsch et al. 1992) It is also enhanced upon electrical 
stimulation of neurones. (Nitsch et al. 1993) There is some evidence that this increase in APPsa 
secretion decreases the production of pA4 (Hung et al. 1993) however this does not appear to 
be the case in neuronal cells. (Leblanc et al. 1998)
Treatment of human umbilical vein endothelial cells (HUVECs), endothelial cells, and neurones 
with interleukin-1 (IL-1) upregulates APP mRNA production, though it does not have this affect in 
glial cells. (Lahiri and Nall, 1995; Forloni etal. 1992; Goldgaberetal. 1989). This IL-1 regulation 
of APP mRNA appears to occur via a pathway mediated by PKC, (Forloni et al. 1992) indicating 
that this second messenger pathway is important in both APP expression and secretion.
1.4.4 APP Expression
As previously stated, APP695 is the predominant isoform found in neuronal cells, while APP751 and 
APP770 are the predominant isoforms in glial cells and throughout the other tissues of the body. 
(Rohan de Silva et al. 1997)
1.4.4.1 Changes in APP Expression
Increased levels of APP mRNA and protein may be a normal feature of ageing. Senescent 
human fibroblasts contain a significant increase in all 3 isoforms of APP when compared to 
fibroblasts in culture at early passage, and this increase in expression is reflected at the protein 
level. (Adler et al. 1991)
APP mRNA levels are also increased after a number of cellular insults both in vivo and in vitro, 
including neurotoxic damage by kainic acid and serum deprivation. (Sudoh et al. 1996; Sola et al.
13
Chapter One - Introduction
1993; Adler et al. 1991). Human fibroblasts rendered quiescent by serum deprivation showed 
increased total levels of APP mRNA when compared to proliferating cells, this increase appeared 
to consist of increases in all isoforms. (Adler et al. 1991) More specifically, it is levels of KPI- 
containing APP isoforms that are increased. (Sudoh et al. 1996; Sola et al. 1993) 
Intracerebroventricular application of kainic acid to rat brain resulted in a large increase in APP770 
mRNA when examined by in situ hybridisation, and a weaker increase in APP751 mRNA. (Sola et 
al. 1993) Serum deprivation induced increases in total APP mRNA in rat C6 glioma cells. This 
increase was entirely due to an increase in APP770, while APP695 mRNA levels decreased slightly. 
Levels of APP751 mRNA did not alter. (Sudoh et al. 1996)
1.4.4.2 APP Expression in AD
There appears to be an overall increase in APP expression in the brains of individuals with AD. In 
situ hybridisation in the pyramidal neurones of the hippocampus shows this increase in APP 
mRNA to be largely due to an increase in the KPI-containing APP isoforms. (Johnson et al. 1990) 
Northern blot and ribonuclease protection assays of the frontal cortex of AD patients also show an 
increase in KPI-containing APP. (Tanaka et al. 1989; Tanaka et al. 1988) In situ hybridisation 
shows an increase in APP mRNA in the nucleus basalis of Meynert of brains of patients with AD, 
(Cohen et al. 1988) though in this area the increase appears to be in APP695. (Palmert et al.
1988) The evidence for an increase in APP mRNA in AD is not unanimous, Harrison et al. 1991 
found no increase when they compared FAD cases with controls.
The relative amounts of each APP protein have also been measured in control and AD brains. 
Analysis of the total purified APP protein from one hemisphere of either control or AD brains, by 
both trypsin inhibition and by reflectance analysis of Western blots, showed KPI-containing APP
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protein levels to be significantly increased in AD brain when compared to controls. (Moir et al. 
1998) Immunohistochemical analysis of the temporal and hippocampal regions showed the 
increase in APP7 5 11APP695 ratio to correlate with the density of SPs in the brain region. The 
same study also showed that the dystrophic neurites associated with many SPs are 
immunopositive for KPI-containing APP. (Hyman et al. 1992) It has been suggested that 
expression of the KPI domain reduces a-secretase cleavage and increases PA4 production. (Ho 
etal. 1996)
These data suggest that it is a specific increase in KPI-containing APP isoforms that is a 
significant event in AD pathology, and that it is possible that APP751 is the more important 
isoform.
1.4.5 Amyloid Precursor like Proteins
There is evidence that APP is one member of a highly conserved family of proteins, with APP-like 
molecules in evolutionary distant organisms, including C. elegans and Drosophila melanogaster. 
Two proteins with a high sequence homology to APP (designated amyloid-precursor-like-proteins 
1 and 2, APLP1 and APLP2) have been identified in the mouse brain. (Slunt etal. 1994; Wasco 
et al. 1992) Human APLP2 homologues of both APLP2 and, more recently, APLP1 have also 
been identified. (Lenkkeri et al. 1998; Webster et al. 1995) APLP2 is present in brain 
cerebrospinal fluid and conditioned media, and appears to undergo similar processing to APP. 
(Lyckman et al. 1998) APLP1 and 2 are increased in the neurones, blood vessels and dystrophic 
neurites associated with SPs in AD brain. (McNamara et al. 1998) Many APP antibodies cross- 
react with APLP2 (Webster et al. 1995; Slunt et al. 1994), though the latter protein does not 
contain the pA4 sequence and is unlikely to be involved in AD pathology.
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1.4.6 APP Functions
The function of APP is unclear, both in the nervous system and in the rest of the body. It is 
apparent that the secreted derivative, APPsa, and the full length protein have specific properties, 
with full length APP potentially acting as a receptor, while the truncated form acts on other cells 
via as yet unidentified receptors.
KPI-containing APP proteins are effective protease inhibitors. (Kitaguchi et al. 1988). The 
secreted form of APP751 is identical to protease nexin-ll, an inhibitor of factor Xla, and a serine 
protease involved in the coagulation cascade. (Smith et al. 1990) Protease nexin-ll is released 
upon platelet aggregation, suggesting that APP751S could be involved in wound repair. (Van 
Nostrand et al. 1990)
APPsa affects intracellular calcium levels in cultured neurones. (Mattson etal. 1993a) Resting 
calcium levels are lowered, leading to protection against glutamate mediated excitotoxicity. 
(Mattson et al. 1993b) The protein can also activate potassium channels, and so hyperpolarize 
the neuronal membrane, suppressing action potentials. (Furukawa et al. 1996). APPsa can lead 
to increased synaptic density and associated increased memory retention when infused into rat 
brains. (Roch et al. 1994)
The function of full length APP is, if anything, even less clear. Full length APP695 is markedly 
induced during neuronal differentiation, abundantly expressed in adult neurones, and transported 
within axons by the fast anterograde system to nerve terminals. (Lyckman et al. 1998; Koo et al.
1990) The holoprotein may be involved in neurite outgrowth or synaptic formation and 
maintenance. It may also be involved in cell-cell or cell-matrix interactions, in which it may 
promote neurite outgrowth. (Koo et al. 1993; Ghiso et al. 1992) In agreement with the results
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obtained when administering APPsa to adult rats, transgenic rats expressing a 1.5 fold increase 
in APP695 over endogenous APP showed an increase in synaptic density. (Mucke et al. 1994) 
However, transgenic mice expressing a 5 fold increase in human APP751 exhibited normal 
learning and memory until 9-10 months of age, when they became impaired in these tasks. 
(Moran etal. 1995)
APP clearly has several roles in the central nervous system, however mice, which lack the APP 
gene, do not show a dramatic neuronal phenotype. Lack of the gene does not confer early 
mortality, or an increased morbidity. Young APP null mice exhibit a mild reduction in locomotion, 
and reduced forelimb grip strength, and deficits in cognitive function and long-term potentiation 
become evident in an age-dependent manner. (Zheng et al. 1996; Zheng et al. 1995) Neurones 
from these mice, cultured at birth, show reduced viability and a reduction in neurite outgrowth. 
The lack of a vital consequence of APP deletion may be due to the fact the APP homologues 
compensate for the missing APP proteins. APP and APLP2 have similar turnover kinetics and 
cell trafficking profiles, indicating that they may have similar roles. (Lyckman et al. 1998) This 
theory is supported by evidence from cells from APP knock-out mice in which APLP2 is up- 
regulated in response to neurotoxic assault from pA4. (White et al. 1998; see Sisodia and 
Gallagher, 1998 for a review of APP function.)
1.5 PRESENILINS
1.5.1 Properties
Presenilins 1 and 2 are highly homologous proteins with six to eight transmembrane regions. 
Hence both the N- and C-terminals face the cytoplasmic side of the membrane, as does the large 
hydrophilic loop between the sixth and seventh transmembrane regions. Cellular levels of the full 
length proteins are low, due to a constitutive proteolytic cleavage site within this loop. (Li and
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Greenwald, 1998) Cleavage generates stable N- and C-terminal fragments, which, once 
produced, form stable high molecular weight complexes, the levels of which appear to be highly 
regulated. (Thinakaran etal. 1997) The constitutive cleavage occurs in the ER, once formed the 
fragments are transported to the Golgi. (See Selkoe, 1998 for review)
1.5.2 Functions
PS1 and PS2 are expressed ubiquitously and at comparable levels in most human tissues, 
including brain. PS1, however is expressed at higher levels in the developing brain, and its 
expression is very similar to the expression of Notch, a protein important in cell fate and 
neurogenesis. (Lee et al. 1996) Further evidence that PS1 may be involved in the Notch 
signalling pathway is the fact that it is highly homologous to the Caenorhabditis elegans protein 
SEL-12 (Berezovska et al. 1997), a facilitator of UN-12/Notch signalling during the determination 
of cell fate in development. (Levitan and Greenwald, 1995) Wild-type human PS1 can rescue the 
SEL-12 mutant phenotype in C. elegans, though most PS1 mutations linked to AD confer only 
partial functional recovery. (Levitan et al. 1996) PS2 may also be involved in this pathway, as its 
expression is similar to that of PS1 and Notch, although it has also been implicated in apoptosis. 
(Wolozin et al. 1996)
PS1 N- and C-terminal fragments form stable complexes with (3-catenin, an important molecule in 
the Wnt signalling pathway. (Murayama et al. 1998; Yu et al. 1998) AD causing PS1 mutations 
decrease the stability of p-catenin in both cultured cells and transgenic mice, also the brains of 
AD patients bearing such mutations contain a significantly decreased level of p-catenin. (Zhang 
et al. 1998) Loss of p-catenin signalling in neurones leads to increased vulnerability to pA4 
induced apoptosis, implying that one way in which PS1 mutations are pathogenic, is by 
decreasing p-catenin levels and rendering neurones vulnerable to pA4. (Zhang etal. 1998)
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Other lines of evidence suggest that PS1 mutations lead to mistrafficking of p-catenin, which may 
also have pathogenic implications for AD. (Nishimura et al. 1999)
Deletion of the gene encoding PS1 produces a lethal phenotype characterised by severely 
disordered somatogenesis and axial skeletal development. Both normal and AD-linked mutant 
PS1 can rescue this phenotype, indicating that PS1 mutations do not confer loss of function.
1.5.3 The Presenilins and pA4
The AD-linked mutations found in PS1 and PS2 (over 50 to date) are all missense mutations. 
Cellular and transgenic studies have shown these mutations to lead to an approximate two-fold 
increase in pA4i-42. (Citron et al. 1997; Mann et al. 1996; Duff et al. 1996; Scheuner et al. 1996) 
This is reflected in the observation that brains of patients bearing PS1 mutations contain 
approximately two-fold more pA4i-42 specific SP, when compared with sporadic AD brains. 
(Lemere et al. 1996)
1.5.3.1 y-Secretase and the Presenilins
AD causing mutations in the presenilin genes lead to an increase in pA4i-42/43 production.
(Tomita et al. 1997; Citron et al. 1997; Scheuner et al. 1996; Duff et al. 1996) There is no 
associated change in APP expression, and its cleavage by a- and p-secretase does not appear 
to be affected. Cells from mice lacking PS1 show a 70-80% decrease in pA4 production, 
together with an increase in both the 83 and 99 residue C-terminal fragments resulting from p-and 
a-secretase. Together, this evidence indicates that PS1 is crucially involved in y-secretase 
cleavage of APP, and that mutations in the presenilins selectively enhance the cleavage of pA4 
after residue 42/43.
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There is some evidence, based on coprecipitation experiments, that the presenilins and APP 
form complexes. (Weidemann et al. 1997) This may regulate the access of y-secretase to the 
peptide bond and so determine the cleavage site. However, other investigators have failed to find 
presenilin / APP complexes, suggesting that the presenilins may regulate trafficking of either APP 
or y-secretase to each other, without interacting directly with APP. (Haass and Selkoe, 1998; see 
Selkoe, 1998 for a review of presenilin and APP processing).
1.6 HEAD TRAUMA AND AD
As well as gene mutations, a significant risk factor for AD is head trauma. (Gentleman and 
Roberts, 1992; Graves et al. 1990) On examining the brains of patients who survived for between 
four hours and 2.5 years after a severe brain trauma, cortical PA4 deposits were seen in 30% of 
the cases. Additionally, APP immunoreactivity was increased in neurones in the vicinity of these 
deposits. (Robertsetal. 1994)
1.6.1 Dementia Pugilistica
Professional boxers often suffer from a dementing syndrome, dementia pugilistica, as a result of 
repeated blows to the head. This disease is characterised by neuronal loss, cortical NFTs and 
diffuse pA4 plaques, as well as other symptoms. The NFTs present in dementia pugilistica are 
indistinguishable form those found in AD brain. (Allsop et al. 1990)
Together, these data imply that severe or repeated head injury could induce an increased 
expression of APP, which in turn could lead to the insoluble pA4 deposits which characterise AD.
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1.7 THE INFLAMMA TORY RESPONSE AND AD
Although AD is not associated with inflammation, there are many characteristics of the AD brain 
which are associated with the acute phase immune response, not least of which are the activated 
microglia found associated with SPs. The SPs themselves are immunopositive for a variety of 
inflammatory mediators, including acute-phase proteins, cytokines, cell adhesion molecules and 
virtually the full range of activated classical pathway complement proteins. (Eikelenboom et al. 
1998; Rogers et al. 1993) pA4 can bind the complement protein C1q in vitro and so activate the 
complement pathway. (McGeer and McGeer, 1996) In the presence of interferon-y pA4 can 
activate microglia, which may in turn lead to neurone injury. (Meda et al. 1995)
While this data does not elucidate the aetiology of AD, it does provide targets for treatment 
strategies. Patients taking anti-inflammatory drugs on a regular basis (such as rheumatoid 
arthritis patients) have a lower frequency of AD, indicating that these drugs may have a 
therapeutic effect in the disease. Initial trails of the nonsteroidal anti-inflammatory (NSAID) drug 
indomethacin had some positive results. (Rogers etal. 1993)
1.8 THE STRESS RESPONSE AND AD
1.8.1 Heat Shock Proteins
All organisms respond to stress by inducing the synthesis of a highly conserved group of proteins 
called the heat-shock proteins (HSPs). The most well-characterised response is that induced by 
hyperthermic shock, though these proteins can also by induced by anoxia, ethanol, certain heavy 
metal ions, and free radicals. (Lindquist and Craig, 1988; Lindquist, 1986) These stress situations 
initiate abnormal protein configurations or denaturing of proteins. HSPs may bind to these 
abnormal proteins preventing aggregation, or facilitating a renaturation or repair process. HSPs 
may also target abnormal proteins for breakdown by proteolysis. (Hamos et al. 1991) Prior
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induction of HSPs may serve to protect cells against a variety of insults, including periods of 
ischemia and excitotoxicty. (Chopp, 1993)
Some HSPs are constitutively expressed in a variety of cell types. In these cells the role of HSPs 
appears to be diverse, including DNA replication, transport of proteins across membranes, 
binding of proteins in the endoplasmic reticulum and uncoating clathrin-coating vesicles.
(Lindquist and Craig, 1988) They may also assist in the folding of newly formed, nascent, 
proteins. (Hamosetal. 1991)
1.8.2 The Stress Response in the AD Brain
There are several indications that neurones in the AD brain may be in a state of stress. Protein 
production and processing is altered, with a decrease in overall protein synthesis, changes in 
protein phosphorylation and a disruption of the cytoskeleton. The NFTs contain 
hyperphosphorylated tau, and have also been shown to contain increased levels of ubiquitin.
(Mori etal. 1987) This is a highly conserved, ubiquitously expressed protein, which is induced by 
stress in all cells. (Lindquist and Craig, 1988)
SPs also contain members of the heat shock family of proteins, specifically heat shock proteins 
72 and 73, increased levels of these proteins are also found in NFTs. (Perez et al. 1991; Hamos 
et al. 1991) Interestingly, HSP72 was found exclusively in SPs and NFTs while another HSP, 
glucose regulated protein, or GRP78 was increased only in neurones that remain cytologically 
normal. This could indicate that HSP72 induction is an early response to the formation of 
abnormal proteins, perhaps targeting them for breakdown, while GRP78 protects cells from the 
neurotoxic effects of these abnormal proteins. (Chopp, 1993; Hamos et al. 1991) HSP mRNA is 
also increased in the frontal cortex of AD patients, as well as in other neurodegenerative
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disorders. (Harrison et al. 1993) This increase did not correlate with pre-mortem factors such as 
pyrexia or coma, supporting the existence of a stress response in AD brains.
1.8.3 APP and the Heat Shock Response
The increase in HSP levels in response to stress is controlled at the transcription level. A 
transcriptional activator, the heat shock factor, binds to a short highly conserved region of the 
heat shock gene, known as the heat shock element (HSE). (Sorger, 1991) The promoter region 
of the APP gene contains a sequence homologous to the HSE, suggesting that APP levels may 
also be changed in response to cellular stress. (Salbaum et al. 1988)
A number of studies into the effect of heat shock and other means of stress on APP levels have 
been carried out in a variety of cell types, including PC12 neuronal cells, HUVECs and human 
lymphoblastoid cells. Periods of increased temperature were shown to decrease APP 
phosphorylation levels, induce the production of additional APP polypeptides (Johnson et at. 
1993a; Johnson et al. 1993b), increase levels of APP mRNA (Ciallella et al. 1994; Abe et al.
1991), increase total cellular levels of APP, and increase levels of APP secretion (Ciallella et al. 
1994). In human embryonal carcinoma cells transiently transfected with a region of the APP gene 
promoter, APP transcription was shown to be stimulated by heat shock, ethanol and sodium 
arsenite treatment. (Dewji et al. 1995) It is also interesting to note that a period of heat shock 
induced increased phosphorylation of tau in neuronal PC12 cells. (Johnson etal. 1993b)
These results suggest that some of the pathological changes seen in AD may be a result of the 
stress response. If neuronal cells under cytological stress upregulate APP, it is possible that one 
of the effects of this would be to increase levels of pA4. As pA4 may be neurotoxic, it is 
reasonable to suppose that cells exposed to increased levels of the peptide would express signs
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of being in a state of cellular stress, and as a result increase levels of APP, leading to a vicious 
circle of increased pA4 production. (See Section 1.9)
1.9 pA4 INVOLVEMENT IN AD
As has been previously stated, the spread of AD pathology appears to follow the path of cortical 
connectivity, suggesting it is propagated by some agent, which is produced by the cortical 
neurones. (Pearson and Powell, 1989) pA4 is the most popular candidate for this agent, with the 
“amyloid cascade hypothesis” suggesting that the neurotoxic effects of pA4 are responsible for 
cell death. (Hardy and Higgins, 1992)
There are many lines of evidence to back up this hypothesis (see Figure 1.3 for a summary). As 
previously described, pA4 has neurotoxic properties. APP is upregulated in response to cellular 
stress of many varieties, and it is reasonable to assume that an increase in APP will lead to an 
increase in secreted pA4. In this way the pathology could be propagated along cortical 
pathways, with increased levels of pA4 leading to cellular stress and upregulation of APP, which 
in turn would lead to increased levels of pA4.
PA4 is critical in the pathogenesis of EOFAD. Mutations in APP, PS1 and PS2 all increase PA4 
production, with mutations in the presenilins specifically increasing the more toxic form pA4i-4m 
ApoE appears to be involved in pA4 disposal or deposition. (LaDu et al. 1994) Patients with one 
or two s4 alleles have a significantly higher density of both plaque and vascular pA4 deposits in 
their brains than other AD patients. (Hyman et al. 1995; Schmechel et al. 1993)
Head trauma, a major risk factor for AD, increases APP expression, and leads to pA4 deposits in 
the brain. (Roberts et al. 1994) It has also been shown that there is an inflammatory element to
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the AD brain, and that this response can be propagated by {3A4. These data serve to support the 
amyloid cascade hypothesis, by showing that increased levels of pA4 lead to increased 
expression of APP, possibly by several mechanisms. pA4 can activate the complement 
pathway, leading to increased cytokines such as IL-1, which regulates APP expression and 
production. The acute phase response leads to increased free radicals, which could be 
neurotoxic, leading to initiation of the stress response and increased levels of APP. (See Figure 
1.3)
Since increases in soluble levels of pA4 appear to be pivotal in FAD, it is proposed that pA4 is 
also increased in sporadic AD (SAD). It is therefore important to study APP processing, to 
identify events or conditions in the normal brain that could lead to a build up of pA4. As it has 
been reported that expression of APP751 can lead to increases in pA4 production, study of the 
processing of this APP isoform could lead to greater understanding of the aetiology of SAD.
1.10 METHODS OF STUDYING AD
In 1995 the first successful transgenic mouse model for AD was developed. (Games et al. 1995) 
The animals express a human APP mini-gene, encoding the codon 717, valine to phenylalanine 
mutation. The animals exhibit AD pathology, and show learning defects. (See Price etal. 1998 
for a review of null and mutant APP transgenic mice) Transgenic animals for the presenilin 
mutations have now also been developed. These animals are undoubtedly useful for examining 
the pathogenesis of FAD, and will be vital in testing new treatment strategies. However, they 
have told us little about the aetiology and pathogenesis of SAD at present.
The transgenic animals provide a useful tool to identify proteins and processes of potential 
interest in SAD, but to understand this disease these processes must be examined using the
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wild-type proteins, comparing them in control and SAD brain and other tissue. Ways of doing this 
include the examination of post-mortem human brain tissue, primary cells lines derived from AD 
and control patients, and the manipulation of established cell lines. All these techniques, 
however, have their drawbacks.
Human brain tissue, both control and AD, is difficult to obtain, and often there is a long delay 
between the time of death and the tissue being available to researchers. This post-mortem delay 
can result in changes in the brain chemistry, leading to misleading and confusing results from 
biochemical tests.
Cell lines are easier to obtain and work with, but they also have drawbacks. APP expression 
varies with species, and between tissues within each species. This means that each cell line will 
express different isoforms of APP and may use different processing pathways. To obtain the best 
model of the APP expression in the human brain it is, therefore, desirable to work on human 
neurones. However neurones are post-mitotic, and therefore cannot be kept in continuous 
culture. It is possible to work with primary cultures of human neurones but these are difficult to 
obtain and manipulate.
1.11 NTERA2 CELLS
The cell line NTera2 (NT2) is derived from a human teratocarcinoma. Cells from these 
carcinomas have the appearance of embryonic stem cells. NT2 cells can be induced to 
differentiate into a number of phenotypes by incubating them with retinoic acid. (Andrews et al. 
1985; Andrews et al. 1984) Among these phenotypes are cells with the characteristics of central 
nervous system neurones. These cells (NT2N cells) are post-mitotic, and express neuronal 
markers, such as neurofilament proteins and synaptophysin. (Ackerman et al. 1994) After
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retinoic acid differentiation the neuronal precursor cells can be selectively plated out, and 
incubated with mitotic inhibitors, to give cultures of neurones with over ninety-nine percent purity. 
(Pleasure et al. 1992) After one to two weeks in culture the cells form bundles of cell bodies with 
complex systems of axons and dendrites connecting the bundles. It has been shown that 
functional synapses form between the cells. NT2 cells are trisomic for several chromosomes, 
including chromosome 21. In consequence both stem and neuronal cells secrete significant 
amounts of APP. Previous work on the mRNA of these cells has shown that the stem cells 
express predominantly APP770, with some APP695; while NT2N cells express predominantly 
APP695, with some APP751.
These criteria make NT2 and NT2N cells a good model for studying at least one of the processes 
implicated in the pathology of AD. They are easy to culture and manipulate. They are human 
neuronal cells, and therefore are a better model of the human brain than any other cell line. They 
express endogenous APP, without the need to transfect the cells and possibly disrupt the normal 
chemical pathways within the cells. Also the neuronal cells express the same APP isoforms as 
found in the brain.
1.12 HYPOTHESES
The work presented in this thesis was designed to test the following hypotheses:
NTera2 neuronal cells make a good In vitro model of human CNS neurones with regard to the 
expression and processing of APP. Upon differentiation from the stem cell to the neuronal 
phenotype, APP expression will change and alternative processing pathways for the protein will 
be activated. In contrast to the stem cells, neuronal cells will possess amyloidogenic means of 
APP breakdown.
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NTera2 neuronal and stem cells will respond to cellular stress in the same manner as human and 
animal cell lines previously tested. Cellular stress will induce a “heat-shock response”, as a result 
of which APP, specifically the KPI-containing isoforms, will be upregulated. As a component of 
this response APP processing pathways may be altered.
1.13 AIMS OF THE WORK PRESENTED IN THIS THESIS
• To develop a method of producing NTera2 neuronal cells
•  To characterise the APP expression and production in NTera2 stem and neuronal cells
•  To develop a method of subjecting NTera2 stem and neuronal cells to cellular stress
• To investigate the effects of this stress on APP expression and processing
28
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Figure 1.1 APP STRUCTURE AND CLEAVAGE SITES
The diagram shows the processing of APP770. APP751 and APP695 are processed by the same 
secretase activities, though the secreted product lacks either the OX-2 domain in the case of 
APP751, or both the OX-2 and KPI domains in the case of APP695.
a) Full length APP770 (not to scale)
There is a 17 amino acid signal sequence at the N-terminal. APP770 contains both the 56 
amino acid KPI region (coded for on codon 7) and the 19 amino acid MRC OX-2 domain 
(coded for on codon 8). The pA4 sequence (encoded by parts of codons 16 and 17) occupies 
amino acids 671-713, the last 14 of which are part of the transmembrane domain (the 
membrane is represented by the hatched box)
b) a-secretase cleavage
a-secretase cleaves between amino acids 16 and 17 of pA4 to release the large extra-cellular 
domain from the cell. The resulting 83 amino acid C-terminal may then be cleaved by y- 
secretase to generate p3.
c) p-secretase cleavage
p-secretase cleaves at the N-terminus of pA4, releasing a truncated APPs from the cell. The 
99 amino acid C-terminal fragment is then cleaved by y-secretase to release pA4.
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Figure 1.2 CELLULAR PROCESSING OF APR AND POTENTIAL SITES OF 
pA4 PRODUCTION
APP is matured through the central secretion pathway, with a proportion of the full length 
protein that reaches the cell surface being cleaved by either a- or p-secretase. The resulting 
C-terminal fragments are re-internalised via clathrin coated vesicles to early endosomes, 
where they may be cleaved by y-secretase to generate p3 and pA4, which are then released 
from the cell. Alternatively, the C-terminal fragments may be degraded in late endosomes and 
lysosomes, a process that may also generate pA4.
A proportion of the full length, cell surface APP is also re-internalised in clathrin coated 
vesicles. This protein may be recycled to the cell surface, cleaved in the early endosomes by 
any of the 3 secretase activities, or degraded in the endosomal I lysosomal pathway.
Finally, a proportion of APP is cleaved by p- and y-secretase as it matures through the ER 
and Golgi. In this system, the ER is the major site of pA4i-42/43 production, while the majority 
of pA4i-4o is produced in the Golgi.
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Figure 1.3 FACTORS WHICH COULD LEAD TO INCREASED pA4 IN THE 
AD BRAIN
A schematic diagram to show the possible causes of increased APP and pA4 in the AD brain, 
and the “vicious circle” nature of these increases, providing support for the amyloid cascade 
hypothesis.
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Appendix A contains details of the solutions used and suppliers.
2.1 CELL CULTURE
NTera2/clone D1 cells were obtained from Prof. P. Andrews of the University of Sheffield.
2.1.1 NT2 Stem Cells
NT2 cells were cultured in Dulbecco’s modified Eagles medium (DMEM) with 10% heat 
inactivated foetal bovine serum (FBS) and penicillin/streptomycin (P/S) at 37°C) 10% CC>2/90% 
air in a humid environment. Confluent cultures were split 1:3 (resulting in approximately 4 x 106 
cells seeded per T75 flask (Falcon)) using a non-enzymatic salt solution (cell dissociation 
solution) or by dislodging with glass beads (Andrews et al. 1985). Trypsin/EDTA (TE) was not 
used as it may promote stem cell differentiation.
The beads (BDH) were 3 mm in diameter and had been treated overnight with concentrated 
hydrochloric acid (HCI), neutralised with concentrated sodium hydroxide (NaOH), washed 
overnight with tap water, and finally rinsed with dFhO. The beads were then decanted into test 
tubes with foil caps and autoclaved in batches immediately prior to use. Half the media was 
decanted from the flask and 10-20 sterile glass beads added. The beads were rolled over the 
surface of the flask to dislodge the cells. The resulting cell suspension was then pipetted into 
fresh culture flasks and fresh complete media (cDMEM) added.
Cell viability was assessed visually the day following the cell split. Healthy NT2 cells adhere to 
the culture vessel, while dead or damaged cells detach and are visible floating in the media. Cell 
viability was invariably greater than 95%.
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2.1.2 NT2N Cells
Details of the method of neuronal differentiation and purification are to be found in Chapter 3. 
Briefly, 3.5 x 105 NT2 cells were seeded in a T75 flask (Falcon) and fed weekly with cDMEM 
containing 10-5 M retinoic acid (RA) for 24 days. The cultures were then dislodged with TE and 
split 1:3 into cDMEM containing mitotic inhibitors (cDMEM+l). These cultures were fed twice 
weekly with cDMEM+l for 14 days. After this time the neuronal cells could be seen as phase 
bright cell bundles lying on top of a layer of non-neuronal cells, these cell bundles could be 
detached by shaking the culture vessel. Once in suspension the cells can be transferred to 
culture vessels pre-treated with poly-D-lysine and Matrigel. Although at this point it was not 
possible to obtain accurate cell counts, each experiment was carried out on a single batch of 
NT2N cells, resulting in comparable numbers of cells per flask.
Cultures of NT2N cells were fed weekly with cDMEM and maintained in 10% CO2 / 90% air in a 
humid environment. Cell viability was assessed visually on the day following the replating, and 
twice weekly thereafter. Healthy NT2N cells elaborate cell processes, and both processes and 
cell bodies adhere to the culture vessel. Non-viable cells do not elaborate processes, and 
ultimately the cell bodies detach from the culture vessel. Any cultures with less than 90% viability 
were discarded.
2.1.3 Coating Flasks/Slides
2.1.3.1 Poly-D-Lysine
One hundred jug/ml stock was diluted prior to use dilute 1:10 with sterile dH20. Approximately 
50% of the usual medium volume was added to the vessel (enough to cover bottom) and left for 
at least 2 hours. The fluid was then aspirated off and the vessel allowed to air dry.
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2.1.3.2 Matrigel
Twenty jul of Matrigel diluted 1:36 with DMEM was added to the poly-D-lysine treated vessel and 
spread evenly over the surface with a fire polished and shaped Pasteur pipette. Excess liquid 
was aspirated off and the vessel allowed to air dry. This step was repeated immediately prior to 
seeding the cells.
2.1.4 Cell Photography
Unless otherwise stated, all cells were viewed and photographed using an Olympus CK2 
microscope, using the x20 objective lens. Photographs were taken using a Polaroid Micro SLR 
camera loaded with Polaroid 667 film.
2.2 PREPARATION OF CELL SOLUBLE AND MEMBRANE PROTEINS
Media was aspirated from a T25 culture flask and 10 ml DMEM was added to wash the cells. 
Cells were removed by mechanical means (shaking in the case of neurones, scraping with glass 
beads or a disposable cell scraper in the case of stem cells) and the cell suspension centrifuged 
at 170 g (Baird & Tatlock auto bench centrifuge) for 10 minutes to pellet cells. From this point, all 
solutions and cell pellets or suspensions were kept on ice. The DMEM was aspirated and cells 
resuspended in homogenising buffer plus the following protease inhibitors: leupeptin, pepstatin A, 
and phenylmethylsulfonyl fluoride (PMSF). Unless otherwise stated cells from one T75, or 3 T25 
flasks were homogenised in 1.0 ml buffer. The cell suspension was passed through 0.1 mm 
diameter capillary tubing 20 times, this process homogenised the cells by shearing. The 
homogenate was centrifuged at 100 g (Baird & Tatlock auto bench centrifuge) for 10 minutes to 
remove unbroken cells and nuclei, and then the supernatant was taken and centrifuged at 50,000 
g (Sorval T21) for 1 hour. The supernatant was collected and used as the soluble fraction, the 
pellet of membrane proteins was resuspended in half the original volume of homogenising buffer 
with inhibitors and used as the membrane fraction.
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The protein concentration of the sample was determined by a Bicinchoninic Acid (BCA) protein 
assay (see 2.5), and the samples mixed with an equal volume of sodium-dodecylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer before running on an acrylamide 
gel.
2.3 PREPARATION OF WHOLE CELL LYSATES
The cells were harvested from a T25 flask by either tapping the culture vessel (NT2N) or by 
scraping with glass beads (NT2). Centrifuging at 100 g (Baird and Tatlock auto bench centrifuge) 
pelleted the cells, and the supernatant was collected. The cell pellet was washed in 5 ml DMEM 
and re-centrifuged. The supernatant was aspirated and the cell pellet dissolved in TRIS buffered 
saline (TBS) containing 0.1% sodium-dodecylsulphate (SDS) (unless otherwise indicated the cells 
from 1 T25 flask were solubilised in 100 \i\ TBS). The samples were heated to 60°C for 10 
minutes and allowed to cool before Triton X-100 (Tx100) was added to a final concentration of 
0.8% to neutralise the SDS, and the protein concentration of the sample determined by a BCA 
protein assay (see 2.5). The sample was mixed with an equal volume of SDS-PAGE sample 
buffer before running on an acrylamide gel. For cells grown in a 12 well plate, the conditioned 
media was collected from each well and the cells washed with 1 ml DMEM. 100 \i\ TBS 
containing 0.1% SDS was added directly to each well. The resulting samples were then pooled 
and treated as above.
2.4 PREPARATION OF MEDIA SAMPLES
Cell cultures were washed with approximately 5 ml DMEM per T25 flask and fresh cDMEM added 
(3 ml per T25 flask for 24 hour collections, 5 ml per T25 for 7 day samples). Cells were incubated 
for the required length of time, then the conditioned media decanted into tubes and stored at 4°C.
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The samples were analysed by either SDS-PAGE (see 2.7) followed by western blotting (see 
2.10) or by immunoprecipitation (see 2.11) followed by SDS-PAGE and western blotting. Prior to 
analysis, the proteins in each sample were concentrated as follows. Samples comprising of 
conditioned cDMEM were concentrated by ammonium sulphate fractionation as described below 
(see 2.4.1). Conditioned Optimem samples could not be treated in this way, as the total protein 
concentration was too low, so they were concentrated by ultra-centrifugation (see 2.4.2). After 
concentration all samples were stored at -20°C.
Ammonium Sulphate Fractionation
Three hundred mg ammonium sulphate was added to 1 ml of media sample (Wertkin et at. 1993). 
This was mixed at room temperature for 1 hour, before being centrifuged at 600 g (Fisher 
Scientific force 7 microfuge) for 10 minutes. The supernatant was aspirated and the pellet 
resuspended in 100 pil TBS (resulting in a 10-fold concentration).
2.4.2 Ultra-Centrifugation
This was achieved using a centricon-10 (Amicon) with a 10 kDa molecular weight cut off point. 
Two ml of sample was added to the top chamber and spun at 5000 g (Sorval T21) until only 200 
jul remained (approximately 1 hour), resulting in a 10-fold concentration.
2.5 BCA PROTEIN ASSAY
2.5.1 Introduction
Measurement of protein concentration was based on the biuret reaction. The disadvantage of 
some methods (such as the Lowry method) is that they cannot be used in the presence of non­
ionic detergents and some buffer salts, which form insoluble precipitates with the Folin-Ciocalteau 
reagent. The BCA assay uses bicinchoninic acid to monitor the Cu1+formed during the biuret
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reaction. This can be used in the presence of 0.1 M TRIS or 1.0% SDS. (See Smith et al. 1985 
for a full table of interfering compounds).
2.5.2 Method
A kit was purchased from Sigma and the recommended protocol followed. BCA reagent was 
prepared by mixing bicinchoninic acid solution with 4% copper sulphate solution in the ratio 50:1. 
Serial dilutions of the unknown samples were prepared along with a range of bovine serum 
albumin (BSA) standards from 0 to 1.0 mg/ml. 10 of each sample or standard was added to 
three wells of a 96 well plate and 200 jul BCA reagent added. The plate was incubated at 37°C 
for 30 minutes, allowed to cool to room temperature, then the optical density read at 570 nm with 
a multiscan plate reader (Labsystems).
A standard curve was plotted using a linear regression and the protein concentrations of the 
unknown samples calculated using Microsoft Excel. BSA standards were prepared in all 
experimental solutions used (see Figures 2.1 and 2.2). All solutions, except sample buffer with 
dithiothreitol (DTT), gave linear results with the BSA standards, therefore standards were 
routinely prepared in the same solution as the sample to be tested.
2.6 PREPARATION OF MONKEY BRAIN EXTRACT
As monkey brain is a rich source of APP, and this APP shows high homology with human APP, 
samples of this material were used as positive controls during western blotting and 
immunoprecipitations. Frontal cortex of monkey (Macaca fasicularis) brain, previously stored at - 
20°C (source: University of Washington Primate Centre, Seattle, Washington), was homogenised 
in 10 volumes of homogenising buffer, with protease inhibitors added as previously described 
(see 2.2). The homogenate was centrifuged at 170 g (Baird & Tatlock auto bench centrifuge) for 
10 minutes to remove unbroken cells and nuclei, then the supernatant was taken and centrifuged
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at 50,000 g (Sorval T21) for 1 hour. The supernatant was collected and used as the soluble 
fraction, the pellet of membrane proteins was resuspended in half the original volume of 
homogenising buffer with inhibitors, and this was then used as the membrane fraction. These 
stocks were stored at -20°C.
2.7 SODIUM-DODECYLSULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE)
Samples were mixed with a buffer containing SDS and either 2-mercaptoethano! or DTT and 
heated to 90°C for 2 minutes to denature the proteins. The samples were then analysed on an 
acrylamide gel using the BioRad “mini-gel” system. All gels were 0.75 mm in thickness and 7.5% 
acrylamide, unless otherwise stated. Samples were loaded using either a 10 or 15 well comb. In 
the case of immunoprecipitation results or media samples 20 p\ total volume was loaded. 
Immunoprecipitation results gave insufficient sample to determine the protein concentration, and 
the different protein concentrations of cDMEM and Optimem media did not allow direct protein 
concentration comparison. For cell samples the protein concentration of the sample was 
determined and either 5 or 10 jj.g total protein loaded (as indicated in the results section). In initial 
experiments, cell samples were loaded using the same volume in each lane, without correcting 
for protein concentration. The protein concentration was determined after the gels were run, but 
unfortunately insufficient of the sample remained for the gels to be duplicated with protein loading 
corrected. The gel was run in a TRIS/glycine buffer at a constant voltage, usually 100 V.
(Adapted from Laemmli, 1970).
2.8 TRICINE GELS
The SDS-PAGE method of protein separation does not resolve proteins below 10 kDa molecular 
weight. To overcome this, a method using TRICINE in the running buffer was developed 
(Schagger and Von Jagow, 1987). Use of urea in the resolving gel instead of glycerol also
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improves the resolution of low molecular weight proteins. By this method it was possible to 
clearly separate proteins with molecular weights as low as 4 kDa. As before, proteins were 
denatured in sample buffer, before being analysed on a 12% acrylamide, 0.75 mm mini-gel. Gels 
were run at a constant voltage of 80 V, and the gel tank was placed in a bowl of ice to prevent 
overheating of the gel.
2.9 PROTEIN TRANSFER TO MEMBRANE
Proteins were transferred to a nitro-cellulose (0.45 ju pore size; Amersham) or polyvinylidene 
difluoride (PVDF) (Bio-Rad) membrane in 10 mM 3-[cyclohexylamino]-1-propanesulfonic acid 
(CAPS), 10% methanol, adjusted to pH 10.5 with sodium hydroxide (NaOH). (Adapted from 
Matsudaira, 1987).
2.9.1 Method
The gel was immersed in transfer buffer for about 5 minutes, as wasjhe membrane (PVDF was 
pre-wet in methanol before immersing in buffer). Gel and filter were sandwiched together, with a 
pre-wet piece of filter paper on either side, ensuring that all air bubbles were excluded. The 
resulting sandwich was surrounded with foam pads and placed in a BioRad mini-gel transfer 
apparatus, ensuring that the gel was closest to the cathode. A frozen cooling pack was inserted 
into the tank, and the tank filled with buffer. The protein transfer was run for 40-60 minutes at 0.2 
A constant current. After transfer the membrane was rinsed in TBS and stored in TBS at 4°C for 
up to 7 days, or wrapped in cling film and stored at -20°C.
2.10 WESTERN BLOTTING
2.10.1 Method
Membranes were blocked in blotto, a 5% solution of non-fat milk protein in TBS (see Appendix A), 
for 30 minutes at room temperature or overnight at 4°C. Blots were incubated with primary
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antibody for 2 hours at room temperature, washed with three 5 minute washes in TBS with added 
Tween-20 (TBS-Tw), and incubated with secondary antibody for a further hour. Blots were then 
washed with one 15 minute and two 5 minute with TBS-Tw, plus a final 5 minute wash with TBS 
(for enhanced chemiluminescence, ECL) or alkaline phosphatase (AP) buffer and developed. All 
antibodies were diluted in blotto. Primary antibody concentrations are indicated in results, 
secondary antibodies were used at a concentration of 1:2000 unless otherwise stated.
2.10.2 Development
Antibodies conjugated to horseradish peroxidase (HRP) were visualised using ECL (Amersham), 
with the reagents prepared according to the manufacturers’ instructions. Equal volumes of 
reagents 1 and 2 were mixed to give a final volume of 8 ml per blot. The blots were incubated in 
this solution for 5 minutes, before being transferred to a dark room where they were wrapped in 
cling film and exposed to x-ray film (X-OMAT, XAR-5, Kodak) for between 30 seconds and 30 
minutes. The film was then developed using standard protocols (Kodak).
Antibodies conjugated to AP were visualised with nitro blue tetrazolium (NBT) / bromo-chloro- 
indolyl phosphate (BCIP) in AP buffer. Equal volumes of NBT and BCIP solutions were mixed to 
a total volume of 5 ml per blot. This was then added to the blot and incubated for up to one hour, 
with fresh NBT/BCIP solution applied after 30 minutes if necessary.
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Table 2.1 Specificity And Source of Primary Antibodies Used in This
Thesis
Antibody Type Specificity
Full Length 
or Secreted 
Protein
Source
22C11 Mouse monoclonal APP695, APP751, 
APP770, APLP2
Both Boehringer
Mannheim
993** Rabbit polyclonal APP751, APP770 Both Produced in the lab
3B11 Mouse monoclonal APLP2 Both Kindly donated by 
M-T Webster
6E10 Mouse monoclonal APP695.APP751,
APP770
Secreted only Seneteck
EH4 Mouse monoclonal Designed to recognise 
APP695, APP751,
APP770
Secreted only Produced in the lab
FC8* Mouse monoclonal Designed to recognise 
APP695, APP751,
APP770
Secreted only Produced in the lab
HD11* Mouse monoclonal Designed to recognise 
APP695, APP751,
APP770
Both Produced in the lab
HE1* Mouse monoclonal Designed to recognise 
APP695, APP751,
APP770
Both Produced in the lab
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Table 2.1 (cont.) Specificity and Source of Primary Antibodies Used in
This Thesis
Antibody Type Specificity
Full Length 
or Secreted 
Protein
Source
1032** Rabbit polyclonal PA4 N/A Produced in the 
lab
58617** Rabbit polyclonal pA4 N/A Produced in the 
lab
58618** Rabbit polyclonal pA4 N/A Produced in the 
lab
6F/3D Mouse monoclonal PA4 N/A Produced in the 
lab
HSP70 Mouse monoclonal Constitutive and 
inducible forms of 
HSP70
N/A Sigma
* these antibodies were produced and characterised as part of the investigations carried out in 
this thesis, and are further discussed in Section 4.4.
** these antibodies were produced and characterised by Dr D Parkinson prior to the work carried 
out in this thesis
2.10.3 Determination of Molecular Weight
Pre-stained molecular weight markers (Sigma) were run on the SDS-PAGE I TRIS-TRICINE gels 
along with the samples. After western blotting the resulting x-ray film was lined up with the 
original nitro-cellulose or PVDF membrane and scanned (Umax Astra 1200S) into the Kodak
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Digital Science 1D imaging program. Based on the mobility of the pre-stained standards, the 
program calculated the molecular weight of bands obtained by western blotting. The pre-stained 
markers used are detailed in Tables 2.3 and 2.4.
Table 2.3 Details of Secondary Antibodies Used in This Thesis
Antibody Conjugate Host Animal Source
Anti-Mouse IgG . Alkaline Phosphatase Goat SigmaO
Anti-Mouse IgG Horseradish Peroxidase Sheep Boehringer Mannheim
Anti-Rabbit IgG Horseradish Peroxidase Sheep Boehringer Mannheim
Table 2.2 Pre-stained Molecular Weight Markers 
Used For SDS-PAGE
Protein Molecular Weight (kDa)
Triosephosphate Isomerase 26.6
Lactic Dehydrogenase 36.5
Ovalbumin 45.0
Pyruvate Kinase 58.0
Fructose-6-phosphate Kinase 84.0
p-Galatosidase 116.0
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Table 2.4 Pre-stained Molecular Weight Markers 
Used For TRIS-TRICINE Gels
Polypeptide Molecular Weight (kDa)
Triosephosphate Isomerase 26.6
Myoglobin 17.0
a-Lactalbumin 14.2
Aprotinin 6.5
Insulin Chain B, Oxidised 
<
3.5
Bradykinin 1.1
2.11 IMMUNOPRECJPnATJONS
2.11.1 Introduction
Using immunoprecipitation it is possible to selectively concentrate a specific protein from a 
mixture. This has a threefold benefit; it can be used to concentrate a protein which is at a very 
low concentration; to pick out one particular protein from a sample which contains a high total 
protein concentration; or to separate one protein from a sample which contains many proteins of 
similar molecular weight to the protein of interest.
Primary antibody is added to the sample, which binds to the protein of interest. Agarose beads 
with specific proteins bonded to them are then added. The proteins on the beads bind to the 
antibody in the antibody-antigen complex. Centrifugation is used to pellet the beads, bringing the 
antibody-antigen complex with them. The supernatant is aspirated and the proteins eluted from 
the beads in SDS-PAGE sample buffer, prior to analysis.
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There are several different agarose beads available for this procedure, each with a different 
protein bound to them, and tests were earned out to determine which type of bead was best for 
each antibody. In the case of rabbit antibodies agarose beads bound to protein A were used. 
Several different beads were tested for mouse antibodies including protein.A, protein G and goat- 
anti-mouse-IgG .antibodies. Protein A did not bind the mouse antibodies, while both protein G and 
thej3Qat-anti-mQus.e-lgG beads_did bind. However when samples recovered using protein G were 
analysed on a western blot proteins bands could not be distinguished due to smearing of the 
sample. (See Figure 2.3) This was found to be related to the secondary antibody used in the 
immunoblot and presumably was due to some protein G remaining in the sample and non- 
specifically binding to the secondary antibody. Therefore protein A beads were used for rabbit 
antibodies, and goat-anti-mouse-IgG beads for mouse antibodies.
2.11.2 Method
Samples were diluted in immunoprecipitation buffer if necessary. Unless otherwise stated, all 
samples were denatured withJM% S ^  The sample was
then cooled, centrifuged at 600 g (Fisher Scientific Force 7 microfuge) and Tx100 was added to 
0.8%, volume/volume. The sample was then vortexed and the centrifugation repeated. Media 
samples were buffered with TRIS.HCI pH 7.4 to a final concentration of 15 mM. Primary antibody 
was added at concentrations stated and samples were mixed at room temperature for 2hours. 50 
jliI of the appropriate agarose bead slurry (diluted to 50% with dH20) was added and the samples 
mixed for a further hour.
Tubes were centrifuged at 2000 rpm (Baird & Tatlock auto bench centrifuge) for 5 minutes and 
supernatant aspirated. OnejnLsLXBS was added, and the tubes were mixed for 5 minutes to
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wash the beads. The tubes were then re-centrifuged, the supernatant aspirated, and the beads 
eluted with SDS-PAGE sample buffer. Immunoprecipitates from 1 ml of initial media or cell
|  annwwi" imnrnii .
sample were eluted in 100 jal of Ix^SD^PAGE sample buffer, resulting in a 10x concentration.
2.12 SERIAL IMMUNOPRECIPITA TIONS
2.12.1 Introduction
When using monoclonal antibodies to analyse a protein sample it is important to be aware of any 
cross-reactivity of the antibody. This can either be between different isoforms of the same 
protein, or between two or more similar proteins. While this can be overcome by using a different 
antibody for each protein or isoform this is not always possible due to experimental and financial 
constraints. One way to overcome the problem is to use a series of immunoprecipitation steps to 
clear any unwanted proteins from the sample, then analysing the remaining proteins of interest. 
For example, most commercially ,available_antibodies ito.APP also react with, APLP2 (Slunt et al. 
j1994]i,jyvhich could give misleading results. To overcome this problem an antibody (3B11, 
Webster et al. 1995) which is specific for APLP2 was obtained. Using serial 
immunoprecipitations media samples were first cleared of APLP2 using 3B11, following which 
immunoprecipitation steps with the commercial APP antibodies that would yield only APP, were 
carried out.
In a similar way, serial immunoprecipitations can be used to separate different isoforms of a 
protein, or different cleavage products of a full-length precursor protein.
2.12.2 Method
The initial method follows that of standard immunoprecipitations with the sample and antibody 
being incubated for 1 hour at room temperature. However, after pelleting beads the supernatant
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was decanted into a clean tube and a further antibody added. The beads were washed and 
eluted as previously, while the second antibody incubated with the sample. This process was 
repeated as above for each antibody step.
2.13 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
ELISAs were used to test the specificity of monoclonal antibodies. Ninety-six well plates (Nunc 
Maxisorb, flat bottomed wells) were prepared by adding to each well 100 jul of a 5 jug / ml solution 
of the peptide antigen or BSA in phosphate buffered saline (PBS) (resulting in 500 ng of peptide 
per well). The plate was incubated at 37°C for 1 hour then washed 3 times with dhbO. The plate 
was blocked with 100 jul per well of a 1 mg I ml solution of BSA in PBS, incubated at room 
temperature for 1 hour.
Cell culture supernatants containing the monoclonal antibodies to be tested were mixed with an 
equal volume of 1 mg I ml BSA in PBS and 100 jul of this solution added to each appropriate well, 
at least 3 wells were used for each peptide I antibody combination. The plate was incubated at 
room temperature for 2 hours, then washed 3 times with TBS.
A 1:2000 dilution of goat anti-mouse IgG conjugated to alkaline phosphatase (Sigma) was 
prepared in 1 mg I ml BSA in TBS and 100 jul added to each well. The plate was incubated at 
room temperature for 1 hour, then washed 3 times with TBS. 10 mM p-nitrophenyl phosphate 
was prepared in AP buffer, and 100 \x\ per well added to the plate. After 15 minutes the reaction 
was stopped with 100 jul per well 2 M sodium hydroxide, and the optical density of each well read 
on a plate reader at 405 nm. The results were analysed using Microsoft Excel.
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2.14 ANTIBODY CONCENTRATION ON A PROTEIN G COLUMN
1 ml of protein G bound agarose beads was added to a 0.7 cm diameter disposable mini-column 
(Bio-Rad). 5 ml binding buffer was added and pumped through to pack the beads. Hybridoma 
supernatant containing the antibody was then pumped through the column at a flow rate of 0.5 ml 
I min. The beads were washed with 5 ml binding buffer, then eluted with 0.1 M glycine pH 2.6. 1 
ml fractions were collected and immediately neutralised with 250 jul 0.5 M TRIS pH 8. The 
antibody containing fraction was identified by determining the optical density at 260 and 280 nm 
using a Genequant II. The protein concentration of the fraction was also calculated at this time.
2.15 IN SITU HYBRIDISATION
2.15.1 Fixation of Cells
NT2 and NT2N cells were grown on coverslips, pre-coated with poly-D-lysine and Matrigel in the 
case of NT2N cells (see Section 2.1.3). Cells were incubated with cDMEM or Optimem (1 ml per 
coverslip) for 24 hours, then washed in DMEM and fixed by immersion in chilled (-20°C) acetone 
for 5 minutes. The coverslips were allowed to air dry before being mounted onto glass 
microscope slides ready for in situ hybridisation.
2.15.2 Labelling of Oligonucleotide Probes
All probes used have been previously shown by the Pearson lab to be specific for the mRNA 
required (see Table 2.5 for sequences and specificity). The method is based on that described by 
Heath et al. 1996. The oligonucleotide probes were 3’ tail labelled with [35S] dATP using a 
commercially available kit (NEN/DuPont oligonucleotide 3’ labelling system). Radiolabelled probe 
was separated from any unincorporated nucleotides by chromatography using a nucleic acid 
purification cartridge (“NENSORB”, NEN/DuPont). The amount of radioactivity incorporated into 
the probe was measure on a scintillation counter, and the volume of probe containing 106 counts
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per minute was calculated. Mr M Sanders carried out this work; the author performed all other 
procedures.
Table 2.5 Probe Sequences
Probe Length Sequence Reference Ti Tw
APPeg
5
30 5’ CTG CTG TTG TAG GAA 
CTCGAA CCACCT CCT 3’
(Ponte et al. 
1988)
27°C 52.5°C
APP75
1
60 5’ CAT CAG GGGTAC TGG 
CTG CTG TTG TAG GAA TGG 
CGC TGCCACACA CGG CCA 
TGC AGT ACT 3’
(Kitaguchi et 
al. 1988)
41.6°C 54.4°C
APP77
0
57 5' GTT TAA CAG GAT CTC 
GGG CAA GAG GTT CCT GGG 
TAG TCT TGAAAC TTT GGG 
ACA 3’
(Kitaguchi et 
al. 1988)
33.6°C 56.1°C
HSP 30 5’ CGA TCT CCTTCA TCT 
TGG TCAGCA CCA TGG 3’
(Shimizu et 
al. 1999)
28°C 54°C
2.15.3 In Situ Hybridisation Procedure
The slides to be hybridised were placed on sheets of chromatography paper soaked in 4x 
standard sodium citrate (SSC) buffer. Labelled probe was mixed with hybridisation buffer to give 
106 counts in 100 jul and this volume was applied to each slide. Slides were then incubated at 
the optimum incubation temperature (Tj) for each probe (see Table 2.6} overnight.
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Table 2.6 Washing Temperatures for 
Oligonucleotide Probes
Probe Length
(bases)
Ti Tw
APP695 30 27°C 52.5°C
APP751 60 41.6°C 54.4°C
APP770 57 33.6°C 56.1 °C
HSP 30 28°C 54°C
Tj - incubation temperature 
Tw-washing temperature
APP - Amyloid Precursor Protein 
HSP - Heat Shock Protein
Slides were then washed in 1x SSC at room temperature, followed by four 15 minute washes in 
1x SSC at the optimum washing temperature (Tw) for each probe (see Table 2.4). This was 
followed by a wash in 1x SSC at room temperature for 1 hour and a final rinse in dbfeO. Slides 
were allowed to air dry.
2.15.4 Autoradiography
Slides were dipped in Ilford photographic emulsion to examine cellular distribution of mRNA. 
Slides were dipped in liquid emulsion at 40°C, placed on a cold plate for 15 minutes to allow the 
emulsion to gel, then allowed to air dry for 3-4 hours. The slides were placed in lightproof boxes 
and placed at 4°C for an exposure time of 7 weeks. All the above procedures were carried out in 
the dark.
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2.*/5.5 Development and Quantification.
Slides were developed in Phenisol for 2 minutes, washed in 2% acetic acid for 30 seconds, fixed 
in 30% sodium thiosulphate for 5 minutes and rinsed in running water for 20 minutes. They were 
allowed to air dry before being counterstained with 0.1% Cresyl fast violet for 1 minute and 
washed in distilled water. The slide were then dehydrated in serial alcohols (70%, 80%, 90% and 
100% -1 minute in each) before clearing in xylene for at least 5 minutes and mounted with DPX
Image analysis was performed using a Seescan image analyser system (Seescan Instruments, 
Cambridge). Individual cells were highlighted and the total area of the cell calculated, along with 
the area covered with silver grains. The mean size of grain was measured, allowing the mean 
number of grains per cell to be calculated. Fifty randomly selected cells were counted for each 
experimental procedure and probe. The background level of grains was calculated by counting 
grains over 5, randomly selected and non-cell containing, areas of each slide equivalent in size to 
the average cell size for that slide. These counts were averaged, and subtracted from cell grain 
counts for each slide. The non-parametric Mann Whitney U test was used to compare the mean 
number of grains per cell for each probe (Levene’s test for equality of variance showed the results 
to have a non-normal distribution).
Photographs of the stained cells were taken using an Olympus BX60 microscope and the x40 
objective lens. Images were captured using a JVC 3CCD colour video camera and Neotech 
Image Grabber PC software.
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Figure 2.1 DITHIOTHREITOL (DTT) SAMPLE BUFFER INTERFERES WITH 
A BCA PROTEIN ASSAY
E ffect of DTT on a BCA P ro te in  A ssa y
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BSA standards were prepared in either dH20 or DTT sample buffer diluted 1:10 or 1:20 with 
dhhO. A BCA protein assay was carried out as described. BSA in dH20 gives a linear result with 
increasing concentrations, while even the 1:20 dilution of DTT buffer gives very erratic readings.
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Figure 2.2 BCA PROTEIN ASSAYS CAN BE CARRIED OUT IN THE 
PRESENCE OF SDS/TX100 OR HOMOGENISING BUFFER
E ffect o f D e te rg en ts  on a BCA P ro te in  A ssa y0.350
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-A—0.2% SDS /1.6% 7X100 
—  Homogenising Buffer
BSA standards were prepared in either d ^O , SDS 17X100 or homogenising buffer, at 
concentrations used in preparation of cell samples. A BCA protein assay was carried out as 
described. All solutions give linear results with increasing concentrations of BSA.
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Figure 2.3 COMPARISON OF EFFECTIVENESS OF PROTEIN A, PROTEIN 
G AND GOAT-ANTI-MOUSE-IgG BEADS AT RECOVERING MOUSE IgG
Monoclonal antibody 22C11 or TBS was added to 0.5 ml TBS, and recovered with agarose beads 
bound to the appropriate protein. The samples were analysed on a 7.5% acrylamide gel and 
transferred to nitro-cellulose membrane. The membrane was then immunoblotted using a HRP- 
conjugated anti-mouse IgG secondary antibody only. The blot was developed using ECL.
Lane 1 22C11 and goat-anti-mouse-IgG beads
Lane 2 goat-anti-mouse-IgG beads only
Lane 3 22C11 and Protein G beads
Lane 4 Protein G beads only
Lane 5 22C11 and Protein A beads
Lane 6 Protein A beads only
Figures to the right of the blot indicate the mobility of molecular weight markers.
As can be seen in lanes 3 and 4, the use of Protein G beads leads to smearing of the 
immunoblot, even after no immunoprecipitation has occurred.
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Chapter Three - Production Of NTera2 Neurones
3.1 INTRODUCTION
3.1.1 NTera2-Clone D1
The Tera2 cell line was derived from a lung metastasis of a 22 year old Caucasian man with a 
primary testicular germ cell tumour. Low passage Tera2 cells (first characterised in Andrews et 
al. 1984) exhibit a modal 61,XY karyotype with a range of 59 to 63 chromosomes. They contain 
single, normal X and Y chromosomes, and are disomic for chromosomes 4,5,6,8,10,13,14,
15,18 and 19. They are trisomic for chromosomes 3,7,9 and 11, while 80% of the cells are 
trisomic for chromosomes 20,21 and 22 and 60% trisomic for chromosome 16.
The NTera2 cell line was cloned from these cells and exhibits a similar karyotype. Specifically, 
clone NTera2/D1 (NT2/D1) has a modal 63,XY karyotype, (range 54-63) and exhibits many of the 
morphologic and biochemical features of other established human embryonal carcinoma (EC) cell 
lines. NTera2 (NT2) cells do not resemble Tera2 cultures and probably arose from a minor 
population of EC cells. When injected into athymic mice NT2/D1 cells form tumours containing a 
variety of somatic tissues including neural elements. In vitro the cells must be maintained at high 
density to maintain their EC characteristics. (Andrews et a!. 1984)
3.1.2 Differentiation Of NT2JD1 Cells
Like many murine EC cell lines, NT2/D1 cells are pluripotent (Andrews etal. 1984). When 
treated with 10-5 M all-trans-retinoic-acid (RA) for seven days, immunoreactivity of an embryonal 
cell surface marker, SSEA-3, decreases (Andrews, 1984). After one day of RA treatment, 
followed by replating, most cells undergo morphological differentiation. After seven days less
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than 20% of cells are SSEA-3 positive. Among the differentiated cells is a population which 
exhibit a neurone-like morphology. Treatment with RA for as few as 7 days is enough to induce 
the presence of these cells, though the cells must be cultured for a further 7-14 days before the 
neuronal precursor cells are evident. (Andrews, 1984) Although several other compounds can 
induce this differentiation, none are as effective as RA at non-cytotoxic concentrations (Andrews 
et al. 1986). Unlike the EC stem cells and other differentiated cells, these neurone-like cells react 
with tetanus toxin and exhibit the presence of neurofilament 200 by immunoreactivity (Andrews, 
1984). Furthermore, after 2 weeks of RA treatment, the neurone-like cells express all three 
classes of neurofilament protein, and do not express vimentin filaments (found in some neurones, 
glial and other cells) or glial filaments. Although NT2 stem cells express cytokeratin filament (an 
EC cell intermediate filament) the neurone-like cells do not (Lee and Andrews, 1986).
3.1.3 NT2N Cells Appear To Be Embryonic CNS Neurones
Pure cultures of the neurone-like cells (NT2N cells) can be obtained by selective replating and 
treatment of cultures with mitotic inhibitors (see 3.2; Pleasure et al. 1992). These pure cultures 
have been extensively studied in an attempt to characterise them. The cells are motile, clumping 
together to form cellular aggregates, and are post-mitotic. They do not incorporate 
bromodeoxyuridine, and are not affected by mitotic inhibitors. Using immunocytochemistry, it has 
been shown that NT2N cells express several neurone specific markers, summarised in Table 3.1. 
Most of the proteins listed are expressed in embryonic forms or levels.
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Table 3.1 Neuronal Markers Expressed By NT2N Cells 
(adapted from Pleasure et al. 1992)
Neuronal marker Function Expressed by 
NT2N cells
NF-L Neurofilament sub-units ✓
NF-M ✓
NF-H ✓
NF-66 CNS specific neurofilament sub-unit ✓
peripherin PNS specific neurofilament sub-unit X
MAP1A Cytoskeletal proteins ✓
MAP1B ✓
MAP2 ✓
Tau ✓
110 kDa tau isoform PNS specific X
NCAM Neuronal cell adhesion molecule ✓
GAP-43 Growth associated protein, found in 
growth cones
✓
Synaptophysin Markers for secretory activity ✓
Chromogranin ✓
NF-L, NF-M, NF-H, NF-66 - Neurofilament protein L, M, H, 66 
MAPI A, MAP1B, MAP2 - Microtubule Associated Protein 1A, 1B,2 
NCAM - Neuronal Cell Adhesion Molecule 
GAP-43 - Growth Associated Protein 43
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NT2N cells exhibit a neurone-like morphology, elaborating processes which fall into two classes: 
ones that are thick at the base and taper progressively from the cell body, and a second which 
are thin and untapering. The distribution of cytoskeletal elements confirms that these are 
dendrites and axons, respectively (Pleasure et al. 1992).
3.1.4 NT2N Cells Express Functional Neurotransmitter Receptors
NT2N cells express at least two types of glutamate receptor, /V-methyl-D-aspartate (NMDA) and 
a-amino-3-hydroxy-5-methylisoxazole-4-propionate I kainate (AMPA/kainate or non-NMDA) 
receptors (Younkin et al. 1993). Patch-clamping experiments show that both of these receptors 
respond to glutamate, and this response can be abolished by application of a combination of 
NMDA and non-NMDA antagonists. NT2N cells also exhibit glutamate excitotoxicity; 1 mM 
glutamate added to the culture media for 15 minutes compromises membrane integrity and 
impairs mitochondrial function of 6  week old NT2N cell cultures. It has no effect on NT2 stem 
cells or 2 week old neuronal cultures (Younkin et al. 1993).
There is some evidence that NT2N cell cultures contain at least 20% cholinergic neurones (Zeller 
and Strauss, 1995). NT2N cells express muscarinic acetylcholine receptors, primarily the m3 
subtype, which is linked to the phospholipase C signal transduction pathway. They also contain 
all the elements of the muscarinic / phospholipase C signal transduction pathway, and it has been 
shown that in response to the agonist carbachol, 1,2-diacyl-sn-glycerol (DAG), /nyo-inositoM ,4,5- 
trisphophate (lns(1 ,4 ,5 )P3) and intracellular calcium (Ca2+) levels all rise (Wolf et al. 1995).
3.1.5 NTera2 Cells Produce APP
As a consequence of being trisomic for chromosome 21, NT2 and NT2N cells produce readily 
detectable quantities of APP (Wertkin et al. 1993). There is a change in APP expression after
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NT2 cells are induced to differentiate into the neuronal phenotype, with NT2 stem cells 
expressing predominantly APP751 and APP770, while the NT2N cells express predominantly 
APP695 (Ackerman et al. 1994; Wertkin et al. 1993).
3.1.6 Summary of Introduction
In summary, NT2N cells are post-mitotic and exhibit a neuronal morphology with axons and 
dendrites. They have receptors that respond to neurotransmitters, and the proteins expressed 
indicate that the cells most closely resemble embryonic CNS neurones. Since the cells are 
human in origin, they potentially provide a good model for studying normal neuronal function, and 
also processes leading to neurodegenerative diseases. Naturally, obtaining pure cultures of 
these cells is of paramount importance. The work discussed in this chapter describes different 
techniques tried in order to produce the highest yield of pure neurones after RA differentiation.
3.2 CELL CULTURE METHODS
The cell culture methods used and the results obtained will be presented in combination.
3.2.1 Maintenance of Stem Cell Cultures
Stem cell cultures of NT2 cells were maintained as described in Section 2.1.
3.2.2 Neuronal Differentiation and Purification
3.2.2.1 Differentiation (See Figure 3.1)
Prof. Peter Andrews of Sheffield University (adapted from Pleasure et al. 1992) recommended the 
initial method used for neuronal purification. The procedure is detailed in full in Appendix C. In 
brief, cells were seeded at a density of 106 cells per T75 and fed with 10-5 M RA for 24 days. On 
day 25 the cells were split into media without RA to allow neurone precursor cells to settle on the 
top of the cell layer (replate #1). On the next 2 days the cell cultures were treated with TE to
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remove selectively these precursor cells (replates #2 and #3). The precursors were replated at a 
density of approximately 6 x 106 cells per T25 flask and fed with cDMEM containing mitotic 
inhibitors (1 piM cytosine arabinoside, 10 juM fluorodeoxyuridine and 10 piM uridine).
Figure 3.1 Original Protocol For Obtaining Neuronal Cultures
Feed with cDMEM containing mitotic inhibitors twice weekly
Feed with 10 p MRA twice weekly for 23 days
Cultures fed with cDMEM
Replate #1 (day 24) - cells are split 1:2
1 million NT2 cells seeded per T75
Replate #2 (day 25)
Use trypsin to selectively remove neurone precursor cells 
Seed at approximately 6 million cells per T25
Replate #3 (day 26)
Use trypsin to selectively remove neurone precursor cells 
Seed at approximately 6 million cells per T25
3.2.2.2 Purification
Although the selective replating of neuronal precursors provided enriched cultures of NT2N cells, 
there were also other cells present. These cells did not resemble NT2 stem cells, being much 
larger, and formed a monolayer beneath the neuronal cells. The neuronal precursors migrated 
across this monolayer to form cell aggregates. After 7-10 days in culture, multiple processes 
could be seen interconnecting these cell clusters. Some of these processes also appeared to be 
forming connections with the non-neuronal monolayer (see Figure 3.2).
Treatment with mitotic inhibitors was continued until all the non-neuronal cells died, leaving only 
the mature NT2N cells. Cultures were used as neurones when judged pure by eye; several fields
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per flask were viewed at x10 magnification with a phase contrast microscope, if no non-neuronal 
cells were seen the cultures were assumed pure. This purification step could take several weeks, 
and varied greatly from batch to batch of cultures, with some cultures reaching a pure state in 7- 
10 days, while other cultures contained contaminating cells for up to 4 weeks. It was also 
problematic, as the NT2N cells did not survive for more then a few days when the cultures were 
pure, tending to detach from the culture vessel, and so had to be used immediately. To try and 
improve the rate of purification, and of neuronal survival, several alternative methods were tried.
3.2.3 Alternative Methods
3.2.3.1 Increased Neuronal Survival Rate.
Other sources have reported the influence of non-neuronal cells on neurone survival rate 
(Pleasure et al. 1992). Following the protocol laid out in this paper for pre-treating culture flasks 
before seeding out neurone precursors was found greatly to improve the length of time neurone 
cultures could be kept. Flasks were treated with one coat of poly-D-lysine and two coats of 
Matrigel (see Section 2.1.3 for details). This encouraged neurite outgrowth, and also prolonged 
the survival of contaminating non-neuronal cells.
3.2.3.2 Increased Levels of Neuronal Purification
After replate #1, neuronal precursor cells could be seen as phase bright cells lying on top of 
multiple layers of smaller cells. Although the aim of replates #2 and #3 was to remove as many 
of the neuronal precursors as possible, complete removal was never achieved. If the remaining 
cells were continued in culture, fed with cDMEM, maturation of the NT2N cells took place. As in 
pure cultures the cells formed aggregates and elaborated processes, but due to the lack of mitotic 
inhibitors these neuronal cells were quickly overgrown by non-neuronal ones. To combat this, 
mitotic inhibitors were added to the media immediately after replate #1. This prevented NT2N
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cells being overgrown by contaminating ones, while allowing them to mature and elaborate 
processes.
After 2 weeks culture in the presence of mitotic inhibitors, the NT2N cells had formed cellular 
aggregates and processes, and were loosely attached to a monolayer of non-neuronal cells. 
Tapping of the culture vessel was sufficient to remove selectively the neurones, which were then 
replated into flasks pre-treated with poly-D-lysine and Matrigel and fed with cDMEM. After 3 to 5 
days in culture the neurones had adhered to the vessel and recommenced neurite outgrowth.
The cells were ready to use after 7 to 10 days in culture and could be maintained for 2 to 3 
months. The level of purity of cultures obtained by this level was much higher than other methods 
(compare neurones in Figure 3.2a with those in Figure 3.3), though on occasion contaminating 
cells were still present. The removal of these was attempted by reintroducing 10 juM 
fluorodeoxyuridine and 10 jiM uridine, but this had the effect of killing all cells in culture, so 
impure cultures were discarded.
3.2.3.3 Improved Neuronal Yield
To maximise neuronal yield and replate efficiency, RA cultures were split at different densities at 
replate #1, from 1:1 to 1:6. The purpose of this split was to allow neuronal precursors to settle on 
top of the other cells present. It was postulated that a split to a lower cell density would allow a 
greater number of precursors to migrate and therefore increase the neuronal yield.
As expected splits of 1:1 and 1:2 resulted in a higher number of non-neuronal cells which 
decreased the replate efficiency of neurones. However, splits of 1:5 or 1:6 resulted in decreased 
neuronal survival rate. Therefore a split of 1:3 was chosen as the most efficient for both neurone 
survival and replate ability (see Figure 3.4).
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The refined method of neuronal differentiation and purification which was adopted for subsequent 
studies is outlined in Table 3.2 below, and detailed in Appendix B.
Table 3.2 Improved Protocol for Neuronal Differentiation
Day Procedure Culture Media
0 Split a confluent T25 flask of stem cells 1:10 cDMEM with 10-5 M RA
7,14, 21 Feed cells cDMEM with 10-5 MRA
24 Split cells 1:3 cDMEM with mitotic 
inhibitors (cDMEM+l)
28 Feed cells cDMEM+l
31 Feed cells cDMEM
35 Feed cells cDMEM
38 Mechanically dislodge neuronal cells and 
replate onto culture vessels coated with 
poly-D-lysine and Matrigel
cDMEM
Every 7 
days
Feed neuronal cells cDMEM
3.3 SUMMARY
If NT2N cells in vitro are to be used as a model for human CNS neurones in vivo, standard 
methods of differentiation and purification are essential. As has been reported previously, 
differentiation of NT2 cells to NT2N cells using RA is a terminal differentiation; NT2N cells 
maintain their neuronal morphology for many months in culture in the absence of RA. However, it 
is not known if the length of time cells are cultured in RA affects the eventual phenotype. Seven 
days is enough to result in eventual neuronal characteristics (Andrews, 1984), though published
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protocols use 21-28 days culture with RA (Prof. Andrews personal communication; Pleasure et 
ai. 1992). NT2N cells developed this way have been characterised for many neuronal markers 
(Wolf et al. 1995; Ackerman et al. 1994; Younkin et al. 1993; Pleasure et al. 1992; Lee and 
Andrews, 1986) and appear to be embryonic CNS neurones, but it is vital to remember that these 
are cultures derived from a tumour cell line, not primary neuronal cultures. Variable neuronal 
phenotype may occur due to the variable karyotype of the NT2 stem cells. Culture conditions of 
the NT2 stem cells must be rigorously monitored to prevent spontaneous differentiation, which 
may also lead to variable neuronal phenotype. An awareness of the effect of the concentration of 
RA and the length of time it is present in the culture is also important. To ensure that results 
obtained from NT2N cells are comparable to those expected from in vivo studies, a consistent 
method for preparing the cultures should be used.
Similarly the purity of the NT2N cell cultures is of utmost importance. Though NT2 and NT2N 
cells have been extensively studied, little work has been done on the phenotype of the non­
neuronal or “background” cells present in NT2N cultures. As discussed in this chapter and 
elsewhere (Pleasure et al. 1992), these cells promote the survival of neurones, and so can be 
assumed to provide support, either nutritional, biochemical or mechanical, to the neuronal cells. 
During the course of this work, it was discovered that these cells also secrete some proteins 
(specifically APP, discussed further in Chapter 4). In view of this fact, if NT2N cells are to be 
used in biochemical secretion or metabolism studies, the presence of non-neuronal cells must be 
eliminated to prevent confounding of the results.
The work presented in this chapter describes an improved protocol for the differentiation and 
purification of NT2N cells from NT2 stem cells. This method ensures that all NT2N cells will be 
comparable in terms of RA effects, and by eliminating all trace of non-neuronal cells it is possible
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to be confident that the results obtained are from a cell which is the closest model of a human 
CNS neurone available at the present time.
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Figure 3.2 NT2 STEM CELLS AND NEURONAL CELLS
(a) NT2 stem cells, passage 36. Magnification x100.
Cells form a continuous monolayer.
Cells were maintained in cDMEM, and split 1:3 when confluent using scraping.
(b) NT2N cells, purified using the initial method recommended by Prof. Andrews. 
Magnification x1000.
The neuronal cell bodies form phase bright aggregates. They can be seen to be sitting on top of 
a monolayer of non-neuronal cells, which are not NT2 stem cells. The neuronal cells have 
elaborated processes that seem to connect with both the cell types present.
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Figure 3.3 INCREASED PURIFICATION LEVELS ARE OBTAINED BY  
ALTERING THE PROTOCOL USED FOR REPLATING THE NEURONAL 
PRECURSOR CELLS
By allowing the neuronal precursors to mature before replating onto plastic coated with poly-D- 
lysine and Matrigel it is possible to replate only NT2N cells, resulting in an absence of background 
cells. As previously, the cell bodies form phase bright aggregates and elaborate processes which 
interconnect with each other and with these aggregates. The cultures shown are all from different 
batches of neurones, as can be seen the level of purification is the same for each, the only 
difference is in the size of the cell body aggregates. The cultures shown are also representative 
of cells after different lengths of time in culture.
(a) batch 010497P35 (after 2 weeks in culture)
(b) batch 240397P44 (after 3 weeks in culture)
(c) batch 130297P38 (after 9 weeks in culture)
All photographs are at x1000 magnification.
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Figure 3.4 EFFECT OF SPLIT RATIO ON RA-TREATED NT2 CELLS
Cells were treated with RA for 25 days, then split using TE and cultured in the presence of mitotic 
inhibitors for 10 days. The neuronal precursor cells can be seen as small phase bright cells on 
the top of the other cellular layers (examples indicated by arrowheads). They have already begun 
to elaborate processes. Magnification x500.
(a) 1:2 split
(b) 1:3 split
(c) 1:4 split
(d) 1:5 split
(e) 1:6 split
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Chapter Four - Characterisation Of APP Production 
And Processing In NTera2 Stem Cells And Neurones
4.1 INTRODUCTION
As discussed in Chapter 3, NT2 and NT2N cells potentially provide a valuable system for 
investigating human neurodegenerative diseases. The stem cells are easy to maintain in large 
numbers in culture, while the neuronal cells are one of the best models of human CNS neurones 
currently available for in vitro research. They have an additional advantage for researchers 
wishing to study AD, as a result of being trisomic for chromosome 21 (Andrews et ai. 1984). Both 
NT2 and NT2N cells produce an easily detectable amount of endogenous APP (Wertkin et al. 
1993).
APP production and processing was studied in both cell types, to obtain an understanding of 
what changes in processing of APP may accompany neuronal differentiation. APP has previously 
been studied in NT2 and NT2N cells at both the mRNA and the protein level. However there is 
some inconsistency in the results. RT-PCR studies have shown that both cell types contain all 
three APP isoforms, but that NT2N cells contain predominantly APP695 mRNA, while stem cells 
contain predominantly APP751 and APP770 mRNA (Ackerman etal. 1994; Wertkin etal. 1993).
PCR studies of cDNA libraries produced from the cells found APP695 in both libraries, while 
APP770 existed solely in the stem cell library and APP751 solely in the neuronal library (Ackerman 
etal. 1994).
Protein studies on cell lysates have shown NT2 cells to contain predominantly APP751 and I or 
APP770, with a trace of APP695 while the neuronal cells contain only APP695 (Wertkin et al. 1993).
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The same study reported that NT2  cells secrete APP751/770 while NT2 N cells secrete only APPegs, 
though two bands were present on the immunoblot, the larger one was attributed to APP 
secretion from contaminating cells. However, these results may be misleading, as the study 
concerned used only the monoclonal antibody LN2 1 , which recognises all isoforms of APP and 
which may also cross react with APLP2 . Identification of APP isoforms was based on size alone, 
which could be problematic as immature and fully glycosylated forms of APP run at different sizes 
on a gel, with mature APP695 being the same weight as immature APP751 and APP770. Another 
reason for these apparently contradictory results could be due to spontaneous differentiation of 
stem cells due to alterations in culturing conditions, leading to a variation in neuronal phenotype.
APP isoforms expressed by NT2 and NT2N cells grown in this laboratory were analysed using 
immunoblotting. A number of antibodies were used to distinguish between the different isoforms 
of APP, as well as APLP2. Intracellular and secreted proteins were examined in both cell types. 
Once the expression pattern of APP in the cells was established, processing pathways were 
examined, to investigate any differences in amyloidogenic and non-amyloidogenic processing 
between stem cells and neurones.
4.2 METHODS
4.2.1 APP Production and Secretion
NT2 and NT2N cells were cultured as described in Chapters 2 and 3. For each experiment, one 
T75 flask of each cell type was incubated with 12 ml fresh culture media for 24 hours, then the 
conditioned media was collected and concentrated using ammonium sulphate fractionation. Cell 
pellets were collected, resuspended in 250 jul homogenising buffer with protease inhibitors and 
homogenised to give soluble and membrane protein fractions as described. Samples were
70
Chapter Four - Characterisation Of APP Production And Processing In NTera2 Stem Cells And 
____________________________________________________ Neurones
separated on a 7% SDS-PAGE gel and transferred to nitro-cellulose membrane prior to analysis 
by western blotting.
4.2.2 Antibodies
Samples were examined by immunoblotting with several antibodies as detailed in Table 4.1. The 
antibodies were used at the concentrations or dilutions indicated in Table 4.4 and incubated at 
room temperature for 2 hours. The blots were then incubated with HRP-conjugated secondary
Table 4.1 Antibodies Used In Immunoblotting
Antibody Type Epitope
APP isoforms 
detected Source
22C11 Mouse
monoclonal
12 amino acids at the 
NH2 terminus of APP
APP695, APP751 
APP770,APLP2
Boehringer
Mannheim
993 Rabbit
polyclonal
Within the KPI domain APP751, APP770 Produced in the 
lab
3B11 Mouse
monoclonal
Within amino acids 598- 
617 of APLP2
APLP2 Kindly donated 
by M-T Webster
6E10 Mouse
monoclonal
Within amino acids 1-28 
of the pA4 domain of 
APP .
APP695.APP751 
APP770, not 
APLP2 or 
APPsp
Seneteck
antibodies at room temperature for 1 hour, and developed using ECL.
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Table 4.2 Working Concentration of Antibodies
Antibody Dilution Final Concentration
22C11 1:100 0.5 jug / ml
993 1:500 Diluted from immune serum
3B11 1:70 Diluted from cell culture supernatant
6E10 1:100 Diluted from cell culture supernatant
4.2.3 Contaminating Cells
An NT2N cell culture containing a monolayer of non-neuronal cells was incubated in culture 
media, 12 ml cDMEM, in a T75 culture vessel, for 24 hours. The conditioned media was 
collected, and the neuronal cells removed by shaking the culture vessel. The remaining 
background cells were incubated in 12 ml fresh culture media for a further 24 hours, after which 
the media was collected and the cells discarded. Conditioned media from both periods, along 
with unconditioned cDMEM was concentrated 10-fold using ammonium sulphate fractionate, 
separated on a 7% SDS-PAGE gel and transferred to nitro-cellulose membrane. This was then 
immunoblotted with antibodies 22C11 and 993.
4.2.4 Monoclonal Antibody Production
4.2.4.1 Western Blotting
The 100 most positive clones from each fusion were further tested for the ability to western blot, 
and to immunoprecipitate APP. Monkey cerebral cortex, soluble extract was run on a 7% SDS- 
PAGE gel and transferred to nitro-cellulose membrane as a source of APP for testing of western 
blotting capabilities. Cell culture supernatants were mixed with an equal volume of blotto and 
incubated with the blot for 2 hours. The blots were then incubated with an AP-conjugated
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secondary antibody and developed with NBT/BCIP. Control blots were incubated with 0.5 jug I ml 
22C11 and developed in the same way.
4.2.4.2 Immunoprecipitation
For immunoprecipitation experiments, 200 jul of the monkey brain extract was mixed with 600 jul 
immunoprecipitation buffer. 200 jul of the cell culture supernatant was added and the mixture 
incubated at room temperature for 2 hours. 100 j l a I  of a 50% solution of goat anti-mouse IgG 
bound agarose beads was added and incubated for a further hour. The beads were eluted in 50 
jil SDS-PAGE sample buffer, and 20 jul of each sample run on a 7% SDS-PAGE gel. The gel 
was transferred to nitro-cellulose membrane and western blotted with 0.5 jug / ml 22C11. The 
blot was developed using chromogenic techniques.
4.2.5 Amyloidogenic Cleavage ofAPP from NT2 and NT2N Cells
A T75 flask of each NT2 and NT2N cells was incubated with 12 ml cDMEM for 24 hours. The 
media was collected, along with two control samples of unconditioned cDMEM. One ml of each 
sample was subjected to a serial immunoprecipitation procedure as described in Section 2.12.
The first control sample was incubated with 40 jul 22C11 (2 jug), the second with 40 jul 6E10 (cell 
culture supernatant). The test samples were incubated with a series of 3 repetitions of 40 jul 
6E10, followed by a final immunoprecipitation step with 40 }ul 22C11. The resulting proteins were 
eluted with 50 jul SDS-PAGE sample buffer, 20 jul of each sample was loaded onto a 7% SDS- 
PAGE gel and transferred to nitro-cellulose membrane.
Duplicate gels were run, with both being transferred to nitro-cellulose membrane. The first 
membrane was western blotted with 6E10 and the second with 22C11 (each antibody was at a 
1:100 dilution, primary antibody incubated for 2 hours). Blots were developed using ECL.
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4.2.6 Detection of pA4
Solutions of synthetic pA4^o (Sigma) were prepared in dhfeO at various concentrations, and 
mixed with SDS-PAGE sample buffer. 20 p\ of each dilution was loaded on two 12% TRIS- 
TRICINE gels. One gel was transferred to nitro-cellulose membrane, the other was transferred to 
PVDF. Each membrane was cut in half and all four membranes were western blotted using 6E10 
at a dilution of 1:100 for 2 hours. One half of each membrane was then incubated with an anti­
mouse IgG secondary antibody conjugated to HRP, the other half with an anti-mouse IgG 
secondary antibody conjugated to AP. Each membrane was incubated for 1 hour at room 
temperature. The blots incubated with the HRP-conjugated antibody were then incubated with 
ECL solution and exposed to X-ray film, while the blots incubated with the AP-conjugated 
antibody were incubated with NBT/BCIP solution for one hour.
4.2.7pA4 Immunoprecipitations
Several antibodies, detailed in Table 4.3 were tested for the ability to immunoprecipitate pA4 out 
of solution. Synthetic pA4 solutions were prepared at a concentration of 200 ng / ml in a solution 
of 1 mg / ml BSA in TBS. 0.5 ml of this solution was incubated with each antibody to be tested 
for 2 hours at room temperature, the resulting antibody/peptide complex was then recovered 
using agarose beads. The beads were eluted in 25 jul SDS-PAGE sample buffer, and 20 jil of 
this was run on a 12% TRIS-TRICINE gel, as described previously. The gel was then transferred 
to nitro-cellulose membrane and immunoblotted with antibody 6E10, again as described 
previously.
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Table 4.3 Antibodies to J3A4
Antibody Type Epitope Source
6E10 Mouse monoclonal Within amino acids 
1-28 of PA4
Commercial,
Seneteck
1032* Rabbit polyclonal Within amino acids 
1-19 of pA4
Produced in the lab
58617* Rabbit polyclonal Within amino acids 
1-9 of pA4
Produced in the lab
58618* Rabbit polyclonal Within amino acids 
1-9 of pA4
Produced in the lab
6F/3D Mouse monoclonal Within amino acids 
8-17 of pA4
Commercial, Dako
* These antibodies were produced and characterised by Dr D Parkinson before the
onset of the work described in this thesis.
4.2.8 Method
NT2 cells were grown to confluence in a 12 well plate. Media from each well was collected and 
pooled, to give 12 ml of 3 day conditioned media, and the cells were then harvested using the 
method in Section 2.3. NT2N cells and media from a T25 culture flask were collected and the 
cells processed as described in Section 2.3.
One hundred p\ of each cell sample and 1 ml of each media sample was immunoprecipitated with 
100 jiil of antibody 6E10 overnight, as described in Section 2.11. The antibody/antigen complex
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was recovered using 100 jul of agarose bound anti-mouse-IgG, and the beads were eluted in 100 
jul SDS-PAGE sample buffer.
20 jul of each sample was loaded onto each of a 7% SDS-PAGE gel, and a 12% TRIS-TRICINE 
gel. Both gels were run as previously described, and then transferred to nitro-cellulose 
membrane. Each nitro-cellulose membrane was immunoblotted with antibody 6E10 and 
developed using ECL as described previously.
4.2.9 Immunoprecipitation of Synthetic J3A4 from Conditioned Media
100 ng pA4 was added to 0.5 ml unconditioned cDMEM and to media conditioned by NT2 cells 
for 24 hours. The samples were incubated with 40 jul 6E10 as previously described, the antibody 
was recovered by addition of 50 jul anti-mouse-IgG agarose beads, and the beads eluted in 50 jul 
SDS-PAGE sample buffer. 20 jul of each sample was separated on a 12% acrylamide TRIS- 
TRICINE gel, which was transferred to nitro-cellulose membrane and immunoblotted with 6E10 
as before.
4.3 APP PRODUCTION AND SECRETION
NTera2 stem and neuronal cells were examined by the methods details in Section 4.2.1 to 
characterise the production and secretion ofAPP by each cell type.
4.3.1 Results
The first task was to assess APLP2 production and secretion by NT2 and NT2N cells, this was 
examined using the specific monoclonal antibody 3B11. Using this antibody, it was not possible to 
detect any APLP2 in the NT2N cells, nor was any of this protein detected in the media from these 
cells. A single band of approximately 100 kDa was detected in the membrane fraction of NT2 
cells, but not in the soluble fraction or in secreted proteins (see Figure 4.1a). From these results
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it was determined that NT2N cells do not make detectable amounts of APLP2, and that, while 
NT2 cells do make a detectable amount of the protein, it is not secreted at detectable levels. 
Therefore any proteins detected in the media of either cell type with antibodies 22C11 or 993 are 
APP isoforms.
Antibody 22C11 detected 3 bands, of approximately 115,128 and 137 kDa, in both soluble and 
membrane fractions of NT2 cells (see Figure 4.1b). The staining was more intense in the 
membrane fraction, and of this, the two larger bands were predominant. A single band of 
approximately 128 kDa was detected in the media of these cells. Immunoblotting with antibody 
993 detected two bands of approximately 128 ap,dJL37J;Qajn the soluble and membrane 
fractions, and a single band ofJ28J(Da jnjhemedia (see Figure 4.1c).
NT2N cells did not contain detectable amounts ofAPP in the soluble fraction of the cellular 
proteins, but 2^bands were identified with antibody 22C11 in the membrane fraction (see Figure 
4.1b). The major band was approximately 113 kDa, with a band at 130 kDa also visible. Both of 
these bands were also detectable in the media from these cells. Antibody 993 did not detect any 
intracellular APP, but detected a single band of approximately 130 kDa in the media from the cells 
[see Figure 4.1c).
4.3.2 Conclusion
From these data it was concluded that NT2 cells make predominantly APP751 and I or APP770, 
which is secreted (see Table 4.4). A small amount of APP695 is produced, but could not be 
detected in the media. As expected, the majority of intracellular APP is membrane bound. The 
two bands detected by antibody 993 in the cellular fractions of the cells probably represent
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immature and mature, fully glycosylated, forms of APP751 and APP770, as it is not possible to 
separate the two isoforms on a gel.
Table 4.4 Molecular Weights OfAPP Isoforms In NT2 Cells, Along With
The Antibodies Detecting Them
APP751/770 A P P 695
Immature Mature Soluble Immature Mature Soluble
Size (kDa) 128 137 128 115 128 N/A
22C11 S y y y y y
993 y y y X X X
6E10 X X y X X y
3B11 X X X X X X
NT2N cells make predominantly APP695, which is secreted (see Table 4.5). One or both of the 
KPI-containing APP isoforms is also made and secreted, and since this isoform is not detected in 
the cellular proteins, it may be assumed that is has a rapid turnover within the cell. NT2N cells do 
not make or secrete a detectable amount of APLP2, while NT2 cells make only a small amount, 
which is membrane associated and does not appear to be secreted at detectable levels.
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Table 4.5 Molecular Weights OfAPP Isoforms In NT2N Cells, Along With
The Antibodies Detecting Them
APP751/770 A P P 695
Immature Mature Soluble Immature Mature Soluble
Size (kDa) 130 N/A 130 113 130 113
22C11 S y y y y y
993 y y y X X X
6E10 X X y X X y
3B11 X X X X X X
4.4 CONTAMINATING CELLS
As described in Chapter 3 cultures of NT2N cells may also contain non-neuronal “background” 
cells. These cells appear to provide support for the neuronal cells (see Sections 32.2.2 and 
3.2.3.1) and may contribute to secreted proteins found in the media of these cultures. Other 
researchers have attributed KPI-containing APP isoforms found in neuronal cultures to 
contamination from these cells (Wertkin et al. 1993). In order to determine if these cells do 
secrete APP, media from mixed cultures, and from cultures of background cells only, was 
analysed, as described in Section 4.2.3.
4.4.1 Results
A faint band of approximately 135 kDa was detected in unconditioned media, this is presumably 
due to the presence of bovine APP in the FBS added to the media (see Figure 4.2a). This band 
was also present, at a greater densityjD,the.condjtlQned media from the background cells only.
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Media from the mixed cell culture also contained this band, along with another of approximately 
115 kDa.
Antibody 993 detected a single band of 135 kDa in all three media samples (see Figure 4.2b).
This was faintest in the unconditioned media sample, and strongest in the media from the mixed 
cell population.
4.4.2 Conclusion
This data shows that any APP695 detected in the media of mixed cell populations can be attributed 
to the presence of neuronal cells. However, the same cannot be said for any KPI-containing 
isoforms detected. The background cells secrete an appreciable amount of KPI-containing APP, 
though it is not possible to say which isoform exactly. However the KPI-containing band was 
more intense in media from the mixed cell population than from the background cells alone, 
indicating that the neuronal cells do secrete one or more of those isoforms. As a result of this 
finding, any NT2N culture that contained contaminating cells was discarded, and all experiments 
were performed on cultures that contained only neuronal cells.
4.5 DESIGN AND TESTING OF MONOCLONAL ANTIBODIES
4.5.1 J3-Secretase Specific Antibody
In order to differentiate between amyloidogenic and non-amyloidogenic pathways ofAPP 
secretion, it was decided to attempt to produce a monoclonal antibody that was specific for 
APPsp. The aim was to produce an antibody that would recognise only soluble APP that had 
been cleaved at the amino terminus of pA4, i.e. by p-secretase, and not APPsa. It was 
predicted that as a result of this, the proportion of secreted APP that had undergone 
amyloidogenic cleavage could be determined.
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4.5.1.1 Antibody Design and Production
The sequence of APP770 was retrieved from the Swisspro database, at the European 
Bioinformatics Institute site on the Internet, and the required peptide sequence identified. The 
peptide (peptide 303, see Figure 4.3) was synthesised by Research Genetics, USA and once 
received was conjugated to BSA using glutaraldehyde. This protein antigen was then sent to 
Sheffield Hybridomas, where it was injected into mice that were later screened for antibody 
production. The strongest responding mouse was identified and the spleen removed, 
homogenised and the cells fused with a myeloma cell line. The hybridoma cells were then cloned 
out and each clone tested for the production of the relevant monoclonal antibody. This initial 
testing was by ELISA (immunisation, fusion and initial testing earned out by Sheffield 
Hybridomas). Two fusions were carried out, resulting in approximately 1000 clones to be tested.
4.5.1.2 Further Testing
Clones were tested against peptides 303 and 304 (see Figure 4.3) to identify an antibody that was 
specific for the cleavage product. All positively testing clones reacted with both peptides, 
indicating that no antibody was specific for APPsp. Since the antigen chosen is APP specific, 
and not found in APLP2 the antibodies were cloned further to produce an APP specific antibody. 
Clones identified as positive by Sheffield Hybridomas were passed on to this lab for further 
screening, as described in Sections 4.2.4.1 and 4.2.42
4.5.1.3 Results
After these tests, 2 clones, EH4 and FC8 appeared to immunoprecipitate APP successfully out of 
a solution of proteins extracted from monkey frontal cortex (see Figure 4.4a), though neither 
reacted with APP on an immunoblot. However, when the immunoprecipitation results were 
western blotted with the anti-mouse IgG secondary antibody only, a band at approximately 130 
kDa was detected. Since this band ran at the same weight as APP it was not possible to
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differentiate between the two proteins. Attempts to purify the antibodies on a Protein G column, 
as described in Section 2.14, were unsuccessful, as the non-specific band was still present after 
purification (see Figure 4.4b)
4.5.2 a-Secretase Specific Antibody
An alternative strategy to study amyloid production is to use antibodies that recognise epitopes 
within the pA4 sequence. To this end a further antibody was developed, against an epitope in the 
first 12 amino acids of pA4, immediately C-terminal to the p-secretase cleavage site. This 
antibody was intended to be used to differentiate between full length APP and APLP2, and 
between APPsa and APPsp. APLP2 does not contain the pA4 sequence, therefore the antibody 
produced would be APP specific. Also, since p-secretase cleaves APP after the amino-terminus 
of pA4, the antibody would recognise secreted APP that had been cleaved by a-secretase only.
The peptide antigen (peptide 305, see Figure 4.3) was synthesised and the antibodies produced 
by Sheffield Hybridomas as previously. Hybridomas were screened by ELISA for secretion of a 
relevant antibody and positively testing clones were further tested for western blotting and 
immunoprecipitation capabilities, as before. The clones were graded according to performance, 
and the most promising ones identified for further cloning. As previously, 2 fusions were carried 
out, resulting in approximately 1000 initial clones, of which approximately 150 were further tested 
by western blotting and immunoprecipitation. This resulted in 10 clones chosen for re-cloning.
Of these, 2 clones were successfully re-cloned, HE1 and HD11. These were used to 
immunoprecipitate full-length secreted APP from the conditioned media of NT2 cells. This was 
not successful, despite initial positive results when immunoprecipitating APP from monkey brain
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extract. To ensure that the clones were still secreting the relevant antibody, both antibodies were
tested on an ELISA, as described in Section 2.13.
Each antibody was tested against several peptides, one positive, and several negative controls. 
The results showed that each antibody recognised almost any peptide bound to BSA with 
glutaraldehyde (see Figure 4.5}. They appeared to be specific for the linking region of the 
antigen, not the specific peptide, or the BSA sequence.
4.6 AMYLOIDOGENIC CLEAVAGE OFAPP FROM NT2 AND NT2N CELLS
Following the failure to produce antibodies specific for individual secretion activities, a commercial 
antibody, 6E10, became available. This antibody recognises an epitope in amino acids 1-28 of 
the pA4 domain ofAPP and, therefore, will only react with secreted APP which has been cleaved 
by a-secretase, not p-secretase cleaved APP, or secreted APLP2. This antibody was used, in 
conjunction with antibody 22C11, in serial immunoprecipitation experiments, to determine what 
proportion of secreted APP was processed via amyloidogenic pathways.
4.6.1 Results (See Figure 4.6J
No APP was detected by immunoprecipitation with 6E10 in the control sample. A faint band was 
visible after immunoprecipitation with 22C11 (compare lanes 1 and 2 in Figure 4.6a and b), this is 
probably due to bovine APP present in the FBS added to the complete media.
Immunoprecipitations with 6E10 from NT2 conditioned media detected 2 bands of approximately 
110 and 135 kDa, with the larger band predominant. Both bands decreased in intensity with each 
successive immunoprecipitation step (see Figure 4.6a and b lanes 4-6). Immunoprecipitation with 
22C11 also resulted in these two bands, but as they were detected with both 22011 and 6E10 on 
western blotting, it is not possible to say whether these bands are due to APPsa which was not
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completely cleared by the 6E10 immunoprecipitation steps, or if they indicate the presence of 
APPsp. If lane 7 is compared on Figure 4.6a and b, it can be seen that the intensity of the 2 
bands is similar on each immunoblot, which may indicate that they are due to the presence of 
APPsa, and that a further immunoprecipitation step with 6E10 may remove them.
Immunoprecipitations with 6E10 from NT2N conditioned media gave similar results, recovering 2 
APP bands of 115 and 140 kDa, though in this case the smaller band was predominant (see 
Figure 4.6a and b, lanes 9-11). When immunoblotted with 22C11 the final immunoprecipitation 
step also resulted in these two bands. However, these bands were not detected after 
immunoblotting with 6E10 (compare lane 12, Figure 4.6 and b). This indicates that the 6E10 
immunoprecipitation steps did clear all APPsa, and the protein recovered by 22C11 was APPsp.
4.6.2 Conclusions
Both NT2 and NT2N cells secrete APP, which can be detected by immunoprecipitation with 
antibodies 22C11 and 6E10. It seems likely that all secreted APP from NT2 cells is a result of 
non-amyloidogenic cleavage, and that the majority ofAPP secreted by NT2N cells is also derived 
from this pathway. However, a small proportion ofAPP appears to undergo amyloidogenic 
breakdown in NT2N cells. Although the presence of APPsp is not conclusive proof that the 
neuronal cells make pA4, it is an indication that at least one of the secretase activities required 
for this, is present and functional in these cells. This result agrees with results from other 
research groups, which have detected secreted and intracellular pA4 in the neuronal cells, but 
not in the stem cells (Wertkin et ai. 1993).
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4.7 DETECTION OFpA4
The results of the serial immunoprecipitation studies indicated that NT2N cells may produce pA4. 
Using pulse chase labelling methods other groups have shown that the cells do make pA4, and 
that most of this is secreted into the media (Wertkin et el. 1993). Work was carried out to see if 
the neurones produced by the methods described in this work also secrete pA4.
4.7.1 Preliminary Studies
4.7.1.1 Detection of PA4
Initial studies were earned out to see if a peptide as small as the 4 kDa pA4 peptide could be 
resolved on a gel, and to discover what sensitivity could be achieved by western blotting, as 
described in Section 4.2.6.
On the nitro-cellulose membrane the pA4 was seen as a tight band running at approximately 4 
kDa (see Figure 4.7). The system was sensitive enough to detect the smallest amount of pA4 
used, 50 ng, and comparable results were obtained with both the ECL and the chromogenic 
techniques. However, the pA4 did not appear to bind to the PVDF membrane as it could not be 
detected with either ECL or chromogenic means.
4.7.1.2 PA4 Immunoprecipitations
Several antibodies were tested for the ability to immunoprecipitate pA4 out of solution, as 
described in Section 4.2.7. As can be seen in Figure 4.8, the only antibody that successfully 
recovered pA4 was 6E10. However if lane 1, which contains a control of 50 ng of pA4, is 
compared with lane 2, which would contain 80 ng of pA4 if there was 100% recovery, it can be 
seen that the actual recovery level is less than 50 %.
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4.7.2 J3A4 Immunoprecipitation From NT2 and NT2N Cells and Media
NT2 and NT2N cell and media samples were tested by immunoprecipitation for the presence of 
0A4, as described in Section 4.2.8. pA4 was not detected in any of the immunoprecipitations, 
though synthetic pA4 that was run as a positive control, was detected on the western blot (see 
Figure 4.9a). Full length APP was detected in both cell and media samples (see Figure 4.9b), 
indicating that 6E10 will immunoprecipitate APP under the conditions used.
4.7.2.1 Conclusion
It is not possible to detect intracellular pA4 using the techniques described. This is unsurprising, 
since NT2 cells have not previously been shown to make pA4, and while the NT2N cells do 
produce some pA4, it is rapidly secreted after its formation. (Wertkin ef al. 1993)
It was not possible to immunoprecipitate PA4 from the media of either cell type, not even from 
media that had been conditioned by NT2N cells for 7 days. This is more surprising, as the 
previous study showed NT2N cells continually to secrete the peptide. The lack of success of the 
present study may be due to two factors; either the levels of pA4 are too low to be detected by 
the methods used, or the presence of full length APP in the media from cultured cells interferes 
with the immunoprecipitation at the antibody concentration used.
4.7.3 Immunoprecipitation of Synthetic J3A4 from Conditioned Media
In order to test the hypothesis that 6E10 cannot immunoprecipitate 0A4 from conditioned media, 
either due to the chemical composition of the media, or to the fact that any full length APP 
present saturates the antibody, synthetic 0A4 was added to conditioned and unconditioned 
media, as described in Section 4.2.9.
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PA4 was recovered from both media samples, though when compared with the control sample of
50 ng pA4 run on the gel it is possible to see that there is less than 50% recovery (see Figure
4.10 compare lanes 2 and 3 with lane 1)
4.7.4pA4 Conclusions
These studies show that it is possible to separate synthetic pA4 on a TRICINE gel, to detect it on 
a western blot, and to immunoprecipitate it from the conditioned media of NT2 cells. However, it 
was not possible to detect endogenous pA4, either in whole cell extract or in conditioned media 
of NT2N cells. Since the techniques have been proved to work, the lack of success in detecting 
endogenous pA4 may be attributed to the very low concentrations present. To detect it 
techniques with greater sensitivity, which were not available in the laboratory, must be used.
4.8 CONCLUSION
Using SDS-PAGE and western blotting techniques it is possible to identify the APP isoforms 
expressed by both NT2 and NT2N cells. These techniques can differentiate between APP and 
APLP2, and can identify whether the APP produced is KPI-containing or APP695. It is also 
possible to look at intracellular APP and determine whether it is membrane bound or soluble. 
Secreted APP can be collected, and after concentration, it can also be analysed by SDS-PAGE 
and western blotting to determine which isoforms are secreted from each cell type.
The cleavage pathways used by each cell type can also be investigated. Using serial 
immunoprecipitation from conditioned media it is possible to determine what proportion of the 
secreted APP is processed via amyloidogenic or non-amyloidogenic pathways. 6E10 can be 
used to clear the media of APPsa, or non-amyloidogenic APP, and any remaining secreted APP, 
which must be APPsp, is immunoprecipitated by 22C11.
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Although this study was not able to detect endogenous |3A4 either in whole cell extracts of NT2N 
cells, or in the conditioned media from these cells, it did show that it is possible to resolve and 
detect pA4 using a TRIS-TRICINE gel system, transfer to nitro-cellulose membrane, and western 
blotting. It is also possible to immunoprecipitate synthetic pA4 from conditioned cell culture 
media, showing that the presence of APPs does not interfere with the immunoprecipitation 
system. Further work needs to be done to increase the sensitivity of these methods, either by 
concentrating the pA4 in the conditioned media by gel filtration chromatography or by pulsing the 
cells with radioactivity to label the pA4 and increase detection sensitivity. Nevertheless, as 
previously stated, the serial immunoprecipitation techniques developed did allow the APP 
processing pathways in NT2 and NT2N cells to be studied.
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Figure 4.1 APP PRODUCTION AND SECRETION BY NT2 AND NT2N CELLS
Cell samples were processed to give soluble and membrane proteins, samples of conditioned 
media were concentrated 10-fold. All samples were mixed with SDS-PAGE sample buffer and 20 
jul of each loaded on 7% SDS-PAGE gels, which were then transferred to nitro-cellulose 
membranes and immunoblotted with antibodies 3B11, 22C11 and 993.
Lane Cells Fraction Total Protein Loaded
1 NT2 Soluble 12 ug
2 Membrane 9 ng
3 Media 5-fold final concentration*
4 NT2N Soluble 5t*g
5 Membrane 4ng
6 Media 5-fold final concentration*
* Approximately 800 jug total protein, the majority of which derives from the FBS 
Figures to the right of the blot indicate the mobility of molecular weight markers.
Only the membrane fraction of NT2 cells contains APLP2. NT2 cells contain 3 major APP bands, 
at 115,128 and 137 kDa, and secrete the 128 kDa form. NT2N cells contain a major band of 113 
kDa, with a second band at 130 kDa. Both of these forms are secreted, but only the larger one is 
detected by 993, indicating that the smaller protein is APP695.
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Figure 4.2 APP SECRETION BY CELLS PRESENT AFTER RA INDUCED 
DIFFERENTIATION OF NT2 CELL CULTURES
Media samples from a cell culture containing neuronal and background cells, and from a 
population containing only the background cells, along with unconditioned cDMEM were 
concentrated 10-fold. 20 jj l \ of each sample was loaded onto 7% SDS-PAGE gels. The gels 
were transferred to nitro-cellulose membrane and immunoblotted with antibodies 22C11 and 993. 
Lane 1 Media from non-neuronal cells 
Lane 2 Media from the mixed cell population 
Lane 3 Unconditioned cDMEM 
Figures to the right of the blot indicate the mobility of molecular weight markers.
The mixed cell population secretes 2 APP forms, of 113 and 130 kDa, however, by comparing the 
secretion from the background cells only, it can be seen that the 113 kDa form ofAPP is secreted 
by the neuronal cells only, while the 130 kDa form is secreted by both cell types.
BACKGROUD MIXED UNCONDITIONED
CELLS CELL MEDIA
POPULATION
a) 22C11
^ — 116 kDa
b) 993
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Figure 4.3 APP770 SEQUENCE AND ANTIBODY RECOGNITION SITES
Amino acid sequence of APP770, with lines to indicate the peptide antigens synthesised for the 
use of antibody production and testing.
1 MLPGLALLL LAAWTARAL EVPTD GNAGL LAEPQIAMFCGR
41 LNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPEL
81 QITNWEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVG
121 E F VSDALL VPD KCKF LHQ E RMD VC ETHLHWHTVAKETC S E
161 KSTNLHDYGMLL PCGIDKFRGVEFVCCPLAEESDNVDSAD
201 AE E D D S D VWWGGADTD YAD GS E D KWE VAE EEEVAEVEEE
241 EADDDEDDEDGDEVEEEAEEPYEEATE RTTSIATTTTTTT
281 E SVE E W R E  VC S E Q AETGP C RAM IS  RWYF D VTE GKCAP F F
321 YGGC GGNRNNF DTE EY CMAVC GSAMS Q SLLKTTQE PLARD
361 PVKL PTTAASTP DAVD KYL ETP GD ENEHAHF Q KAKE RL EA
401 KHRE RMS QVMREWE EAE RQAKNL P KAD KKAVIQHFQEKVE
441 S L E Q EAAWE RQQ LVETHMARVEAMLND RRRLAL ENYITAL
481 QAVP PRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDP
521 KKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQD
561 EVDELLQKE QNYS D DVLANMISEPRISYGNDALMPSLTET
601 KTTVEL L PVNGEFSLDDLQ PWHS F GAD SVPANTENEVE PV
| 303 |
| 304 |
| 305
641 DARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSG
681 YE VHHQ KLVFFAEDV GSVTRGAIIGLMVGGVVIAJVIVITL
721 fMKKKQ YTSIHHGWE VD AAVTP E E RHL S KMQQNGYENP 
761 TYKFFEQMQW
Red KPI domain
Purple 0X2 domain
Blue beta-amyloid region
Italic transmembrane domain
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Figure 4.4 IMMUNOPRECIPITATIONS WITH FC8 AND EH4
a) Cell culture supernatant from each clone was used to immunoprecipitate APP from monkey 
brain. The samples were separated on a 7% SDS-PAGE gel, and immunoblotted with 22C11. 
The blot was developed using NBT/BCIP.
Lane 1 EH4
Lane 2 FC8
Lane 3 Monkey brain extract, positive control for the immunoblot
b) Increasing amounts of purified FC8 was incubated with monkey brain extract, as described, 
The samples were separated on a 10% gel, and immunoblotted using an anti-mouse IgG 
secondary antibody conjugated to AP, only. The blot was developed using NBT/BCIP.
Lane 1 5 jul FC8
Lane 2 10 jJFC8
Lane 3 20 jul FC8
Lane 4 50 jul FC8
Figures to the right of the blot indicate the mobility of molecular weight markers.
The initial blot shows a band running at the same weight as APP, but as can be seen in the
second blot, the anti-mouse-IgG antibody detects this band only, indicating that it is not APP.
The band is present even after purifying the cell culture supernatant on a protein G column.
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Figure 4.5 ELISA SHOWING THAT HE1 AND HD11 REACT WITH THE 
CROSS LINKER
0.9 -
0.5
Q 0.4
□ HE1 
■ HD11
Peptide
Peptide 1 BSA blank
Peptide 2 305, positive control
Peptide 3 304, negative control
Peptide 4 P104, negative control
DAEFRHDSGYEV
EEISEVKMDA
CYFQNAQMSEDNHL
All peptides were conjugated to BSA using glutaraldehyde. Although neither antibody recognises 
BSA only, both recognise all 3 of the peptide antigens, indicating that they may recognise the 
cross-linking region.
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Figure 4.6 NT2N CELLS SECRETE APP VIA BOTH AMYLOIDOGENIC AND 
NON-AMYLOIDOGENIC PATHWAYS, NT2 CELLS USE ONLY NON- 
AMYLOIDOGENIC ONES
APP was immunoprecipitated from NT2 and NT2N conditioned media, using serial 
immunoprecipitations with 6E10 and 22C11. Control immunoprecipitations with 22C11 or 6E10 
were performed on unconditioned media. The samples were run on 7% SDS-PAGE gels that 
were transferred to nitro-cellulose membranes and blotted with 22C11 or 6E10.
Lane Media Antibody
1 Unconditioned control cDMEM 22C11
2 6E10
3 Blank
4 NT2 conditioned cDMEM 6E10 #1
5 6E10 #2
6 6E10 #3
7 22C11
8 Blank
9 NT2N conditioned cDMEM 6E10 #1
10 6E10 #2
11 6E10 #3
12 22C11
Figures to the right of the blot indicate the mobility of molecular weight markers.
NT2 cells appear to secrete only APPsa, detected by both 22C11 and 6E10, while NT2N cells 
appear to secrete an appreciable amount of APPsp (compare lane 12 in a and b).
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Figure 4.7 DETECTION OF SYNTHETIC bA4 ON A WESTERN BLOT
Solutions of various concentrations of synthetic pA4i-4o were prepared and run on a 12% TRIS- 
TRICINE gel. The gel was transferred to nitro-cellulose membrane and immunoblotted with 
6E10. The blot was developed using ECL.
Lane 1 50 ng pA4i-4o
Lane 2 100 ng pA4i-4o
Lane 3 150 ng pA4i-4o
Lane 4 200 ng pA4i-4o
Lane 5 250 ng pA4i-4o
Figures to the right of the blot indicate the mobility of molecular weight markers.
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Figure 4.8 IMMUOPRECIPITATION OF SYNTHETIC pA4 USING SEVERAL 
ANTIBODIES
Synthetic pA4 in a 1 mg I ml solution of BSA in TBS was incubated with 50 jig of various 
antibodies for 2 hours at room temperature. The antibody complex was recovered with agarose 
beads that were eluted in of SDS-PAGE sample buffer. Samples were separated on a 12.5% 
TRIS-TRICINE gel, transferred to nitro-cellulose membrane and blotted with 6E10.
Lane Antibody Epitope
1 No immunoprecipitation, 100 ng PA4
2 6E10 Within amino acids 1-28 pA4
3 1032 Within amino acids 1-19 pA4
4 58617 Within amino acids 1-9 PA4
5 58618 Within amino acids 1-9 pA4
6 6F/3D Within amino acids 8-17 pA4
Figures to the right of the blot indicate the mobility of molecular weight markers.
Only antibody 6E10 successfully recovered the pA4 peptide.
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Figure 4.9 J3A4 CANNOT BE IMMUNOPRECIPITATED FROM WHOLE CELL 
EXTRACTS, OR FRO M  THE CONDITIONED MEDIA OF NT2N CELLS
6E10 was used to immunoprecipitate |3A4 from whole cell extracts, and conditioned media. The 
samples were separated on either a 12% acrylamide TRIS-TRICINE, or a 7% SDS-PAGE gel. 
The gels were transferred to nitro-cellulose membrane and immunoblotted with 6E10.
a) 12% acrylamide TRIS-TRICINE gel
Lane 1 50 ng synthetic {3A4
Lane 2 100 ng synthetic (3A4
Lane 3 Immunoprecipitation from NT2 whole cell extracts
Lane 4 Immunoprecipitation from NT2N whole cell extracts
Lane 5 Immunoprecipitation from 7 day conditioned NT2N media
b) 7% acrylamide SDS-PAGE gel
Lane 1 Immunoprecipitation from NT2 whole cell extracts
Lane 2 Immunoprecipitation from NT2N whole cell extracts
Lane 3 Immunoprecipitation from 3 day conditioned NT2 media
Lane 4 Immunoprecipitation from 7 day conditioned NT2N media
Figures to the right of the blot indicate the mobility of molecular weight markers.
Endogenous pA4 could not be detected in any of the samples using this method.
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Figure 4.10 IT IS POSSIBLE TO IMMUNOPRECIPITATE SYNTHETIC bA4 
FROM CONDITIONED MEDIA
Synthetic pA4 was added to unconditioned cDMEM or 24 hour conditioned NT2 media. 
Immunoprecipitation with 6E10 was used to recover the peptide. Samples were separated on a 
12% acrylamide TRIS-TRICINE gel, which was transferred to nitro-cellulose membrane and 
immunoblotted with 6E10 as before.
Lane 1 50 ng pA4
Lane 2 synthetic (3A4 immunoprecipitated from unconditioned DMEM 
Lane 3 synthetic j3A4 immunoprecipitated from 24 hour NT2 conditioned DMEM 
Figures to the right of the blot indicate the mobility of molecular weight markers.
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Chapter Five - Effects Of Heat Shock On NTera2 Stem 
Cells And Neurones
5.1 INTRODUCTION
As discussed in the introduction, there are several indications that neurones in the AD brain may 
be in a state of stress. Protein production and processing is altered, with a decrease in overall 
protein synthesis and changes in protein phosphorylation, there is also a disruption of the 
cytoskeleton. Levels of ubiquitin and associated proteins are increased (Wang et al. 1991), and 
heat shock proteins 72 and 73 have been found in both senile plaques and neurofibrillary tangles 
(Hamos et al. 1991). Since APP contains a heat shock element in the promoter region of its gene 
(Salbaum etal. 1988), a number of studies have been done to investigate the effects of heat 
shock or other metabolic stresses on the expression of APP. These studies have included 
research on various cell types, and have investigated APP in several ways.
Research on glioma cell lines transfected with APP fusion protein constructs, indicated that heat 
shock may lead to mis-compartmentalisation of APP (Pappolla et al. 1995). The fusion proteins 
were tagged with SEAP, a secreted derivative of placental alkaline phosphatase. After a heat 
shock for 30 minutes at 44°C and recovery at 37°C, more than 90% of the cells had 
accumulated the fusion protein in their cytoplasm, in contrast the control transfected cells did not 
show alkaline phosphatase activity when examined by immunocytochemistry,
Heat shock also induces changes in APP processing, in PC12 cells that had been treated with 
nerve growth factor to induce a neuronal phenotype (Johnson et al. 1993a). A 30 minute
99
incubation at 45°C induced the production of two additional APP polypeptides, of approximately 
95 and 120 kDa, which were not present in control cells. While levels of constitutively expressed 
APP did not change, there was an overall rise in APP levels due to the production of these new 
polypeptides. There was also a 70% decrease in the phosphorylation levels of APP, compared 
with only a 20% decrease in protein phosphorylation levels overall.
Heat shock induces changes in APP mRNA, also. Human lymphoblastoid cells lines, from 
normal subjects were subjected to a 42°C heat shock for 30 minutes, then allowed to recover at 
37°C for various lengths of time (Abe et al. 1991). When examined by northern blot there was a 
40-60% increase in APP mRNA at 3 and 8 hours recovery, which had returned to normal levels 
by 48 hours recovery. The probe used detected all isoforms of APP mRNA as a single band, so 
there was no indication as to whether the increase was isoform specific.
Secreted APP is also affected by heat stress (Ciallella et al. 1994). Human umbilical vein 
endothelium cells (HUVECs) were subjected to 42°C for 15 to 30 minutes, then allowed to 
recover at 37°C. Northern blotting showed that APP mRNA was increased at all time points up to 
24 hours recovery, and was greatest (an approximately seven-fold increase) after 4 hours 
recovery. Western blotting of conditioned media also showed an increase in secreted APP at all 
time points, though this was greatest after only one hour recovery. Intracellular APP also 
increased, as seen by immunocytochemistry, in this case the increase was greatest at 12 hours 
recovery.
As neurones are post-mitotic, protecting themselves from stress is, perhaps, more crucial than for 
other cell types which can regenerate cell numbers. There is some evidence that different cell
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types in the brain respond to stress differently (Satoh and Kim, 1994), after heat-shock 
experiments on primary cell cultures of human foetal neurones, astrocytes, microglia and 
oligodendrocytes, the pattern of induction of the 72 kDa heat shock protein (HSP72) varied for 
each cell type. Western blots showed that the protein was highest in the astrocytes and microglia 
after 8 hours recovery at 37°C, while it peaked in the neurones after 24 hours recovery. 
Immunocytochemistry showed that only a percentage of each cell type showed HSP72 
immunoreactivity.
For the reasons described previously, NT2 stem cells and neurones may provide a good system 
in which to study APP processing. Both cell types produce and secrete easily detectable 
quantities of APP, and there is a shift in the pattern of APP expression on differentiation of the 
stem cells to the neuronal phenotype. If APP is involved in the heat shock response, and it is an 
element of this which triggers some or all of the pathology of AD, then a human CNS neuronal 
cell line is one of the best models in which to study the phenomenon.
A previous study has looked at APP expression by heat-stressed NT2 cells (Dewji et al. 1995). 
However, the work used cells transiently transfected with a fragment of the APP gene promoter 
cloned into a luciferase expression vector, and not endogenous proteins, or indeed the full length 
APP gene. Also the experiments looked only at transfected stem cells, not neuronal cells, and as 
previously stated, there may be a different response from the two phenotypes.
5.2 PRELIMINARY EXPERIMENTS
The stress response of cells in culture is cell type specific. There is no standard heat-stress 
protocol, temperatures ranging from 42-45°C have been used, and the length of time the cells are 
exposed to the high temperature can vary from 15 minutes to several hours. The method of heat-
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shock can vary too, some research groups used CO2 incubators set at the higher temperature, 
while others used sealed culture vessels placed in a water bath.
Induction of expression of HSP72 is usually used as a marker of heat shock. This is a member of 
the 70 kDa family of heat shock proteins, and while it is constitutively expressed at low levels in a 
number of cells types, its expression is massively increased in response to several types of 
stress (Satoh and Kim, 1995). Studies were carried out to determine a protocol that would 
successfully give a stress response in NT2 cells, using the induction of HSP70 as a marker for 
stress.
5.2.1 Initial Method
T25 flasks of NT2 and NT2N cells were washed with 5 ml DMEM then fed with 5 ml cDMEM, 
which had been pre-warmed to the stress temperature in a 10% CO2 incubator to equilibrate the 
CO2 levels. The flasks were then placed in the stress environment, for experiments that took 
place in a CO2 incubator the caps of the culture vessels were left loose, for experiments in the 
absence of CO2 the caps were sealed. After the shock period the media was collected and the 
cells either harvested, or fed with fresh cDMEM pre-warmed to 37°C, and returned to the 37°C 
incubator to allow a recovery period. The conditioned media was collected and the cells 
harvested at the times stated in the results section. The cells were processed to give whole cell 
lysates, which were then analysed on a SDS-PAGE gel, transferred to nitro-cellulose membrane 
and immunoblotted with an antibody to the HSP70 family of heat shock proteins (Sigma) which 
recognises both the constitutive and inducible forms of HSP70 (concentration 1:5000,1.9 |ig 
antibody). The blot was developed using ECL.
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5.2.2 Preliminary Results
Initial experiments took place at 42°C in a 10% CO2 incubator. Stress periods of 30 and 60 
minutes had no effect on HSP70 production in NT2 stem cells, however, even the shorter time 
was enough to kill the neuronal cells. Following this, all heat shock work was performed on NT2 
stem cells only.
Two further protocols tried were a 30-minute incubation at 42°C without CO2 , which had no effect 
on HSP70 levels, and a one-hour incubation in a water bath at 45°C, which killed all the cells.
A group doing research into the expression of HSP70 through the cell cycle in several mammalian 
cell lines used a heat stress of 7.5 hours at 42°C (Hang and Fox, 1996). NT2 cells were placed 
at 42°C in a 10% CO2 incubator for 8 hours, after which time they were harvested and the media 
collected. After western blotting the whole cells extracts from heat stressed and control cells, 
with the antibody to HSP70, a single band of approximately 68 kDa was visible in both lanes, but 
an additional band at approximately 85 kDa was visible in the heat shocked cells (see Figure 
5.1).
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Table 5.1 Heat Shock Protocols Attempted
Method Temperature Environment C02
Level
Time Effect on 
NT2 ceils
Effect on 
NT2N cells
1 42°C Incubator 10% 30 min. None Killed all 
cells
2 42°C Incubator 10% 60 min. None N/A
3 42°C Incubator 0% 30 min. None N/A
4 45°C Water Bath 10% 60 min. Killed all 
cells
N/A
5 - Final 42 °C Incubator 10% 8 hours Increased
HSP70
N/A
5.3 EFFECTS OF HEAT SHOCK ON HSP70 PRODUCTION IN NT2 CELLS
5.3.1 Final Method
T25 flasks of NT2 cells were washed with 5 ml DMEM then fed with 5 ml cDMEM, which had 
been pre-warmed to 42° temperature in a water bath. The flasks were then placed in an 
incubator at 42° and 10% CO2, with the caps of the culture vessels were left loose. The flasks 
were left in the incubator for 8 hours, after which the media was collected and the cells either 
harvested, or fed with fresh cDMEM pre-warmed to 37°C, and returned to the 37°C incubator to 
allow a recovery period of up to 24 hours. The conditioned media was collected and the cells 
harvested at the times stated in the results section. The cells were processed to give whole cell 
lysates, which were then analysed on a 7% SDS-PAGE gel, transferred to nitro-cellulose
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membrane and immunoblotted with various antibodies, as described previously (Sections 2.3, 2.7, 
2.9, 2.10 and 5.2.1 and Tables 4.3 and 4.4)
5.3.2 Results
After the heat stress treatment described in Section 5.3.1, the NT2 cell cultures were only slightly 
less confluent than controls, though there were more dead cells floating in the culture media. The 
morphology of the cells changed after heat-shock (see Figure 5.2), with heat-stressed cells 
appearing to display cytoplasmic projections, they also appeared to be less flatly adherent to the 
culture vessel than control cells. When immunoblotted with the antibody against HSP70, control 
cells contained 2 bands, at approximately 67 and 83 kDa. Immediately after heat shocking, cells 
also contained these two bands. However, after 4 hours recovery at 37°C, a third band was 
detected in heat shocked cells, at approximately 78 kDa (see Figure 5.3). This band was present 
in cells up to 24 hours after the heat stress treatment, and never detected in control cells.
5.4 EFFECTS OF HEAT SHOCK ON APP PRODUCTION
5.4.1 Intracellular APP
NT2 cells were heat shocked as described above (Section 5.3.1), and allowed to recover at 37°C 
for up to 24 hours. Cells were collected at 0,4,14,19 and 24 hours recovery, and the cell pellets 
were processed to give whole cell lysates. These were analysed on a SDS-PAGE gel that was 
transferred to nitro-cellulose membrane and western-blotted with antibodies 22C11 and 993.
Antibody 22C11 detected 2 major bands in the cell extracts at all time points, of approximately 
128 and 137 kDa, with a minor band at 115 kDa (see Figure 5.4a). In the control cells the higher 
molecular weight band was predominant. The heat shocked cells harvested without allowing 
recovery at 37°C resembled the control cells. However, after 4 hours at 37°C there was an
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increase in the lower weight molecular band. This band was still dominant at 14 hours recovery, 
but had returned to the control level by 19 hours recovery. There was a slight decrease in 
intensity of the higher molecular weight band after 19 hours recovery, and this band was still 
diminished at 24 hours recovery.
A similar result was obtained when the cell extracts were immunoblotted with 993 (see Figure 
5.4b), indicating that these changes are due to changes in KPI containing APP isoforms.
5.4.2 Secreted APP
The experiment was repeated, with cell and conditioned media samples collected from control 
and heat shocked cells after 0,4,16, and 24 hours recovery at 37°C. The cell samples were 
processed and western blotted as described above. The media samples were concentrated 10- 
fold using ammonium sulphate fractionation, mixed with SDS-PAGE sample buffer and the 
proteins separated on a 7% acrylamide gel. The gel was transferred to nitro-cellulose membrane 
and western blotted with 22C11 and 993.
The cell extracts gave the same result as previously, with 2 bands of approximately 128 and 137 
kDa in all samples. The lower molecular weight band was increased at 4 hours post heat shock 
in the stressed cells, but had returned to normal levels after 16 hours recovery. The higher 
molecular weight band was slightly decreased at 16 and 24 hours recovery. Both antibodies gave 
comparable results.
Western blots of the media samples resulted in one band of approximately 128 kDa (see Figure 
5.5). There was only a slight difference between control and heat shocked samples. There was 
a slight decrease in secretion of APP at 16 hours post heat shock from the stressed cells, and a
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slight increase from the same cells after 24 hours recovery. Western blotting with antibodies 
22C11 and 993 gave identical results, indicating that all changes are in KPI-containing isoforms.
5.5 CONCLUSION
A technique has been developed for inducing a shock response in NT2 cells. This response is 
confirmed by the induction of HSP72 in the cells. This protocol of shocking the cells by a period 
of heat shock, followed by a recovery period at 37°C has an effect on the APP production and 
processing by the cells.
Although at the time point immediately after the heat shock treatment, there is no difference in 
intracellular APP between control and stressed cells, after a 4 hour recovery period there is an 
increase in APP in the stressed cells. Overall APP is increased, with a specific increase in the 
smaller form of APP, this is most likely to be KPI-containing APP which is not fully glycosylated. 
After 16 hours of recovery the higher molecular weight form of APP is decreased in the stressed 
cells. This could be due to the secretion of previously formed mature APP, which is not replaced.
The overall increase in intracellular APP is not mirrored by a concurrent increase in secreted 
APP. Indeed, there is a slight decrease in secretion from stressed cells.
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Figure 5.1 AN 8 HOUR HEAT SHOCK AT 42°C INDUCES THE EXPRESSION 
OF A NEW HSP70 PROTEIN IN NT2 STEM CELLS
Whole cell lysates of control and heat shocked cells were analysed on a 7% SDS-PAGE gel and 
transferred to nitro-cellulose membrane. The nitro-cellulose membrane was immunoblotted with 
an antibody to the HSP70 family of heat shock proteins (Sigma).
Lane 1 Control Cells
Lane 2 Heat Shocked Cells
5 ng total protein loaded per lane
Figures to the right of the blot indicate the mobility of molecular weight markers.
Control cells express a protein of approximately 68 kDa, which is also present in the heat 
shocked cells. However, these cells also exhibit the presence of a second band, of 
approximately 85 kDa.
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Figure 5.2 HEAT SHOCK INDUCES SLIGHT CHANGES IN MORPHOLOGY 
OF NT2 STEM CELLS
NT2 stem cell cultures were incubated at 37°C (control) or 42°C (heat shock) for 8 hours, then 
cultures photographed. Magnification x2000.
a Control cells 
b Heat shocked cells 
The heat shocked culture was slightly less confluent than the control culture, with a small
proportion of cells exhibiting an elongated morphology and a number of processes (indicated by
arrowheads).
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Figure 5.3 RECOVERY AT 37°C AFTER HEAT SHOCK ALLOWS NT2 STEM 
CELLS TO EXPRESS A THIRD PROTEIN IN THE HSP70 FAMILY
Whole cell lysates of control and heat shocked cells were analysed on a 7% SDS-PAGE gel and 
transferred to nitro-cellulose membrane. The nitro-cellulose membrane was immunoblotted with 
an antibody to the HSP70 family of heat shock proteins (Sigma).
Lane Cells Recovery Time
1 Control 0 hours
2 4 hours
3 14 hours
4 19 hours
5 24 hours
6 Blank
7 Heat shocked 0 hours
8 4 hours
9 14 hours
10 19 hours
11 24 hours
10 ng total protein loaded per lane
Figures to the right of the blot indicate the mobility of molecular weight markers.
Both control and heat shocked cells express 2 proteins at approximately 68 and 85 kDa, but after 
4 hours recovery at 37°C the heat shocked cells express a third protein of the HSP70 family of 
approximately 78 kDa.
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Figure 5.4 HEAT SHOCK INDUCES CHANGES IN APP PROCESSING IN 
NT2 STEM CELLS
Whole cell lysates of control and heat shocked cells were analysed on a 7% SDS-PAGE gel and 
transferred to nitro-cellulose membrane. The nitro-cellulose membrane was immunoblotted with 
antibodies 22C11 (a) and 993 (b).
Lane Cells Recovery Time
1 Control 0 hours
2 4 hours
3 14 hours
4 19 hours
5 24 hours
6 Blank
7 Heat shocked 0 hours
8 4 hours
9 14 hours
10 19 hours
11 24 hours
10 ng total protein loaded per lane. Figures to the right of the blot indicate the mobility of 
molecular weight markers.
Heat shock induces an increase in the 128 kDa APP isoform that peaks at 4 hours recovery. 
There is a decrease in the 137 kDa isoform after 19 hours recovery, and this isoform is still 
diminished at 24 hours recovery. This change is seen with both antibodies, indicating that the 
changes are in KPI-containing APP isoforms.
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Figure 5.5 HEAT SHOCK INDUCES ONLY SMALL CHANGES IN SECRETED 
APP FROM NT2 STEM CELLS
Conditioned media from control and heat shocked cells was concentrated 10-fold, mixed with 
SDS-PAGE sample buffer, and analysed on a 7% SDS-PAGE gel. The gel was transferred to 
nitro-cellulose membrane and immunoblotted with antibodies 22C11 (a) and 993 (b).
Lane Cells Recovery Time
1 Control 0 hours
2 Heat shocked
3 Control 4 hours
4 Heat shocked
5 Control 16 hours
6 Heat shocked
7 Control 24 hours
8 Heat shocked
Figures to the right of the blot indicate the mobility of molecular weight markers.
There is little change in APP secretion from NT2 cells following heat shock.
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Chapter Six - Effects Of Optimem On NTera2 Stem 
Ceils And Neurones
6.1 INTRODUCTION
As described in Chapter 5, attempts to induce a stress response by subjecting NT2N cells to a 
period of heat shock were not successful, all experiments resulted in the clusters of cell bodies 
detaching from the culture vessel. The cells did not re-attach after up to 24 hours recovery, and 
appeared to have died. However, a period of heat shock is not the only way to induce the stress 
response in cells. Animal studies have shown HSP72 induction in response to hypoxia, ischemia 
and traumatic injury (Satoh and Kim, 1994). Treatment of cell cultures with cytotoxins such as 
ethanol and sodium arsenite has been used to induce a stress response in NT2 cells (Dewji et al. 
1995). There is also some evidence that a lack of nutrients can induce a heat shock response 
(Lindquist, 1986).
During initial experiments to characterise NT2 and NT2N cells for this work, the cell cultures were 
incubated with Optimem for 24 hours prior to sample collection. Optimem is an alternative, 
reduced serum, nutrient media for cell culture. Prior to its addition to the cell cultures L-glutamine 
was added, but FBS was not. This serum-free media was used to enable any proteins secreted 
from the cells to be detected without the interference from the bovine proteins present in the FBS. 
However, during the course of these experiments it was observed that the morphology of the NT2 
cells changed after incubation in Optimem. The cultures were less confluent than comparable 
cultures that remained in cDMEM, and the cells appeared to be rounded up from the culture 
vessel, when compared with control cells. A number of these cells appeared to have extended 
cellular processes (see Figure 6.1).
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This observation was similar to that seen after the NT2 cells had been subjected to heat shock 
(compare Figures 5.2 and 6.1). These results lead to the hypothesis that incubation in Optimem 
induced a stress response in NT2 cells, therefore it was decided to examine the production of 
HSP70 in cells which had undergone treatment with Optimem.
6.2 METHOD
T25 flasks of NT2 and NT2N cells were incubated with Optimem for 24 hours. The conditioned 
media was collected and concentrated by ultra-centrifugation to give a 10-fold final concentration. 
The cell pellets were processed to give soluble and membrane proteins, as described in Chapter 
2. Protein concentrations of the cell samples were determined using a BCA assay, after which 
the samples were mixed with SDS-PAGE sample buffer and separated on a 7% acrylamide gel. 
The gel was transferred to nitro-cellulose membrane, which was immunoblotted using antibodies 
to APP and the HSP70 family of heat shock proteins as described previously (See Section 5.3.1).
6.3 EFFECTS OF OPTIMEM ON HSP70 PRODUCTION IN NT2 AND NT2N 
CELLS
Western blotting with an antibody which recognises the HSP70 family of heat shock proteins 
(Sigma) gave two bands of approximately 67 and 83 kDa in the soluble compartment of NT2 
cells. There was no change in band intensity between cells incubated with Optimem, and control 
cells incubated in cDMEM (see Figure 6.2).
Immunoblotting of control NT2N cells resulted in a single faint band of approximately 83 kDa in 
the soluble compartment. Cells that had been incubated with Optimem also contained this band 
in the soluble compartment, however it was much more intense. A second band of approximately 
67 kDa was also present in the soluble fraction of these cells (see Figure 6.2).
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6.4 EFFECTS OF OPTIMEM ON INTRACELLULAR APP (SEE FIGURE 6.3;
6.4.1 NT2 Cells
NT2 cells which had been incubated in Optimem contained the same bands as the control cells 
when immunoblotted with 22C11 (see Figure 6.3a), i.e. 3 bands, of approximately 115,128 and 
137 kDa, in both soluble and membrane fractions. Again the staining was more intense in the 
membrane fraction, and of this, the two larger bands were predominant. On immunoblotting with 
antibody 993 only the 128 and 137 kDa bands were present, in both the control and Optimem 
treated cells, confirming these bands as KPI-containing APP (i.e. APP751 and/or APP770).
Equal volumes of each sample were loaded onto the gel, resulting in a different protein 
concentration in each lane (see the legend to Figure 6.3 for exact amounts). This makes it 
difficult to compare the band intensity of each lane directly. However, using Kodak imaging 
software it was possible to quantify the bands and normalise for the amount of protein loaded. 
This confirmed that there was no change in APP production in Optimem treated cells when 
compared to controls (data not shown).
115
Table 6.1 Quantification of Western Blot Shown in Figure 6.3b - NT2
Data Only
Lane Treatment Fraction MW (kDa) Protein
(pg)
Intensity % Control
1 Optimem Soluble 115 8 5823 85
128 8 16901 96
137 8 22846 90
2 Membrane 115 13 81258 108
128 13 113744 90
137 13 181606 98
5 FBS Soluble 115 12 10227 100
128 12 39407 100
137 12 38017 100
6 Membrane 115 9 52283 100
128 9 87246 100
137 9 127484 100
The data in the column “% Control” was derived using the following calculation:
Amount of Protein loaded in FBS Lane
- x 1 0 0 %
Band Intensity x Amount of Protein Loaded
Intensity of Band in FBS Lane
6.4.2 NT2N Cells
Optimem treatment did have an effect on APP production in NT2N cells, however. When 
immunoblotted with antibody 22C11 the soluble fraction of cells incubated with Optimem
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contained a band of approximately 113 kDa, this was not present in the soluble fraction of control 
cells (compare lanes 3 and 7 in Figure 6.3a). This band was not detected with antibody 993, 
indicating that it was APP695 (compare lane 3 in Figures 6.3a and b). Antibody 22C11 detected 
the same bands in the membrane fractions of both the control and Optimem treated NT2N cells, 
i.e. a major band at approximately 113 kDa, with a band at 130 kDa also visible (see Figure 6.3a, 
lanes 4 and 8). As with the NT2 stem cells, the different amount of protein loaded in each lane 
makes direct comparison difficult, but quantification showed that there was an increase in both 
the 113 and the 130 kDa band, on immunoblotting with antibody 22C11, after treatment with 
Optimem {see Table 6.1).
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Table 6.2 Quantification of Western Blot Shown in Figure 6.3a - NT2N
Data Only
Lane Treatment Fraction MW (kDa) Protein
(pg)
intensity % Control
3 Optimem Soluble 113 3 21227 N/A
4 Membrane 113 3 74283 143
130 3 97427 155
7 FBS Soluble 113 5 0 N/A
8 Membrane 113 4 69085 100
130 4 84014 100
The data in the column “% Control” was derived using the following calculation:
Amount of Protein loaded in FBS Lane
— x 100%
Band Intensity x Amount of Protein Loaded
Intensity of Band in FBS Lane 
Antibody 993 detected a faint band of approximately 130 kDa in the membrane fraction of 
Optimem treated NT2N cells, this band was not visible in control cells (compare lanes 4 and 8 in 
Figure 6.3b). Together with the increase in the 130 kDa band seen with antibody 22C11, this 
result indicates that the production of a KPI-containing APP isoform is increased with Optimem 
treatment. Antibody 993 did not detect any APP in the soluble fraction of either the Optimem 
treated, or control, cells (lanes 3 and 7 in Figure 6.3b).
6.5 EFFECTS OF OPTIMEM ON SECRETED APP (SEE FIGURE 6.4;
Unconditioned media samples, i.e. media which had not been exposed to cells, were 
concentrated, separated by SDS-PAGE and immunoblotted along with the conditioned media 
samples. As discussed in Chapter 4 (see Section 4.3.2) the FBS added to DMEM contains
bovine APP, recognised by both antibodies 22C11 and 993 (lane 1 in Figure 6.4a and b). 
Optimem is a reduced serum media, with no added FBS, and therefore contains no components 
recognised by either antibody on an immunoblot (data not shown).
Incubation with Optimem did not appear to affect APP secretion by NT2 stem cells. A single 
band of approximately 128 kDa was detected in the media of both the control and the Optimem- 
incubated NT2 cells. This band was detected with both antibodies 22C11 and 993 indicating that 
it was derived from a KPI containing isoform of APP (see lanes 2 and 3, Figure 6.4a and b).
Media from control NT2N cells contained 2 bands of approximately 113 kDa and 130 kDa when 
immunoblotted with antibody 22C11 (see Figure 6.4a, lane 5). Only the 130 kDa band was 
detected with antibody 993 (see Figure 6.4b, lane 5). Conditioned Optimem from these cells 
contained only the band at 113 kDa when immunoblotted with antibody 22C11. This band was 
not detected by antibody 993, indicating that these cells secrete only APP derived from APP695 
(compare lane 4 in Figures 6.4a and b). Quantification of the blot shown in Figure 6.4b confirms 
that NT2N cells cultured in cDMEM do secrete a KPI-containing APP isoform(s), as the band in 
lane 5 (NT2N conditioned cDMEM) is almost twice the intensity of the band in lane 1 
(unconditioned cDMEM) (see Table 6.2)
Table 6.3 Quantification of the Immunoblot Shown in Figure 6.4b (Blotted 
With Antibody 993)
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Lane Cell Media MW (kDa) Intensity % Controi
1 none cDMEM 128 39069 100
2 NT2 Optimem 128 87890 N/A
3 NT2 cDMEM 128 104215 267
4 NT2N Optimem N/A 0 N/A
5 NT2N cDMEM 130 72369 185
The data in the column “% Control’ was derived using the following calculation:
Band Intensity ,nnn.-------------------------------  x 100%Unconditioned Media Band Intensity
6.6 CONCLUSION
Although due to experimental problems, it was not possible to induce a stress response in the 
NT2N cells by a period of heat shock, the results in this chapter show that an alternative protocol 
was successful. Incubating cells with serum free Optimem for 24 hours induced the production of 
HSP72 in the neuronal cells, though it did not have the same effect on the NT2 stem cells.
The stress period had a profound effect on the processing of APP in the NT2N cells. There was 
an overall increase in intracellular APP, including increases in APP695 in both the soluble and 
membrane fractions, along with an increase in membrane bound KPI-containing isoforms. 
However, this increase is not accompanied by an increase in APP secretion. Indeed, there is a 
decrease in the secretion of KPI-containing isoforms to below the level of detection.
Optimem does not appear to have such a profound effect on NT2 cells. Although the morphology 
of the cells changes, there is no increase in HSP70 production, and there are only slight changes 
in APP processing. This may be because the stem cells require a recovery period following the
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stress before the changes in protein production become apparent. An alternative explanation is 
that the stem cells are more resistant to stress conditions than the neuronal cells. This theory is 
backed up by their tolerance of short periods of heat shock, as described in Chapter 5.
A more direct comparison of the effects of cDMEM and Optimem on APP processing could be 
carried out using a western blot with equal amount of protein loaded in each lane. However, 
small sample volumes prevented repeat gels to be prepared which had been corrected for protein 
loading. Due to time and financial constraints it was not possible to repeat the entire experiment, 
therefore the results presented in this chapter have to be analysed with a degree of caution. 
Nevertheless, it is possible to conclude that incubation in Optimem does induce a stress 
response in NT2N cells. It is also apparent that either as a component of this response, or as a 
result of it, APP processing is altered in these cells. The preliminary results presented here 
indicate that the major effect is on KPI-containing APP isoforms, with an increase in production 
and concurrent decrease in secretion, though further experiments would have to be carried out to 
confirm this.
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Figure 6.1 24 HOURS INCUBATION WITH OPTIMEM INDUCES CHANGES 
IN THE MORPHOLOGY OF NT2 STEM CELLS
NT2 stem cells were incubated with Optimem for 24 hours; a parallel control culture was 
incubated with fresh cDMEM for the same time period. After the 24 hour period both cultures 
were photographed. Magnification
a control cells
b cells after incubation with Optimem
After the incubation with Optimem the culture is less confluent than controls, with many of the 
cells appearing to extend cellar processes. When viewed under the phase contrast microscope, 
the cell bodies in Optimem incubated cultures appeared to be more spherical and less flatly 
adherent to the culture vessel than controls.
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a) Control Cells
b) Optimem Treated Cells
Figure 6.2 A 24 HOUR INCUBATION IN OPTIMEM INDUCES A CHANGE IN 
HSP70 EXPRESSION IN NT2N CELLS, THOUGH NOT IN NT2 CELLS
NT2 and NT2N cells were incubated with Optimem or cDMEM for 24 hours. After the 24 hour 
period all cultures were harvested and processed to give soluble and membrane protein fractions. 
These were analysed on a 7% SDS-PAGE gel, transferred to nitro-cellulose membrane and 
immunoblotted with an antibody to the HSP70 family of heat shock proteins (Sigma). The blot 
was developed using chromogenic methods.
Lane Cells Treatment Fraction
1 NT2 Control Soluble
2 Membrane
3 Optimem Soluble
4 Membrane
5 NT2N Control Soluble
6 Membrane
7 Optimem Soluble
8 Membrane
5 jag total protein loaded per lane
Figures to the right of the blot indicate the mobility of molecular weight markers.
NT2 cells contain two bands of approximately 67 and 83 kDa in the soluble compartment, there is 
no change in band intensity between control and Optimem treated cells. NT2N control cells 
contain only the 67 kDa band in the soluble compartment. Optimem treated cells also contain this 
band, but it is much more intense. A second band of approximately 83 kDa is also present in the 
soluble proteins of these cells.
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Figure 6.3 OPTIMEM TREATMENT INDUCES CHANGES IN APP 
EXPRESSION IN BOTH NT2 AND NT2N CELLS
Optimem treated and control cells were processed to give soluble and membrane protein 
fractions, these were separated on a 7% SDS-PAGE gel, transferred to nitro-cellulose membrane 
and immunoblotted with antibodies 22C11 (a) and 993 (b).
Figures to the right o
Lane Treatment Cells Fraction Total Protein Loaded
1 Optimem NT2 Soluble 8ng
2 Membrane 13 ng
3 NT2N Soluble 3ng
4 Membrane 3ng
5 Control NT2 Soluble 1 2  ug
6 Membrane 9 ng
7 NT2N Soluble 5ng
8 Membrane 4ng
the blot indicate the mobility of molecular weight markers.
Treatment with Optimem induces an increase in APP in the soluble fraction of NT2N cells, seen 
in a and not b, indicating that it is an increase in APP695. The Optimem treatment also induces an 
increase in membrane bound APP in these cells, seen in both a and b, indicating that it is an 
increase in KPI-containing isoforms.
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Figure 6.4 TREATMENT WITH OPTIMEM INDUCES PROFOUND CHANGES 
IN SECRETED APP FROM NT2N CELLS
Conditioned cDMEM and Optimem from NT2 and NT2N cells, along with unconditioned control 
cDMEM, was concentrated 10-fold, mixed with SDS-PAGE sample buffer and analysed on a 7% 
SDS-PAGE gel. The gel was transferred to nitro-cellulose membrane and immunoblotted with 
22C11 (a) and 993 (b).
Lane 1 Control cDMEM, not exposed to cells
Lane 2 NT2 conditioned Optimem
Lane 3 NT2 conditioned cDMEM
Lane 4 NT2N conditioned Optimem
Lane 5 NT2N conditioned cDMEM
Figures to the right of the blot indicate the mobility of molecular weight markers.
Incubation with Optimem does not appear to affect APP secretion from NT2 cells. NT2N cells 
after Optimem treatment reduce the secretion of APP, to below the level of detection in the case 
of the KPI-containing isoforms.
a) 22C11
b) 993
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Chapter Seven - In Situ Hybridisation
7.1 INTRODUCTION
The work described in the previous chapters has shown that subjecting NT2 and NT2N cells to 
stressful conditions has an effect on the processing of APP. In the case of both cell types, stress 
increases the production of APP, though this appears to be retained inside the cells, as there is 
not an accompanying increase in APP secretion. Since the APP increase is detected with 
antibodies 22C11 and 993 in both cell types, it would appear to be due to an increase in 
production of KPI-containing APP isoforms.
Using the antibodies available, it is not possible to distinguish between APP751 and APP770 by 
Western blotting. For this reason, it was decided to examine the effects of stress on APP mRNA 
production, as probes are available for all three major APP isoforms.
7.2 METHOD (SEE SECTION 2.15;
Cells were grown on glass coverslips and treated as described in Section 2.15.1. Three 
coverslips of each cell type, and each treatment, were labelled with probes against APP695, 
APP751, APP77oand the inducible form of HSP70 (see Table 7.1 for probe sequences), giving a 
total of 12 coverslips per probe. The coverslips, attached to glass microscope slides, were 
dipped in photographic emulsion for autoradiography, and left to develop for 7 weeks.
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Table 7.1 Probe Sequences
Probe Length Sequence Reference Ti Tw
APP69
5
30 5’ CTG CTG TTG TAG GAA CTC 
GAACCACCT CCT 3’
(Ponte et al. 
1988)
27°C 52.5°C
APP75
1
60 5’ CAT CAG GGG TAC TGG CTG 
CTG TTG TAG GAA TGG CGC 
TGCCACACA CGG CCATGC 
AGT ACT 3’
(Kitaguchi et 
al. 1988)
41.6°C 54.4°C
APP77
0
57 5’ GTT TAA CAG GAT CTC GGG 
CAA GAG GTT CCT GGG TAG TCT 
TGAAAC TTT GGG ACA 3’
(Kitaguchi et 
al. 1988)
33.6°C 56.1°C
HSP 30 5’ CGATCT CCT TCATCT TGG 
TCA GCA CCA TGG 3’
(Shimizu et 
al. 1999)
28°C 54°C
After 7 weeks the slides were developed the cells counter stained with Cresyl violet, and the cells 
examined by image analysis. Grain counts were performed for up to 50 cells per experimental 
procedure and probe. Image analysis was performed using a Seescan image analyser system 
(Seescan Instruments, Cambridge).
7.3 RESULTS
7.3.1 NT2 Cells (See Figure 7.3)
Treatment of NT2 cells with Optimem for 24 hours resulted in significant changes in mRNA 
expression (see Table 7.2). There was a 14-fold increase in expression of HSP mRNA, indicating
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that the treatment had induced a stress response in the cells. There was no change in APP695 
mRNA, but there was a 12-fold increase in APP751 and a 2-fold increase in APP770 mRNA. 
Levene’s test for equality of variance showed the results to have a non-normal distribution, so the 
non-parametric Mann Whitney U test was used to compare the means. These increases proved 
to be significant at the p<0.0001 level. This data is shown graphically in Figure 7.1.
Table 7.2 Expression of APP mRNAs In NT2 Control and Stressed
Cells
Control (cDMEM) cells Optimem cells
N Mean Grain 
Count per Cell
SE N Mean Grain 
Count per Cell
SE
APP695 50 6.59 1.24 50 4.36 0.83
APP751 50 9.63 3.55 50 118.35** 10.23
APP770 50 174.65 15.10 49 314.64** 25.47
HSP70 50 1.82 0.73 50 25.47** 4.46
**p<0.0001 (Mann Whitney U test)
7.3.2 NT2N Cells (See Figure 7A)
Treatment of NT2N cells with Optimem for 24 hours also resulted in changes in mRNA 
expression (see Table 7.3). There was no significant change in HSP70, APP695 or APP770 
mRNA, but there was a 0.65-fold increase in APP751 mRNA, which was significant at the p<0.05 
level when tested by the Mann Whitney U test. This data is shown graphically in Figure 7.2.
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Table 7.3 Expression of APP mRNAs in NT2N Control and
Stressed Cells
Control (cDMEM) cells Optimem cells
N Mean Grain 
Count per Cell
SE N Mean Grain 
Count per Cell
SE
APP695 38 143.30 13.79 42 177.55 31.44
APP751 32 81.75 15.83 43 135.35* 17.71
APP770 50 157.51 23.55 49 174.41 34.53
HSP70 44 51.70 7.99 45 86.60 13.41
*p<0.05 (Mann Whitney U test)
7.4 CONCLUSION
These results provide further information about the APP expression of both NT2 and NT2N cells 
under normal conditions. NT2 cells produce mainly APP770 mRNA, with very low levels of APP751 
and APP695. NT2N cells appear to make high levels of both APP695 and APP770 mRNA, with a 
moderate amount of APP751. These results disagree with some previous studies, which found 
NT2 stem cells to produce APP770 and APP751 in similar quantities, while the NT2N neuronal cells 
produced only very low levels of these two isoforms (Ackerman et al. 1994; Wertkin et al. 1993). 
The data presented in this chapter is supported by the work presented in Chapter 4, which 
showed NT2N cells to secrete KPI-containing APP. These results also show that overall NT2N 
cells make greater amounts of APP mRNA than NT2 cells.
These data show that treatment with Optimem for 24 hours is sufficient to induce a stress 
response in the NT2 cells. This appears to contradict the protein data, which indicated that
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HSP72 protein levels were not elevated in these cells. However, as discussed in Chapter 6, it 
may be that the cells require a recovery period under normal conditions before the HSP72 protein 
is actually expressed. Alternatively there could be high levels of turnover of HSP72 protein within 
the cells, so that cells collected at different time points within the 24 hour Optimem incubation 
period may have different levels of HSP72 protein. To clarify this point further work should be 
done with altered incubation lengths, and recovery time in cDMEM.
In NT2 stem cells the effects of the stress period on APP mRNA levels is dramatic. There is an 
overall, highly significant, increase in APP mRNA, but this is splice specific. The greatest 
increase is in APP751 mRNA, with an increase in APP770 mRNA and no change in APP695 mRNA 
levels.
Optimem treatment does not have a significant effect on HSP70 mRNA levels in NT2N cells.
This is surprising, considering the marked increase in HSP72 protein levels in these cells after the 
same treatment. There are three possible explanations for the lack of statistical significance of 
the result; the first possibility is that Optimem treatment does not affect HSP70 mRNA levels in 
the neuronal cells, which may indicate that the cells are not actually stressed. This seems 
unlikely, due to the effect the treatment has on the HSP70 family protein levels, and also the 
effect on APP mRNA levels, discussed below. The lack of significance may be due to the sample 
size, if 100 cells had been analysed the result may have reached significant status, however, lack 
of time and resources made this impossible. The third explanation is that the “control” culture 
conditions induced a stress response in the “control” cells. This is supported by the high grain 
count for HSP70 mRNA in these cells (a mean of 51.7 compared to 1.82 for the control NT2 
cells).
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As for the NT2 cells, the effects of the stress response on APP mRNA are significant. Again 
there is an overall increase, and again this is splice specific. There is no change in APP695 or 
APP770 mRNA, but APP751 mRNA is increased 0.67-fold, which is significant at the p<0.05 level. 
This increase is of the same proportion as the increase in HSP70.
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Figure 7.1 TREATMENT WITH OPTIMEM INCREASES PRODUCTION OF 
HSP70 mRNA AND ALTERS PRODUCTION OF APP mRNAs IN NT2 STEM 
CELLS
Stem Cell In Situ Data
350.00
300.00
250.00
8 200.00
O 150.00
100.00
50.00
□  FBS
□  Optimem
mRNA
NT2 cells were grown on coverslips, treated with Optimem for 24 hours, fixed, and incubated with 
probes to H S P70, A P P 695, APP751 and APP770 mRNAs
The data shows a highly significant increase in H S P70, APP751 and APP770 mRNAs after 
incubation with Optimem.
(** pO.0001, Mann Whitney U)
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/Figure 7.2 TREATMENT WITH OPTIMEM INCREASES PRODUCTION OF 
HSP70 mRNA AND ALTERS PRODUCTION OF APP mRNAs IN NT2N 
CELLS
Neuronal Cell In Situ Data
250.00 -r—  , ,    ------ ,
200.00  -
□  FBS
□  Optimem
in T— 0CT> mCD h- r-Q. Q. a.a. a Ql< < <
mRNA
NT2N cells were grown on coverslips, treated with Optimem for 24 hours, fixed, and incubated 
with probes to H SP70, A P P 695, APP751 and APP770 mRNAs
The data shows a significant increase in APP751 mRNA after incubation with Optimem.
(* p<0.05, Mann Whitney U)
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Figure 7.3 OPTIMEM TREATED NT2 STEM CELLS SHOW AN 
UPREGULATION OF APP AND HSP mRNAs
NT2 cells were grown on coverslips, incubated with either cDMEM (control) or Optimem for 
24 hours, fixed, and incubated with probes to H S P70, APP695, APP751 and APP770.
The cells make predominantly APP770 under control conditions (compare ai) bi) and ci)). 
Optimem treatment upregulates production of APP751 mRNA (compare bi) and bii)); APP770 
mRNA (compare ci) and cii)) and H S P70 mRNA (compare di) with dii)).
Magnification x5000
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Figure 7.4 OPTIMEM TREATED NT2N NEURONAL CELLS SHOW AN 
UPREGULATION OF APP751 mRNA
NT2N cells were grown on coverslips, incubated with either cDMEM (control) or Optimem for 
24 hours, fixed, and incubated with probes to HSP70, APP695, APP751 and APP770.
The cells make predominantly all A P P  isoforms under control conditions, with APP695 and APP770 
being the more abundant (compare ai) bi) and ci)). Optimem treatment significantly upregulates 
production of APP751 mRNA (compare bi) and bii)).
Magnification x5000
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Chapter Eight - Discussion
Chapter Eight Discussion
8,1 INTRODUCTION
The deposition of (3A4 in the brain is one of the key features of AD. Gene mutations in the APP, 
PS1 and PS2 genes, which are associated with the early onset form of familial AD, all lead to 
either increased total production pA4 (Haass etal. 1994; Citron etal. 1994; Cai etaL 1993;
Citron et al. 1992), or an increased proportion of pA4i-4m (Citron ef a/. 1997; Scheuner et al. 
1996; Duff et al. 1996; Maruyama et al. 1996) From this evidence it seems likely that the onset of 
sporadic AD is also associated with increased pA4 production. Since pA4 is formed from the 
proteolytic cleavage of APP, any event which increases APP production, or changes APP 
processing, could potentially increase pA4 production.
The promoter region of the APP gene contains a heat shock element, therefore it is likely that 
conditions which cause cells to undergo the stress response could lead to an up-regulation of 
APP. There is also evidence that neurones in the AD brain are in a state of stress. (Harrison et 
al 1993) These data lead to the hypothesis tested in this thesis; that conditions which induce a 
stress response in cells result in an increase in production of APP protein, and that this in turn 
leads to an increase in production of either total, or longer length forms of, pA4. Due to the 
apparent neurotoxicity of pA4, any increase in this peptide could perpetuate the stress response 
in the cells, leading to a “vicious circle” of APP and pA4 production.
The primary objective of this work was to examine the processing of APP in NTera2 stem and 
neuronal cells, both under control conditions and in conditions that are stressful to the cells. 
Immunoprecipitation and western blotting techniques, using a panel of antibodies, were used to
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differentiate between the various different APP isoforms, and to determine whether the APP 
processing was potentially amyloidogenic or not. Evidence of cellular stress was sought by 
examination of the induction of HSP72 protein production by the cells. In situ hybridisation was 
also used to examine mRNA levels in order to confirm the protein findings, and to differentiate 
between the two KPI containing APP isoforms.
8.2 APP PROCESSING IN NT2 AND NT2N CELLS
From the immunoblot data in Chapter 4 it was concluded that NT2 cells make predominantly 
APP751 and / or APP770, with a small amount of APP695 also being produced. The in situ data 
presented in Chapter 1 indicates that the predominant KPI-containing isoform is APP770. As 
expected, the majority of intracellular APP is membrane bound. The KPI containing APP 
isoform(s) is easily detected in the conditioned media of the cells, but the smaller isoform, APP695 
appears to be secreted at levels below the detection of the methods used. (See Figures 4.1 and 
7.1).
NT2N cells make predominantly APP695, which is secreted. One or both of the KPI-containing 
APP isoforms is also made and secreted, and since this isoform is not detected in the cellular 
proteins, it may be assumed that is has a rapid turnover within the cell. The in situ data indicates 
that the KPI-containing isoform is APP770. (See Figures 4.1 and 7.2)
These data confirm the findings of other groups that differentiation of NT2 cells to NT2N cells, 
using retinoic acid, alters the expression and processing of APP isoforms (Ackerman etal. 1994; 
Wertkin et al. 1993). However, in contrast to previous reports, both cell types appear to make at 
least two, if not all three of the major APP isoforms. The change is in the relative proportions of 
the isoforms, both inside the cells, and in the conditioned media. As the cells differentiate the
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major APP isoform switches from being KPI-containing, to being APPsqs, the most abundant 
isoform in the brain. However, the neuronal cells continue to produce and secrete the KPI- 
containing isoforms. This evidence reinforces the hypothesis that these cells provide a good in 
vitro model of human CNS neurones in the brain, as all three isoforms are produced in similar 
relative amounts in vivo in the human brain. (Rohan de Silva etal. 1997)
In the experiments presented in this thesis, soluble and membrane associated APP proteins run 
at similar mobilities on acrylamide gels. This is surprising, as one would expect proteins present 
in the soluble fraction to have been cleaved, and therefore be smaller then the membrane 
associated forms. There are two possible explanations for this. The first is that there is 
incomplete separation of the fractions during the preparation of the samples. The proteins 
detected in the “soluble” fraction are actually membrane associated, and more rigorous separation 
techniques would result in all the cellular APP appearing in the membrane fraction. The second 
possibility is that the proteins are cleaved immediately after glycosylation in the Golgi, resulting in 
proteins that are shorter in length but larger in weight than the membrane bound proteins. This is 
possible, as APP undergoes both N-linked glycosylation, which occurs in the endoplasmic 
reticulum (ER), and O-linked glycosylation, which occurs in the Golgi complex. There is evidence 
to suggest that p-secretase cleavage can occur in both the ER and the Golgi. (Cook et al. 1997)
APP is one member of a family of proteins, including APLP1 and 2, as discussed in the 
introduction (see Section 1.4.5 and Lyckman etal. 1998). Although neither of these proteins 
contain the pA4 sequence, and so are unlikely to be involved with the pathology of AD, they are
highly homologous to APP, and many APP antibodies cross-react with APLP2. (Slunt et al. 1994)(
This fact means that care must be taken when interpreting data obtained using these antibodies. 
As demonstrated by the immunoblot data in Chapter 4, NT2N cells do not make or secrete a
detectable amount of APLP2, while NT2 cells make only a small amount, which Is membrane 
associated, and does not appear to be secreted at detectable levels. As a result of this finding, it 
is possible to be confident that any changes in protein productjop JM§P.ied by western blot,are 
changes jnAPP andngiAElEZ
8.2.1 APP Processing Pathways in NT2 and NT2N Ceiis
Both NT2 and NT2N cells secrete APP, which can be detected by western blotting of the 
conditioned media from the cells. Using serial immunoprecipitations with antibodies 22C11 and 
6E10 it was possible to distinguish between amyloidogenic and non-amyloidogenic cleavage 
pathways. 6E10 removed APPsa from the media, and any remaining APPsJ3 was detected using 
22C11. Although 6E10 would also recognise any APP which had been cleaved by y-secretase, it 
is generally assumed that this enzyme activity occurs after p-secretase cleavage (Cook et al. 
1997; Hartmann et al. 1997), so that the secreted APP species which begins at the amino- 
terminus of APP and ends at the carboxyl-terminus of pA4 does not exist. Therefore it is 
assumed that any APP detected by 6E10 has been cleaved by a-secretase and is non- 
amyloidogenic.
It seems likely that all secreted APP from NT2 cells is a result of non-amyloidogenic cleavage, 
and that the majority of APP secreted by NT2N cells is also derived from this pathway (see 
Section 4.5.2 and Figure 4.6). However, a small proportion of APP appears to undergo 
amyloidogenic breakdown in NT2N cells. All immunoprecipitation steps detected APP of 
molecular weights 115 and 140 kDa, and the relative intensity of the two bands did not change. 
From previous results it was apparent that the 115 kDa APP was APP695 and the 140 kDa one or 
both of the KPI-containing isoforms (see Figure 4.1), therefore it appears that the amyloidogenic 
cleavage of APP in NT2N cells is not isoform specific. It appears that a small percentage of the
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total APP produced by NT2N cells is processed via amyloidogenic pathways, not just a 
percentage of APP695.
Although the presence of APPs(3 is not conclusive proof that the neuronal cells make pA4, it is 
an indication that at least one of the secretase activities required for this is present and functional 
in these cells. This result agrees with results from other research groups, which have detected 
secreted and intracellular pA4 in the neuronal cells, but not in the stem cells (Wertkin et al. 1993), 
The results reported here show that pA4 in the NT2N cells is likely to be derived from all APP 
isoforms.
The methods used in this thesis were not able to detect either intracellular or secreted pA4 from 
either the stem cells or the neuronal cells. It is likely that this is due to problems with the 
sensitivity of the detection methods used, as other groups have reported the presence of pA4 
both in the conditioned media of NT2N cells, and accumulated within the cells (Wertkin et al. 
1993). In that instance the pA4 was detected by radioactive labelling, which was not attempted 
in the course of the work presented in this thesis. Although radioactive labelling may be the 
easiest way with which to detect pA4, the aim of this work was to compare NT2 and NT2N cells 
under normal and stressed conditions, the procedures required for the introduction of a 
radiolabelled compound would add another unknown quantity to that investigation. Prior to the 
introduction of the radiolabelled compound cells must be starved of an essential amino acid, and 
subsequently must be fed with an excess of that amino acid to flush out the radiolabelled 
compound. This step of depriving the cells of an essential nutrient may well have induced a 
stress response in the cells, and so the “normal” conditions would be compromised.
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8.3 EFFECTS OF STRESS ON NT2 STEM CELLS
8.3.1 Effects on HSP70 Protein and mRNA
During the course of this work attempts were made to induce a stress response in NT2 stem cells 
by two different means. Firstly by exposing the cells to a temperature of 42°C for 8 hours, 
followed by recovery at 37°C for 24 hours. Secondly the cells were stressed by incubating them 
in serum-free Optimem media. Intracellular and secreted APP, as well as intracellular proteins of 
the HSP70 family were examined after both treatment strategies. APP and HSP70 mRNA were 
also examined after the Optimem treatment.
The heat shock treatment induced the production of an approximately 78 kDa protein, which 
reacted with an antibody to the HSP70 family of heat shock proteins (see Figure 5.3). This 
protein was never detected in control cells, nor was it present in cells immediately after the 
incubation at 42°C. It was present by 4 hours recovery time at 37°C and remained detectable 
throughout the remaining 24 hour recovery period.
The antibody used to detect HSP70 was obtained from Sigma (Product No. H-5147) and 
recognises both the constitutive (HSP73) and inducible (HSP72) forms of human HSP70. 
(Information taken from Sigma data sheet) There are at least ten recognised members of the 
human HSP70 family (Voellmy et al. 1985; Harrison et al. 1986; Harrison et al. 1987; Leung et al. 
1992; Fathallah etal 1993; Bonnycastle etal. 1994; Tavaria etal. 1995) and the functions of 
many remain unclear. It is not known how many of these the antibody used would react with.
The HSP70 antibody detected a band of 83 kDa in control NT2 and NT2N cells, which was up- 
regulated by NT2N cells after Optimem treatment; a band of 67 kDa was also detected in control 
NT2 cells, though this was only present in NT2N cells after Optimem treatment. An additional
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band at 78 kDa was present in NT2 cells after heat shock treatment, this band was never 
detected in NT2N cells (see Table 8.1). Although the identity of these various isoforms is not 
clear, the fact that there was an upregulation of some or all of them in treated cells was taken as 
an indication that the cells had undergone a stress response. Since it was not the object of the 
work described in this thesis to determine HSP70 expression in NT2 and NT2N cells, the matter 
was not investigated further.
Table 8.1 HSP70 E xp res tion  in  C on tro l a n d  S tressed  NT2 a n d  NT2N Cells
Present in:
HSP70 -  detected Control Heat- Optimem- Control Optimem-
molecular weight. NT2 Shocked NT2 Treated NT2 NT2N Treated NT2N
67 kDa S / / y y X y
78 kDa X S X X X
83 kDa s s y y y y y y y y
j r  Not detectable
S  Present, the number of ticks indicates the relative proportions
Incubation with Optimem did not induce any changes in expression of the HSP70 family of 
proteins in the NT2 stem cells, though there was a highly significant increase in HSP70 mRNA in 
these cells when compared with controls (see Figures 6.2 and 7.1). There are two possible 
explanations for these seemingly contradictory results.
The first is that the protein and mRNA studies were carried out on different sets of cells, at 
different time points. It is possible that for some reason the cells that were taken for proteins 
studies were more resistant to the Optimem incubation than those taken for mRNA studies. This
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resistance could be due to the passage number of the cells, as NTera2 cells have a varying 
karyotype, and may be induced to differentiate by many different culture conditions. To eliminate 
the effects of any spontaneous differentiation as much as possible, all experiments were 
performed on cells with passage numbers between 30 and 40. Another possibility is small 
inconsistencies between the two batches of Optimem used rendered the second batch less 
stressful to the cells. This explanation seems unlikely, due to the fact that both sets of cells 
which had undergone Optimem incubation appeared stressed when viewed under a microscope 
(see Figure 6.1). They were less confluent than control cells and a number of them appeared to 
extend cellular processes.
The second explanation for the inability of Optimem treatment to induce changes in HSP70 
protein production involves the recovery period of the cells, and the production and turnover rate 
of the protein. The induced protein was not present in heat-shocked cells immediately after the 
period of high temperature, it did not appear until the cells had had a recovery period of 4 hours 
(see Figure 5.3). The cells that were treated with Optimem did not undergo a recovery period, but 
were harvested immediately after the Optimem incubation. It is possible that if the cells had been 
re-fed with the control media, and left at 37°C for a period of time, there would be production of 
the 78 kDa HSP70 protein. From the in situ data it is apparent that Optimem treatment does have 
an effect on the levels of HSP70 mRNA, it is possible that the NT2 cells only begin to translate 
that mRNA when it has accumulated to a certain level within the cell, in situ data on the heat- 
shocked cells would help to clarify this point, if it were true one would expect the cells that had 
zero recovery time to have significantly increased levels of HSP70 mRNA, despite having normal 
levels of HSP70 protein. One of the documented responses to cellular stress in numerous cell 
types an overall decrease in protein production. It is possible that the translation of the HSP70 
mRNA to HSP70 protein cannot occur while the cells are still in the stressful environment.
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It is not apparent why incubation with Optimem should have any effect on HSP70 protein or 
mRNA production. Optimem is marketed by Gibco life science as a reduced serum medium. It is 
used routinely by other laboratories to culture NT2 stem and neuronal cells, though in those cases 
FBS is added to the media (Pleasure et at. 1992). Since the exact composition of Optimem is 
confidential information, it is only possible to make theories as to why it induces a stress 
response in NT2 cells, and also in NT2N cells, as discussed below. Optimem has added growth 
factors and trace elements, any one of which may be in some way toxic to NT2 stem and 
neuronal cells. Optimem also contains sodium pyruvate, which is not present in the normal 
DMEM used to culture NT2 cells. However, the most likely explanation is that the stress 
response is caused, not by some component of the media, but by the absence of FBS. A lack of 
essential nutrients is one of the conditions which will induce a stress response in many cell types 
(Lindquist, 1986). There may be a compound in FBS which is essential for the healthy growth of 
NT2 and NT2N cells which is not compensated for in the growth factor enriched Optimem media.
The HSP70 protein data from the heat-shocked cells, and the HSP70 mRNA data from the 
Optimem treated cells proves that the cells are under stressful conditions. Since the primary 
objective of this work is to investigate APP production and processing under normal and stressful 
conditions, the reason Optimem induces the stress response is not as important as the effects of 
that stress on APP processing.
8.3.2 Effects on APP Production
Heat-shock induces an overall increase in APP in NT2 stem cells (see Figure 5.4). This increase 
is not immediately apparent, cells immediately after heat-shock contain the same amount of APP 
as control cells. The increase in APP is not apparent until after 4 hours recovery at 37°C. This
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delay in the effects of heat-shock on APP production mirrors that of the production of the induced 
form of HSP70 protein, and may in some way support the suggestion that NT2 stem cells cannot 
up-regulate protein production whilst still under stressful conditions.
There is a specific increase in the smaller of the 2 major isoforms of APP found in these cells. 
This is a KPI-containing form, though it is not possible to say if it is APP751 or APP770 as both 
isoforms are recognised by the anti-KPI antibody 993, and the two are not separated on a 7% 
SDS-PAGE gel. It is most likely to be immature APP that is not fully glycosylated, which would 
indicate that the protein is being retained in the ER. This could lead to an increase in production 
of pA4i-42 as there is evidence to suggest that this form of the pA4 peptide is produced in the ER. 
(Cook et al. 1997) The in situ data on Optimem treated cells would indicate that this increase is 
due primarily to an increase in APP751 as that isoform showed proportionally the largest increase 
in mRNA levels, a 12-fold increase compared to control cells. APP770 mRNA levels also 
increased 3-fold compared to control cells (see Figure 7.1).
As with HSP70 protein, Optimem incubation had little effect on APP protein production. 
Experimental cells contained the same isoforms of APP as controls, and they were present in the 
same proportions.
The heat-shock induced increase in intracellular APP is not mirrored by a concurrent increase in 
secreted APP. Indeed, there is a slight decrease in secretion from stressed cells (see Figure 
5.5). The implications of this finding are discussed in Section 8.5.
To summarise, stress induces NT2 stem cells to increase production of APP. There is an overall 
increase in intracellular KPI-containing APP, which is retained inside the cells as there is no
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increase in APP secretion. There is no increase in either APP695 protein or mRNA. There is, 
however an increase in APP770 mRNA, and a large increase in APP751 mRNA. This indicates that 
the up-regulation of APP production is splice specific, if the increase in production was not splice 
specific one would expect all APP isoforms to be increased to the same extent, or that the 
predominant isoform in control cells (APP770) would be increased the most. However, as already 
stated, this is not the case in NT2 stem cells. As discussed in Chapter One (see Section 1.4.4.2) 
there is a specific upregulation of APP751, an isoform implicated in the pathology of AD. (Hyman 
etal. 1992; Moir et al. 1998; Johnson etal. 1990; Tanaka etal. 1989; Tanaka etal. 1988). 
Furthermore, the protein appears to be retained in the ER, the site of production of the longer 
forms of pA4 (Cook et al. 1997), which are more likely to form the insoluble amyloid deposits 
typical of the disease. (Gravina et al. 1995)
8.4 EFFECTS OF STRESS ON NT2N NEURONAL CELLS
NT2N cells were stressed by incubating them in serum free Optimem for 24 hours. As discussed 
above, the mechanism by which Optimem causes a stress response is not known, however, 
Optimem treatment induced the production of an 83 kDa band that reacted with antibodies to 
HSP70. This band was not present in control cells, therefore it was assumed that cells containing 
this band were shocked.
8.4.1 Effects on HSP70 Protein and mRNA
Control NT2N cells contained a single band of approximately 83 kDa when immunoblotted with an 
antibody to HSP70 protein. Cells incubated in serum free Optimem media also contained this 
band, though it was much more intense. These cells contained, in addition, an approximately 67 
kDa band, which was not present in controls (see Figure 6.2). However, the results of in situ 
experiments on HSP70 mRNA in control and Optimem treated NT2N cells were not consistent
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with these results. There was no significant increase in HSP70 mRNA in the stressed cells (see 
Figure 7.2).
These results are a reversal of the NT2 stem cells results, in which Optimem treatment did not 
alter HSP70 protein production, but massively increased mRNA levels. This may be due to 
different transcription pathways or differing responses to stress by the two cell types. It could be 
that the stem cells have a high HSP70 protein turnover rate, resulting in very little protein present 
in the cell at one time, despite the presence of high levels of mRNA. In contrast the neuronal 
cells may have a much lower HSP70 protein turnover rate, resulting in large increases in 
intracellular protein from a small increase in mRNA levels.
Other possible explanations for the apparently contradictory HSP70 protein and mRNA results in 
Optimem treated NT2N cells were discussed in Chapter 7. There is an approximately 60% 
increase in HSP70 mRNA in the stressed cells, though this is not a statistically significant 
increase. This could be due to a small sample size, including more cells in the analysis may have 
led to a significant result. The other, very probable, explanation is that the “control” cells used in 
the in situ experiment were already in a state of shock. These cells had high levels of HSP70 
mRNA (a mean of 51.7 grains per cell, in contrast to the control stem cells that contained a mean 
of 1.82 grains per cell). As for the NT2 stem cells, the protein studies and the mRNA studies 
were carried out on two different sets of cells, so the HSP70 protein levels in the in situ cells are 
not known. If this theory is correct, one would expect to have seen increased levels of HSP70 
protein in the FBS treated cells.
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8.4.2 Effects on APP Production and Processing
The period of stress had a profound effect on the processing of APP in the NT2N cells. There is 
an overall increase in intracellular APP in stressed cells when compared with controls (compare 
lanes 4 and 8 in Figure 6.3a). This increase is in all APP isoforms, western blotting the cells with 
antibodies 22C11 and 993 produces the same increase in APP in the shocked cells when 
compared to the controls. The in situ data indicates that the increase in APP protein is mostly 
due to an increase in APP751, there is a 67% increase in the mRNA for that isoform, an increase 
that is significant at the p<0.05 level (see Figure 7.2). There are no significant changes in levels 
of APP695 or APP770 mRNA, which seems to contradict the protein data, which shows a clear 
increase in all isoforms. However, as discussed in section 8.4.1 there are several possible 
explanations for the apparent contradictory nature of the 2 sets of results.
The most profound effect of the stress period was on APP secretion from NT2N cells. Stressed 
cells showed an overall decrease in APP secretion, with a reduction of secretion of KPI- 
containing isoforms to below the limits of detection (see Figure 6.4).
In summary, stressed NT2N cells show an overall increase in APP protein production, with a 
distinct increase in production of KPI-containing isoforms. A decrease in APP secretion, and 
specifically a loss of secretion of KPI-containing isoforms accompany this increase in production. 
The in situ data shows a significant increase in APP751 mRNA, indicating that this isoform may 
be responsible for most of the observed changes.
8.5 SUMMARY (SEE TABLE 8.2 and TABLE 8.3J
Conditions of cellular stress affect APP production and processing in both NT2 and NT2N cells. 
Both heat-shocked stem cells, and Optimem treated neurones show an increase in APP
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production that is not accompanied by an increase in secretion, indeed there seems to be a drop 
in APP secretion. Western blotting indicates that the increase in protein production is due to a 
specific increase in KPI-containing APP, and mRNA studies indicate that in both cell types it is 
specifically APP751 that is affected.
Although each cell type produces all three APP isoforms, they produce them in different ratios, 
and appear to process them through different pathways. However, both cell types show the same 
changes in APP production in response to stress, an increase in APP751. In neither cell type is 
this the predominant isoform under normal conditions, therefore it’s increase is not due to a 
general up-regulation in APP production, since in that case it would be expected that all isoforms 
to be increased to the same degree, or the most predominant isoform under normal conditions to 
show the greatest increase after stress.
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Table 8.2 E xp ress ion  o f  A P P  Iso fo rm s  B y  C o n tro l NT2
a n d  NT2N C ells
APP695 APPkpi APP751 APP770
NT2 Intracellular ✓ y y y N/A N/A
stem Secreted X / / / N/A N/A
cells mRNA y N/A y y y y
NT2N Intracellular y y y y N/A N/A
neuronal Secreted y y y y N/A N/A
cells mRNA y y N/A y y y
Western blotting cannot differentiate between APP751 and APPno, 
therefore protein data is presented together as APPkpi 
X  Not detectable
X  Present the number of ticks indicates the relative proportions
Accompanying this splice specific increase in APP751 is a decrease in APP secretion. In the case 
of the neuronal cells there is no detected secretion of APP770 or APP751 at all under stress 
conditions. If the APP is not secreted, it is more likely to .be broken down within the cell, in which 
case there is a very strong possibility that there would be an increase in production of pA4 in 
response to cellular stress, as a-secretase cleavage occurs predominantly at the cell surface 
(Boseman Roberts et ai. 1994; Sisodia, 1992) while p- and y-secretase cleavage occurs in the 
ER or Golgi (Cook et al. 1997; Hartmann et al. 1997). A proportion of APP which reaches the 
cell surface is not cleaved by a-secretase, but is re-internalised and broken down in the 
endosome I lysosome pathway. (Koo and Squazzo, 1994) It is not known if any particular APP 
isoform is more likely to be processed in an amyloidogenic fashion. The data from serial
150
immunoprecipitation experiments presented here indicates that all isoforms are processed 
through amyloidogenic and non-amyloidogenic pathways in the same proportion. However, it 
would be interesting to see if that was still the case after shock treatment. It is possible that the 
high levels of APP751 would force more of it to be processed via amyloidogenic pathways.
Table 8.3 Changes in Protein and mRNA Expression In NT2 
And NT2N Cells After Stress
APP695 APPkpi APP751 APP770 HSP70
NT2 Intracellular <-> t N/A N/A t
stem Secreted N/A N/A N/A
cells mRNA <r> N/A t t t
NT2N Intracellular 4, t N/A N/A t
neuronal Secreted N/A N/A N/A
cells mRNA <-> N/A t <-» 0
No Change 
T Increase
>I  Decrease
Western blotting cannot differentiate between APP751 and A PPm , therefore protein 
data is presented together as APPkpi
The results presented here are based on the heat-shock results for the stem cells, 
and the Optimem results for the neuronal cells.
8.6 IMPLICATIONS FOR ALZHEIMER'S DISEASE
As discussed in the introduction, Chapter 1, there are several indications that neurones in the AD 
brain are under cellular stress. The work presented in this thesis shows that neurones in this 
condition increase the production of APP, and will most likely also increase production of pA4.
As pA4 may be neurotoxic, it is possible that an increase in the production of the peptide could 
cause neurones in the surrounding area of the brain to suffer conditions of cellular stress, thus 
increasing APP levels. In this way the pathology could spread through the brain. This theory is 
known as the amyloid cascade hypothesis. (Hardy and Higgins, 1992)
Neurones under stress specifically increase levels of APP751 and there are several reports that 
this isoform is increased in the AD brain. (Hyman etal. 1992). In a mouse model of chronic 
inflammation APP751 was increased in areas of neuronal degradation (Brugg et al. 1995). It has 
also been shown that APP751 to APP695 ratio in human, dog and rat brain parallels the ability of 
each brain to form senile plaques. The relative amounts of APP751 in different brain areas also 
mirrors the amount of AD pathology found in each area (Anderson et al. 1989).
Previous work carried out in the Pearson laboratory also implicates APP751 in the processes of 
cellular stress, and maybe in the pathogenesis of AD. Immunohistochemistry on pathologically 
confirmed post-mortem AD brain tissue shows that these brains accumulate APP751 when 
compared to age-matched control brains. In the temporal cortex, pyramidal cells in layer V 
showed the highest immunoreactivity, these cells are also the most vulnerable to NFTs. In the 
visual cortex, which contains fewer NFTs there was less APP751 staining. Plaques that were 
immunopositive for pA4 also reacted with the KPI antibody, which may indicate that the 
dystrophic neurites contain APP751. (Prof. R.C.A. Pearson, personal communication) In a study 
very similar to the one described in this thesis, Dr Shepherd investigated relative levels of APP
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proteins and mRNAs in control and heat-shocked human astrocytes. (Shepherd, 1998) Human 
astrocytes that have been subjected to a period of heat shock show significantly increased levels 
of APP751 mRNA, together with an intracellular accumulation of KPI-containing APP. As with the 
NT2N cells, these astrocytes show a decrease in secreted KPI-containing APP following the 
period of heat shock.
Put together, these findings indicate that APP751 may be the APP isoform which is upregulated in 
response to abnormal cellular conditions, and a change in the relative amounts of this isoform 
may lead to changes in APP processing and pA4  deposition.
Although these findings do not attempt to explain the initial trigger of cellular shock at the 
beginning of the disease progression, they do indicate a means by which the pathology could 
spread through the brain, and also explain the accumulation of extracellular pA4. The initial 
process could be an increase in pA4 levels, specifically the more neurotoxic pA4^2. This 
increase could be due to genetic factors, such as PS1 or PS2 mutations, or a mutation in the APP 
gene, all of which either increase total pA4 levels, or increase the PA4i-42:PA4i-40 ratios. 
Alternatively the increase in pA4 could be due to some, as yet unknown, physiological or 
environmental conditions. There is also the possibility that the initial cause of cellular stress is not 
due to pA4, but that the effect of the stress is an increase in pA4 levels, which in turn propagates 
the cellular stress.
153
8.7 FUTURE WORK
8.7.1 Detection of J3A4
As stated above, the data presented in this thesis shows that human, neuronal cells respond to 
stress by increasing production of APP751, and that this excess protein is not secreted, but 
retained in the cell. With the current understanding of APP processing pathways, and specifically 
the sites of pA4 production (see Selkoe, 1998 for a review), it can be assumed that an increase in 
intracellular APP will lead to an increase in pA4 production. However, to confirm this, it would be 
necessary to establish a technique of detecting pA4 in both the NT2N cells, and the conditioned 
media.
Unfortunately, attempts to detect pA4 by western blotting were not successful. Due to 
constraints of time and finances it was not possible to try alternative techniques of detection. 
However, methods that may be tried include using immunocytochemistry to identify intracellular 
pA4. Secreted pA4 may be detected by first isolating it from the conditioned media, using affinity 
or gel-filtration chromatography, in this way concentrating the peptide before analysis on an SDS- 
PAGE gel and western blotting. Many published studies use a sandwich ELISA method to detect 
pA4 in conditioned media or biological fluids (Haass et al. 1992b; Seubert et al. 1992b), however 
the antibodies used are not commercially available.
8.7.2 The Fate of the Increased APP
To investigate the time course involved in the events following cellular stress, it would be 
necessary to allow the cells a recovery period after the stress event. Protein and mRNA data, 
both intracellular and secreted, would indicate how long the upregulation of APP lasts, and would 
also indicate whether the increased intracellular protein is eventually secreted. It would also be
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interesting to investigate the cellular location of APP following cellular stress. It may be retained 
in the ER or Golgi, where it seems likely it would be cleaved to form pA4. Alternatively it may be 
transported to the axon, where it may be involved in processes to minimise damage.
In situ data on heat shocked stem cells would confirm that the increase in APP seen is an 
increase in APP751, which would confirm that this increase is a general response to cellular 
stress, and is not neurone specific.
8.7.3 The Method of Optimem Stress
The theory that the stress is caused not by some factor in the Optimem media, but by the 
absence of FBS could be tested by repeating the experiment using DMEM with no added FBS as 
the experimental media. If the stress response is due to the lack of essential nutrients the results 
from FBS deprived cells should be the same as those from the cells treated with Optimem.
8.8 CONCLUSION
The work presented in this thesis demonstrates that human neuronal cells, expressing 
endogenous APP show an isoform specific increase of APP751 in response to cellular stress. This 
increase in mRNA and intracellular protein is not accompanied by an increase in secretion. The 
work on NT2 stem cells, as well as work by Dr Shepherd, which found heat-shocked human 
astrocytes accumulate intracellular KPI-containing APP (Shepherd, 1998); indicates that this 
response is not neurone specific.
These data show that APP is an important molecule in the cellular response to stress, and 
indicate that the different isoforms of APP may have different roles. The fact that APP751 does 
not appear to be secreted as effectively after cellular stress provides an insight into one of the 
means by which pA4  could accumulate in SAD. It is possible that continued cellular insult would
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lead to increased pA4 production, which may in turn lead to cellular stress. It is also possible that 
the upregulation of APP751, and its accumulation within the cells could be the trigger that begins 
the “amyloid cascade.
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Appendix A - Reagents
The recipes for solutions are presented in the same order as the methods laid out in Chapter 2. 
The index contains names of protocols, as well as individual solutions. All reagents were 
obtained from Sigma unless otherwise stated.
INDEX
0.1 M EDTA, 204
0.1 M Sodium Acetate Buffer (pH 3.5), 205 
0.1% Cresyl Fast Violet, 205 
0.2 M Phosphate Buffer, 204
100% Deionized Formamide, 203
20x SSC, 203
50x Denhart’s Solution, 203
Alkaline Phosphatase Buffer, 202 
Anode Buffer (Tricine), 200 
ANTIBODY CONCENTRATION ON A 
PROTEIN G COLUMN, 202 
AP Buffer. See Alkaline Phosphatase Buffer 
AraC. See Cytosine Arabinoside
BCA PROTEIN ASSAY, 197 
BCA Reagent, 197
BCIP. See Bromo-chloro-indolyl Phosphate 
Solution 
Binding Buffer, 202 
Blotto, 201
Bromo-chloro-indolyl Phosphate Solution, 
202
Cathode Buffer (Tricine), 200 
cDMEM. See Complete DMEM 
cDMEM +l, 196
CDS. See Cell Dissociation Solution 
CELL CULTURE, 194 
Cell Dissociation Solution, 195 
Complete DMEM, 195 
Coomassie Brilliant Blue Stain, 200 
Cytosine Arabinoside, 196
192
Denatured Herring/Salmon Sperm, 204 
DEPC-Water, 203 
Destain, 200
DMEM. See Dulbecco’s Modified Eagles 
Medium
Dulbecco’s Modified Eagles Medium, 194
Electrode Buffer, 198
FBS. See Foetal Bovine Serum 
FDU. See Fluorodeoxyuridine 
Fix, 199
Fluorodeoxyuridine, 196 
Foetal Bovine Serum, 194
Gel Buffer (Tricine), 200 
Glass Beads, 32
Homogenising Buffer, 197 
Hybridisation Buffer, 204
Immunoprecipitation Buffer, 202 
IMMUNOPRECIPITATIONS, 202 
IN SITU HYBRIDISATION, 203
Matrigel, 196
NBT. See Nitro Blue Tetrazolium 
Nitro Blue Tetrazolium Solution, 202
P/S. See Penicillin and Streptomycin 
Penicillin and Streptomycin, 195 
Poly-D-Lysine, 196
PREPARATION OF CELL SOLUBLE AND 
MEMBRANE PROTEINS, 197 
Protease Inhibitors, 197 
PROTEIN TRANSFER TO MEMBRANE, 
201
R Buffer. See Resolving Gel Buffer 
RA. See Retinoic Acid 
Resolving Gel, 199 
Resolving Gel (Tricine), 200 
Resolving Gel Buffer, 198 
Retinoic Acid, 195
S Buffer. See Stacking Gel Buffer 
Sample Buffer (2ME), 198 
Sample Buffer (DTT), 198 
Sample Buffer (Tricine), 200 
SDS-PAGE. See SODIUM- 
DODECYLSULPHATE
193
POLYACRYLAMIDE GEL 
ELECTROPHORESIS 
SODIUM-DODECYLSULPHATE 
POLYACRYLAMIDE GEL 
ELECTROPHORESIS, 198 
Stacking Gel, 199 
Stacking Gel (Tricine), 201 
Stacking Gel Buffer, 198
TBS. See TRIS Buffered Saline 
TBS-Tw. See TBS-Tween 20
TE. See Trypsin/Ethylenediaminetetraacetic 
Acid
Transfer Buffer, 201 
TRICINE GELS, 200 
TRIS Buffered Saline, 201 
T rypsin/Ethylenediaminetetraacetic Acid,
195
U. See Uridine 
Uridine, 196
TBS-Tween 20,202 WESTERN BLOTTING, 201
CELL CULTURE
All solutions obtained from Gibco Life Sciences
Dulbecco’s Modified Eagles Medium (DMEM)
High glucose (4.5 g/l)
Without sodium pyruvate 
With “Glutamax II”
Stored at +4°C
Foetal Bovine Serum (FBS)
Heat inactivated at 56°C for 30 minutes 
Stored in 25 ml aliquots at -20°C
194
Penicillin and Streptomycin (P/S)
5000 lU/m! penicillin and 5000 ng/ml streptomycin 
Stored in 5 ml aliquots at -20°C
Use at 1:100 dilution to give 50 lU/ml penicillin and 50 jug/ml streptomycin.
Complete DMEM (cDMEM)
500 ml DMEM
50 ml FBS (heat inactivated)
5 ml P/S
Trypsin/EthylenediaminetetraaceticAcid (EDTA) (TE)
0.5 mg/ml trypsin, 0.2 mg/ml (0.7 mM) EDTA in modified Puck’s saline A 
Stored in 10 ml aliquots at -20°C.
Cell Dissociation Solution (CDS) (Sigma)
A non-enzymatic salt solution prepared in Hank’s balanced salt solution without calcium and 
magnesium
Retinoic Acid (RA) (Sigma)
Light sensitive, handle in dimmed light and wrap tubes in use in foil.
Stock is 10 mg/ml in dimethyl sulfoxide (DMSO), 1 ml aliquots stored at -70°C.
Prepare working stock by diluting to 3 mg/ml with DMSO (10 mM).
Store working stock wrapped in foil at 4°C.
Use at 1:1000 (10*5 M final concentration).
Cytosine Arabinoside (AraC) (Sigma)
Stock is 1 mM, dissolve 1.2 mg in 5 ml dH20.
195
Filter sterilise, store in 150 jul aliquots at -20°C.
Use at 1:1000.
Fluorodeoxyuridine (FDU) (Sigma)
Stock is 1 mM, dissolve 12.3 mg in 50 ml dhkO.
Filter sterilise, store in 1.5 ml aliquots at -20°C.
Use at 1:100.
Uridine (U) (Sigma)
Stock is 1 mM, dissolve 12.2 mg in 50 ml dl^O.
Filter sterilise, store in 1.5 ml aliquots at -20°C.
Use at 1:100.
lx  cDMEM+1 
cDMEM (100 ml)
+1 nM AraC (100 jil 1 mM stock)
+10 jiM FDU (1 ml 1 mM stock)
+ 10 jiM U (1 ml 1 mM stock)
Poly-D-Lysine (Sigma)
Stock is 100 jig/ml, dissolve 5 mg in 50 ml sterile dFhO.
Store in 1.5 ml aliquots at -20°C.
Dilute 1:10 with sterile dhhO before use.
Matrigel (Collaborative research)
Forms gel when warm, so keep cool. Thaw overnight at +4°C, dispense in 0.5 ml aliquots, store 
at -20°C.
196
To use, thaw overnight at +4°C, dilute 1:36 with DMEM, store for up to 2 weeks at +4°C. 
PREPARATION OF CELL SOLUBLE AND MEMBRANE PROTEINS
Homogenising Buffer 
10 mM TRIS.HCI pH 7.8 
1 mM EDTA.Na2 
1 mM Sodium chloride (NaCI)
1 mM Potassium chloride (KCI)
Protease Inhibitors
100 mM phenylmethylsulfonyl fluoride (PMSF) in ethanol. Use at 1:100 (1 mM final 
concentration)
1 mg / ml leupeptin. Use at 1:100 (10 jug I ml final concentration)
2 mg I ml trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E64). Use at 1:100 (20 jug I 
ml final concentration)
5 mg / ml pepstatin A. Use at 1:500 (10 jL ig  / ml final concentration)
BCA PROTEIN ASSAY 
BCA Reagent
20 ml Bicinchoninic acid solution 
400 j l i I  4% Copper Sulphate (CUSO4)
SODIUM-DODECYLSULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS (SDS-PAGE)
Resolving Gel Buffer (4xR Buffer)
197
1.5M  T R IS .H C I pH  8 .8
(18.2 g TRIS for 100 ml, + HCI to pH 8.8)
Stacking Gel Buffer (4xS Buffer)
0.5M TRIS.HCI pH 6.8
(6 g TRIS for 100 ml, + HCI to pH 6.8)
Electrode Buffer
6 g TRIS 
28.8 g glycine 
2g SDS 
2 1dH20
Sample Buffer (DTT)
(store at -20°C)
308 mg Dithiothreitol (DTT)
2 ml 10% SDS
3 ml 60% glycerol 
5 ml 4x S buffer
0.5 ml 2 mg/ml bromophenol blue
Sample Buffer (2ME)
100 mg SDS 
1 ml 2-mercaptoethanol
4 ml 60% glycerol
5 ml 4xS buffer
0.5 ml 2 mg/ml bromophenol blue
198
Resolving Gel
(recipe for two mini-gels)
4 ml 2x acrylamide solution 
2 ml 60% glycerol 
2 ml 4xR buffer 
80 jul 10% SDS
80 jul 5% N, N, N’, N’-tetramethylethylenediamine (TEMED)
80 jul 5% ammonium persulphate (APS)
(Load 3.4 ml per gel, overlay with 160^ 1 dH20, allow to polymerise for >1 hour.)
Stacking Gel
(recipe for two mini-gel stacks)
2 ml 8% acrylamide (30% acrylamide in dH20)
1 ml 60% glycerol 
1 ml 4xS buffer
(use 300 jul to wash top of each gel and then add to remaining 3.4 ml:)
34 jul 10 % SDS 
34 jul 5% TEMED 
34 jul 5% APS
Fix
10% acetic acid, 50% methanol
Coomassie Brilliant Blue (CBB) Stain
0.05% w/v CBB R-250 in 10% acetic acid
(0.15 g CBB, dissolve in 270 ml water by stirring for 1 hour, filter, add 30 ml glacial acetic acid)
199
Destain 
5% acetic acid.
TRICINE GELS
Anode Buffer (upper)
0.2 M TRIS pH 8.9
(24.2 g TRIS for 1 1 dH20, + HCI to pH 8.9)
Cathode Buffer (lower)
0.1% SDS, 0.1M TRIS, 0.1 M Tricine pH 8.25
(1 g SDS, 12.1 g TRIS, 17.9 g Tricine for 1 1, no need to adjust pH)
Gel Buffer (3x)
3M TRIS pH 8.25 
(36.3 g TRIS for 100 ml)
Sample Buffer
Laemmli sample buffer with 0.02% Serva Blue G
(0.5% Serva Blue G in 10% acetic acid, add 1 jal to 25 jul sample buffer)
Resolving Gel
3 ml 3x acrylamide solution 
3 ml gel buffer
3.2 g urea +dH20  to 9 ml (or 3 ml 60% glycerol) 
mix
+ 90 jul each 10% SDS, 5% TEMED, 5% APS
200
Stacking Gel
2 ml 4x acrylamide solution (to give final concentration of 4%)
1 ml 3x gel buffer 
1 ml 60% glycerol 
mix
+40 jul each 10% SDS, 5% TEMED, 5% APS 
PROTEIN TRANSFER TO MEMBRANE 
Transfer Buffer
10 mM 3-[Cyclohexylamino]-1-propanesulfonic acid (CAPS) pH 10.3 containing 10% methanol 
(2.2 g CAPS.Na dissolved in 900 ml dH20, adjust to pH 10.3 with 2 M NaOH, then add 100 ml 
MeOH, stir for about 10 minutes)
WESTERN BLOTTING
TRIS Buffered Saline (TBS)
15 mM TRIS.HCI pH 7.4 
140 mM NaCI
Blotto
TBS with 5% bovine milk protein, 0.05% Tween-20
(2.5 g dried skimmed milk, 50 ml TBS, 250 jul 10% Tween-20)
TBS-Tween 20 (TBS-Tw)
TBS +0.01% Tween-20 (200 ml TBS +200 jul 10% Tween-20)
Alkaline Phosphatase (AP) Buffer
201
100 mM TRIS.HCI 
100 mM NaCI
5 mM Magnesium chloride (MgCb) 
pH 9.5
Nitro Blue Tetrazolium (NBT) Solution 
0.6 mg/ml in AP buffer
(6 mg NBT, dissolve in 300 |il MeOH, add 9.7 ml AP buffer)
Bromo-chloro-indolyl Phosphate (BCIP) Solution
0.3 mg/ml in AP buffer
IMMUNOPRECIPITA T/ONS
Immunoprecipitation Buffer
50 mM TRIS.HCI pH 7.5 
150 mM Sodium Chloride 
1 mM EDTA
ANTIBODY CONCENTRATION ON A PROTEIN G COLUMN
Binding Buffer
0.01 M Sodium Phosphate 
0.15 M Sodium Chloride 
0.01 M EDTA
IN SITU HYBRIDISATION
DEPC-Water
202
1 ml Diethyl pyrocarbonate (DEPC)
1 1dH20
Combine and leave covered to stand for at least 3 hours 
Autoclave to destroy DEPC
20xSSC
175.3 g NaCI
88.2 g Sodium citrate
800 ml DEPC-treated water
pH to 7.0 with 1 M NaOH
Make up to 1 1 with DEPC-treated water
5 Ox Denhart’s Solution
5 g Ficoll
5 g Polyvinylpyrrolidone (PVP)
5 g Bovine serum albumin (BSA)
500 ml DEPC-treated dH20
Filter through 0.2 ^m filter, aliquot and store at -20°C
Deionized Formamide 
5 g BioRad AG 501-X8 
50 ml Formamide
Stir for 30 minutes at room temperature. Filter twice with Whatman No. 1, aliquot and store at - 
20°C until needed
Denatured Herring/Salmon Sperm
100 mg Herring/salmon sperm DNA
203
10 ml DEPC-treated water
Stir for 2-4 hours with heating if necessary. Shear by sonification for 60 seconds prior to boiling 
for 10 minutes. Cool rapidly on ice, aliquot (1 ml) and store at -20°C. Before use, boil for 5 
minutes and cool rapidly.
0.1 MEDTA
37.22 gEDTA
800 ml DEPC-treated dH20
Stir and add 10 M NaOH to assist dissolution. pH to 8.0 with solid NaOH (approximately 20g). 
Aliquot at -20°C
0.2 MPhosphate Buffer
A 27.6 g Sodium dihydrogen orthophosphate (NaH2P04)
1 1 DEPC-treated dH20 
B 28.4 g NaH2P04
1 1 DEPC-treated dH20 
Combine 1 part A to 4 parts B to produce the stock solution; store at 4°C
Hybridisation Buffer
10 ml20xSSC
1 ml 50x Denhart’s solution
0.5 ml 0.5 M EDTA
1 ml Denatured herring/salmon sperm
5 mg yeast tRNA
5 mg PolyA
25 ml Deionized formamide
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5 g Dextran sulphate
Make up to 50 ml with 20 mM Phosphate buffer. Aliquot and store at -20°C
0.1 M  Sodium Acetate Buffer (pH 3.5)
13 ml 0.1 M sodium acetate 
87 ml 0.1 M acetic acid
0.1 % Cresyl Fast Violet 
1 g Cresyl fast violet, make up to 1 1 with dH20.
205
Appendix B - Neurone Protocol
TO PRODUCE >99% NEURONE CULTURES
Day Number
1
8,15, 22 
25
28
32
35
39
Example
Friday
Friday
Monday
Thursday
Monday
Thursday
Monday
43 Friday
Feed every 7 days
Procedure
Split confluent T25 of stem cells 1:10, use non-enzymatic
means of detaching from flask and replate in T25 flasks. Make
up to 5 ml media per flask with cDMEM, add RA to 10 piM.
feed with cDMEM plus 10 juM RA.
split 1:3 - wash with 5 ml DMEM, add 2 ml TE, place in
incubator for 5-10 min, inactivate with 8 ml cDMEM. Spin to
pellet cells, re-suspend in 12 ml 1X cDMEM + 1, transfer to T75.
feed with 12 ml 1X cDMEM + 1
feed with 12 ml cDMEM (no inhibitors)
feed with 12 ml cDMEM (no inhibitors)
feed with 10 ml cDMEM, dislodge neurones by tapping flask 5
times per side, collect cell suspension and add to coated
vessels, do not spin.
1 T75 can be replated to 6 chamber slides 
or 112 well plate 
or 2 T25 flasks
Feed with cDMEM
206
NB - Stratagene suggest feeding replated neurone cultures with cDMEM containing 
fluorodeoxyuridine and uridine to remove any contaminating cells, when I have tried this all cells 
died, including neurones.
LABELLING
Stem cells are labelled with passage number and date of split.
When set up in retinoic acid each flask is given a code in the form DDMMYYPXX, where 
DDMMYY is the date, and PXX the passage number of the stem cells. Flasks are labelled "RA”.
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Appendix C - Original Neurone Protocol
Retinoic Acid Differentiation
Aspirate media from a confluent flask of NT2 stem cells.
Add 2 ml TE and incubate until cells are in suspension, inactivate TE by addition of 10 ml 
cDMEM.
Spin at 1000 rpm for 10 minutes to pellet cells, aspirate supernatant and resuspend cells in 
cDMEM containing 10-5 M RA.
Perform a cell count and seed cells at a density of 106 cells per T75 flask, add cDMEM containing 
RA to a final volume of 12 ml per T75.
Feed every 7 days with 12 ml cDMEM with RA.
Repiate #1
On day 24 after seeding.
Aspirate media from culture flask and add 5 ml TE, incubate until all cells are in suspension. 
Inactivate TE by addition of 10 ml cDMEM.
Spin at 1000 rpm for 10 minutes to pellet cells, aspirate supernatant and resuspend cells in 30 ml 
cDMEM.
Transfer to a T165 flask and return to incubator (1:2 split)
Replate #2
On day 25 after seeding.
Aspirate media from T165 flask and add 2 ml TE.
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Observe cells under phase contrast microscope and gently agitate flask to remove neuronal 
precursor cells, these cells are larger and more phase-bright than non-neuronal cells, and are 
found on the top of the cell layers.
Once all precursors are in suspension, inactivate trypsin immediately with 10 ml cDMEM. 
Combine precursors from 2 or more T165 flasks and spin at 1000 rpm for 10 min to pellet 
precursors.
Meanwhile re-feed T165 with 30 ml cDMEM and return to incubator.
Resuspend cell pellet in 10 ml cDMEM + 1.
Perform cell count and seed cells at a density of approximately 6 x 106 cells per T25 flask. 
Add cDMEM + 1 to a total volume of 5 ml per T25 and place in incubator.
Replate #3
On day 26 after seeding.
Repeat protocol for Replate #2, discard T165 flasks after this replate.
Neuronal Purification
Feed neuronal cultures with 5 ml cDMEM + 1 twice weekly.
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